US10399993B2 - Oxabicycloheptanes and oxabicycloheptenes, their preparation and use - Google Patents
Oxabicycloheptanes and oxabicycloheptenes, their preparation and use Download PDFInfo
- Publication number
- US10399993B2 US10399993B2 US16/018,924 US201816018924A US10399993B2 US 10399993 B2 US10399993 B2 US 10399993B2 US 201816018924 A US201816018924 A US 201816018924A US 10399993 B2 US10399993 B2 US 10399993B2
- Authority
- US
- United States
- Prior art keywords
- compound
- substituted
- alkyl
- alkenyl
- alkynyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title description 15
- DYWAPFDKPAHSED-UHFFFAOYSA-N 2-cycloheptyloxepane Chemical class C1CCCCCC1C1OCCCCC1 DYWAPFDKPAHSED-UHFFFAOYSA-N 0.000 title 1
- CJTLZIHNZYQJFJ-UHFFFAOYSA-N 6-(cyclohepten-1-yl)-2,3,4,5-tetrahydrooxepine Chemical class C1CCCCC=C1C1=COCCCC1 CJTLZIHNZYQJFJ-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 297
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 45
- 125000000217 alkyl group Chemical group 0.000 claims description 60
- 125000003342 alkenyl group Chemical group 0.000 claims description 49
- 238000000034 method Methods 0.000 claims description 45
- 125000000304 alkynyl group Chemical group 0.000 claims description 44
- 208000005017 glioblastoma Diseases 0.000 claims description 40
- 125000003118 aryl group Chemical group 0.000 claims description 37
- -1 mercapto, amino, carboxy, cyano, carbamoyl Chemical group 0.000 claims description 35
- 150000003839 salts Chemical class 0.000 claims description 35
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims description 32
- 201000011510 cancer Diseases 0.000 claims description 16
- 125000003107 substituted aryl group Chemical group 0.000 claims description 15
- 125000004426 substituted alkynyl group Chemical group 0.000 claims description 13
- 229910052739 hydrogen Inorganic materials 0.000 claims description 11
- 150000001412 amines Chemical group 0.000 claims description 10
- 206010009944 Colon cancer Diseases 0.000 claims description 7
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 7
- 206010038389 Renal cancer Diseases 0.000 claims description 7
- 229910052794 bromium Inorganic materials 0.000 claims description 7
- 229910052801 chlorine Inorganic materials 0.000 claims description 7
- 229910052731 fluorine Inorganic materials 0.000 claims description 7
- 201000010982 kidney cancer Diseases 0.000 claims description 7
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 5
- 208000000172 Medulloblastoma Diseases 0.000 claims description 5
- 206010033128 Ovarian cancer Diseases 0.000 claims description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 5
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 125000000623 heterocyclic group Chemical group 0.000 claims description 4
- 125000006710 (C2-C12) alkenyl group Chemical group 0.000 claims description 3
- 150000003973 alkyl amines Chemical group 0.000 claims description 3
- 125000005189 alkyl hydroxy group Chemical group 0.000 claims description 3
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 3
- 125000005017 substituted alkenyl group Chemical group 0.000 claims description 3
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 2
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 claims description 2
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical group 0.000 claims description 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims 3
- 125000006711 (C2-C12) alkynyl group Chemical group 0.000 claims 2
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 210000004027 cell Anatomy 0.000 description 117
- GXEKYRXVRROBEV-FBXFSONDSA-N (1r,2s,3r,4s)-7-oxabicyclo[2.2.1]heptane-2,3-dicarboxylic acid Chemical compound C1C[C@@H]2[C@@H](C(O)=O)[C@@H](C(=O)O)[C@H]1O2 GXEKYRXVRROBEV-FBXFSONDSA-N 0.000 description 63
- 230000000694 effects Effects 0.000 description 51
- 102000008169 Co-Repressor Proteins Human genes 0.000 description 39
- 108010060434 Co-Repressor Proteins Proteins 0.000 description 39
- 0 CC(C)CCC(C)C1C*CC1 Chemical compound CC(C)CCC(C)C1C*CC1 0.000 description 38
- 229930002330 retinoic acid Natural products 0.000 description 34
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 31
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 30
- 239000003814 drug Substances 0.000 description 28
- 229940079593 drug Drugs 0.000 description 27
- DHZBEENLJMYSHQ-XCVPVQRUSA-N cantharidin Chemical compound C([C@@H]1O2)C[C@@H]2[C@]2(C)[C@@]1(C)C(=O)OC2=O DHZBEENLJMYSHQ-XCVPVQRUSA-N 0.000 description 26
- JAABVEXCGCXWRR-FBXFSONDSA-N rel-norcantharidin Chemical compound C1C[C@H]2[C@@H]3C(=O)OC(=O)[C@@H]3[C@@H]1O2 JAABVEXCGCXWRR-FBXFSONDSA-N 0.000 description 26
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 21
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
- 229940095758 cantharidin Drugs 0.000 description 21
- 229930008397 cantharidin Natural products 0.000 description 21
- DHZBEENLJMYSHQ-UHFFFAOYSA-N cantharidine Natural products O1C2CCC1C1(C)C2(C)C(=O)OC1=O DHZBEENLJMYSHQ-UHFFFAOYSA-N 0.000 description 21
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 20
- 230000017066 negative regulation of growth Effects 0.000 description 20
- 239000000203 mixture Substances 0.000 description 19
- 238000005160 1H NMR spectroscopy Methods 0.000 description 18
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- 238000003556 assay Methods 0.000 description 18
- 238000012054 celltiter-glo Methods 0.000 description 18
- 230000002401 inhibitory effect Effects 0.000 description 17
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical group CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 15
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 15
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 15
- 229960004679 doxorubicin Drugs 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 239000013641 positive control Substances 0.000 description 14
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 14
- 230000004083 survival effect Effects 0.000 description 14
- 206010006187 Breast cancer Diseases 0.000 description 13
- 208000026310 Breast neoplasm Diseases 0.000 description 13
- FIHGXQPEGFDRHA-UHFFFAOYSA-N CC(C)(C)CC1=CC=CC=C1.CC(C)(C)OC(=O)C(C)(C)C Chemical compound CC(C)(C)CC1=CC=CC=C1.CC(C)(C)OC(=O)C(C)(C)C FIHGXQPEGFDRHA-UHFFFAOYSA-N 0.000 description 13
- 230000005764 inhibitory process Effects 0.000 description 13
- 150000002500 ions Chemical class 0.000 description 13
- 229910052760 oxygen Inorganic materials 0.000 description 13
- 239000002904 solvent Substances 0.000 description 13
- 125000001424 substituent group Chemical group 0.000 description 13
- RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 239000004009 herbicide Substances 0.000 description 12
- 230000012010 growth Effects 0.000 description 11
- 239000003112 inhibitor Substances 0.000 description 11
- 102000003964 Histone deacetylase Human genes 0.000 description 10
- 108090000353 Histone deacetylase Proteins 0.000 description 10
- RTKIYFITIVXBLE-UHFFFAOYSA-N Trichostatin A Natural products ONC(=O)C=CC(C)=CC(C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-UHFFFAOYSA-N 0.000 description 10
- 239000002253 acid Substances 0.000 description 10
- 125000001309 chloro group Chemical group Cl* 0.000 description 10
- 230000002363 herbicidal effect Effects 0.000 description 10
- 230000003389 potentiating effect Effects 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- 229910052717 sulfur Inorganic materials 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 238000004949 mass spectrometry Methods 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 8
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 8
- 239000002246 antineoplastic agent Substances 0.000 description 8
- 230000010261 cell growth Effects 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 239000003446 ligand Substances 0.000 description 8
- 238000001819 mass spectrum Methods 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 8
- 208000003174 Brain Neoplasms Diseases 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 7
- 125000004069 aziridinyl group Chemical group 0.000 description 7
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- WFOVEDJTASPCIR-UHFFFAOYSA-N 3-[(4-methyl-5-pyridin-4-yl-1,2,4-triazol-3-yl)methylamino]-n-[[2-(trifluoromethyl)phenyl]methyl]benzamide Chemical compound N=1N=C(C=2C=CN=CC=2)N(C)C=1CNC(C=1)=CC=CC=1C(=O)NCC1=CC=CC=C1C(F)(F)F WFOVEDJTASPCIR-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 239000000543 intermediate Substances 0.000 description 6
- 210000001178 neural stem cell Anatomy 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 102000027483 retinoid hormone receptors Human genes 0.000 description 6
- 108091008679 retinoid hormone receptors Proteins 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- SBKCDXFXOZWRGL-UHFFFAOYSA-N 2-(4-benzylpiperazine-1-carbonyl)-7-oxabicyclo[2.2.1]heptane-3-carboxylic acid Chemical compound OC(=O)C1C(O2)CCC2C1C(=O)N(CC1)CCN1CC1=CC=CC=C1 SBKCDXFXOZWRGL-UHFFFAOYSA-N 0.000 description 5
- 108010077544 Chromatin Proteins 0.000 description 5
- 206010017533 Fungal infection Diseases 0.000 description 5
- 206010018338 Glioma Diseases 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 208000031888 Mycoses Diseases 0.000 description 5
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 5
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 5
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 239000003054 catalyst Substances 0.000 description 5
- 210000003483 chromatin Anatomy 0.000 description 5
- 231100000673 dose–response relationship Toxicity 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- SHGAZHPCJJPHSC-XFYACQKRSA-N isotretinoin Chemical compound OC(=O)/C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-XFYACQKRSA-N 0.000 description 5
- 208000032839 leukemia Diseases 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- BVDPDUZHRIPVSF-UHFFFAOYSA-N methyl 2-(4-benzylpiperazine-1-carbonyl)-7-oxabicyclo[2.2.1]heptane-3-carboxylate Chemical compound COC(=O)C1C(O2)CCC2C1C(=O)N(CC1)CCN1CC1=CC=CC=C1 BVDPDUZHRIPVSF-UHFFFAOYSA-N 0.000 description 5
- QNDVLZJODHBUFM-WFXQOWMNSA-N okadaic acid Chemical compound C([C@H](O1)[C@H](C)/C=C/[C@H]2CC[C@@]3(CC[C@H]4O[C@@H](C([C@@H](O)[C@@H]4O3)=C)[C@@H](O)C[C@H](C)[C@@H]3[C@@H](CC[C@@]4(OCCCC4)O3)C)O2)C(C)=C[C@]21O[C@H](C[C@@](C)(O)C(O)=O)CC[C@H]2O QNDVLZJODHBUFM-WFXQOWMNSA-N 0.000 description 5
- VEFJHAYOIAAXEU-UHFFFAOYSA-N okadaic acid Natural products CC(CC(O)C1OC2CCC3(CCC(O3)C=CC(C)C4CC(=CC5(OC(CC(C)(O)C(=O)O)CCC5O)O4)C)OC2C(O)C1C)C6OC7(CCCCO7)CCC6C VEFJHAYOIAAXEU-UHFFFAOYSA-N 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 229960001727 tretinoin Drugs 0.000 description 5
- 241001225321 Aspergillus fumigatus Species 0.000 description 4
- FUYNRMBFOKNBNO-UHFFFAOYSA-N C.C.CC(C)(C)CC1=CC=CC=C1.CC(C)(C)OC(=O)C(C)(C)C Chemical compound C.C.CC(C)(C)CC1=CC=CC=C1.CC(C)(C)OC(=O)C(C)(C)C FUYNRMBFOKNBNO-UHFFFAOYSA-N 0.000 description 4
- 241000222122 Candida albicans Species 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 241000221204 Cryptococcus neoformans Species 0.000 description 4
- 241000233866 Fungi Species 0.000 description 4
- 241000427940 Fusarium solani Species 0.000 description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
- 108010059000 Protein Phosphatase 1 Proteins 0.000 description 4
- 102000005569 Protein Phosphatase 1 Human genes 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- 241000223598 Scedosporium boydii Species 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 102000040945 Transcription factor Human genes 0.000 description 4
- 108091023040 Transcription factor Proteins 0.000 description 4
- 238000005056 compaction Methods 0.000 description 4
- 239000000039 congener Substances 0.000 description 4
- 210000000805 cytoplasm Anatomy 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 4
- 150000007522 mineralic acids Chemical class 0.000 description 4
- 210000004940 nucleus Anatomy 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 208000000587 small cell lung carcinoma Diseases 0.000 description 4
- 159000000000 sodium salts Chemical class 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- IQXXEPZFOOTTBA-UHFFFAOYSA-N 1-benzylpiperazine Chemical compound C=1C=CC=CC=1CN1CCNCC1 IQXXEPZFOOTTBA-UHFFFAOYSA-N 0.000 description 3
- WTBAZICCVWDMOU-UHFFFAOYSA-N 2-[[1-[2-(4-methoxyphenyl)ethyl]piperidin-4-yl]carbamoyl]-7-oxabicyclo[2.2.1]heptane-3-carboxylic acid Chemical compound C1=CC(OC)=CC=C1CCN1CCC(NC(=O)C2C(C3CCC2O3)C(O)=O)CC1 WTBAZICCVWDMOU-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 244000197813 Camelina sativa Species 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 102100021455 Histone deacetylase 3 Human genes 0.000 description 3
- 108010033040 Histones Proteins 0.000 description 3
- 102000006947 Histones Human genes 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- WDBSFMAGIDPLAF-IZUQBHJASA-N O=C(O)C1C(C(=O)N2CCCCC2)[C@@H]2cc[C@H]1O2 Chemical compound O=C(O)C1C(C(=O)N2CCCCC2)[C@@H]2cc[C@H]1O2 WDBSFMAGIDPLAF-IZUQBHJASA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 102000006478 Protein Phosphatase 2 Human genes 0.000 description 3
- 108010058956 Protein Phosphatase 2 Proteins 0.000 description 3
- 240000005384 Rhizopus oryzae Species 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 206010041067 Small cell lung cancer Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 241000223229 Trichophyton rubrum Species 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 238000002827 antifungal susceptibility testing Methods 0.000 description 3
- 229940041181 antineoplastic drug Drugs 0.000 description 3
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 231100000334 hepatotoxic Toxicity 0.000 description 3
- 108010074724 histone deacetylase 3 Proteins 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 229960005280 isotretinoin Drugs 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 239000003934 phosphoprotein phosphatase inhibitor Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 150000004508 retinoic acid derivatives Chemical class 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 3
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 3
- 210000001635 urinary tract Anatomy 0.000 description 3
- QPFMBZIOSGYJDE-UHFFFAOYSA-N 1,1,2,2-tetrachloroethane Chemical compound ClC(Cl)C(Cl)Cl QPFMBZIOSGYJDE-UHFFFAOYSA-N 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- WGCYRFWNGRMRJA-UHFFFAOYSA-N 1-ethylpiperazine Chemical compound CCN1CCNCC1 WGCYRFWNGRMRJA-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000228212 Aspergillus Species 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- VTVRJDQKNQOZPT-UHFFFAOYSA-N C.CC(C)(C)N1CCCCC1.CN(C)CCCC(C)(C)C.COC1=CC=C(CCN2CCC(CC(C)(C)C)CC2)C=C1 Chemical compound C.CC(C)(C)N1CCCCC1.CN(C)CCCC(C)(C)C.COC1=CC=C(CCN2CCC(CC(C)(C)C)CC2)C=C1 VTVRJDQKNQOZPT-UHFFFAOYSA-N 0.000 description 2
- CJGXJKVMUHXVHL-UHFFFAOYSA-N CC(C)(C)CC1=CC=CC=C1 Chemical compound CC(C)(C)CC1=CC=CC=C1 CJGXJKVMUHXVHL-UHFFFAOYSA-N 0.000 description 2
- VXDVSWWVJLAKMG-UHFFFAOYSA-N CC(C)(C)NC1CCN(CCc(cc2)ccc2OC)CC1 Chemical compound CC(C)(C)NC1CCN(CCc(cc2)ccc2OC)CC1 VXDVSWWVJLAKMG-UHFFFAOYSA-N 0.000 description 2
- VXHFNALHLRWIIU-UHFFFAOYSA-N CC(C)(C)OC(=O)C(C)(C)C Chemical compound CC(C)(C)OC(=O)C(C)(C)C VXHFNALHLRWIIU-UHFFFAOYSA-N 0.000 description 2
- QOCRLYULFHGBJT-AFWXGSBKSA-N CN(C)CCNC(=O)C1C(C(=O)O)[C@H]2C=C[C@@H]1O2 Chemical compound CN(C)CCNC(=O)C1C(C(=O)O)[C@H]2C=C[C@@H]1O2 QOCRLYULFHGBJT-AFWXGSBKSA-N 0.000 description 2
- FMDJMSPIVPGLJN-AFWXGSBKSA-N CN(C)CCNC(=O)C1C(C(=O)O)[C@H]2CC[C@@H]1O2 Chemical compound CN(C)CCNC(=O)C1C(C(=O)O)[C@H]2CC[C@@H]1O2 FMDJMSPIVPGLJN-AFWXGSBKSA-N 0.000 description 2
- VRKMCSKALPZIDH-WBCRXPSESA-N COC1=CC=C(CCN2CCC(NC(=O)C3C(C(=O)O)[C@H]4C=C[C@@H]3O4)CC2)C=C1.[H][N+]1(CCC2=CC=C(OC)C=C2)CCC(NC(=O)C2C(C(=O)[O-])[C@H]3C=C[C@@H]2O3)CC1 Chemical compound COC1=CC=C(CCN2CCC(NC(=O)C3C(C(=O)O)[C@H]4C=C[C@@H]3O4)CC2)C=C1.[H][N+]1(CCC2=CC=C(OC)C=C2)CCC(NC(=O)C2C(C(=O)[O-])[C@H]3C=C[C@@H]2O3)CC1 VRKMCSKALPZIDH-WBCRXPSESA-N 0.000 description 2
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 108010016626 Dipeptides Proteins 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- UYLYISCHTFVYHN-NOWQFEBASA-M O=C([O-])C1C[C@@H]2CC[C@H]1O2 Chemical compound O=C([O-])C1C[C@@H]2CC[C@H]1O2 UYLYISCHTFVYHN-NOWQFEBASA-M 0.000 description 2
- UQRKXAMLRXBEKW-BJBIKLFWSA-M O=CC1C(C(=O)[O-])[C@H]2CC[C@@H]1O2 Chemical compound O=CC1C(C(=O)[O-])[C@H]2CC[C@@H]1O2 UQRKXAMLRXBEKW-BJBIKLFWSA-M 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 229940116193 Protein phosphatase inhibitor Drugs 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 238000011579 SCID mouse model Methods 0.000 description 2
- 244000300264 Spinacia oleracea Species 0.000 description 2
- 235000009337 Spinacia oleracea Nutrition 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 241000223230 Trichosporon Species 0.000 description 2
- FKAWLXNLHHIHLA-YCBIHMBMSA-N [(2r,3r,5r,7r,8s,9s)-2-[(1s,3s,4s,5r,6r,7e,9e,11e,13z)-14-cyano-3,5-dihydroxy-1-methoxy-4,6,8,9,13-pentamethyltetradeca-7,9,11,13-tetraenyl]-9-[(e)-3-[2-[(2s)-4-[[(2s,3s,4s)-4-(dimethylamino)-2,3-dihydroxy-5-methoxypentanoyl]amino]butan-2-yl]-1,3-oxazol-4 Chemical compound O1C([C@@H](C)CCNC(=O)[C@@H](O)[C@@H](O)[C@H](COC)N(C)C)=NC(\C=C\C[C@H]2[C@H]([C@H](O)C[C@]3(O2)C([C@@H](OP(O)(O)=O)[C@@H]([C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)\C=C(/C)\C(\C)=C\C=C\C(\C)=C/C#N)OC)O3)(C)C)C)=C1 FKAWLXNLHHIHLA-YCBIHMBMSA-N 0.000 description 2
- XBPFUNIGMQMISX-UHFFFAOYSA-M [H]N1CCN(C(=O)CCC(=O)[O-])CC1 Chemical compound [H]N1CCN(C(=O)CCC(=O)[O-])CC1 XBPFUNIGMQMISX-UHFFFAOYSA-M 0.000 description 2
- JIVVYPLWMLXTDM-ZRUFSTJUSA-M [H][C@@]1(C(=O)[O-])[C@H]2CC[C@H](O2)[C@]1([H])C(=O)N1CCN([H])(C)CC1 Chemical compound [H][C@@]1(C(=O)[O-])[C@H]2CC[C@H](O2)[C@]1([H])C(=O)N1CCN([H])(C)CC1 JIVVYPLWMLXTDM-ZRUFSTJUSA-M 0.000 description 2
- MSSVTAQQRKJESB-ONEGZZNKSA-O [H][N+]1(C)CCN(C(=O)/C=C/C)CC1 Chemical compound [H][N+]1(C)CCN(C(=O)/C=C/C)CC1 MSSVTAQQRKJESB-ONEGZZNKSA-O 0.000 description 2
- WAKNQQVWPGKEKU-UHFFFAOYSA-O [H][N+]1(C)CCN(C(C)(C)C)CC1 Chemical compound [H][N+]1(C)CCN(C(C)(C)C)CC1 WAKNQQVWPGKEKU-UHFFFAOYSA-O 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 230000000843 anti-fungal effect Effects 0.000 description 2
- 229940034982 antineoplastic agent Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000002815 broth microdilution Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 230000005956 cytoplasmic translocation Effects 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 239000002837 defoliant Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 229940088679 drug related substance Drugs 0.000 description 2
- INVTYAOGFAGBOE-UHFFFAOYSA-N entinostat Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)OCC1=CC=CN=C1 INVTYAOGFAGBOE-UHFFFAOYSA-N 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 229920001477 hydrophilic polymer Polymers 0.000 description 2
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 231100001231 less toxic Toxicity 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 208000013371 ovarian adenocarcinoma Diseases 0.000 description 2
- 201000006588 ovary adenocarcinoma Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 201000001514 prostate carcinoma Diseases 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000007430 reference method Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 108090000064 retinoic acid receptors Proteins 0.000 description 2
- 102000003702 retinoic acid receptors Human genes 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 2
- 150000002266 vitamin A derivatives Chemical class 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- ZVEMACCDKBQNGX-KALODSIISA-N (2s)-2-amino-5-(diaminomethylideneamino)pentanoic acid;butanoic acid Chemical compound CCCC(O)=O.CCCC(O)=O.CCCC(O)=O.CCCC(O)=O.OC(=O)[C@@H](N)CCCN=C(N)N.OC(=O)[C@@H](N)CCCN=C(N)N.OC(=O)[C@@H](N)CCCN=C(N)N ZVEMACCDKBQNGX-KALODSIISA-N 0.000 description 1
- YUXKOWPNKJSTPQ-AXWWPMSFSA-N (2s,3r)-2-amino-3-hydroxybutanoic acid;(2s)-2-amino-3-hydroxypropanoic acid Chemical compound OC[C@H](N)C(O)=O.C[C@@H](O)[C@H](N)C(O)=O YUXKOWPNKJSTPQ-AXWWPMSFSA-N 0.000 description 1
- JWOGUUIOCYMBPV-GMFLJSBRSA-N (3S,6S,9S,12R)-3-[(2S)-Butan-2-yl]-6-[(1-methoxyindol-3-yl)methyl]-9-(6-oxooctyl)-1,4,7,10-tetrazabicyclo[10.4.0]hexadecane-2,5,8,11-tetrone Chemical compound N1C(=O)[C@H](CCCCCC(=O)CC)NC(=O)[C@H]2CCCCN2C(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]1CC1=CN(OC)C2=CC=CC=C12 JWOGUUIOCYMBPV-GMFLJSBRSA-N 0.000 description 1
- LLOKIGWPNVSDGJ-AFBVCZJXSA-N (3s,6s,9s,12r)-3,6-dibenzyl-9-[6-[(2s)-oxiran-2-yl]-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone Chemical compound C([C@H]1C(=O)N2CCC[C@@H]2C(=O)N[C@H](C(N[C@@H](CC=2C=CC=CC=2)C(=O)N1)=O)CCCCCC(=O)[C@H]1OC1)C1=CC=CC=C1 LLOKIGWPNVSDGJ-AFBVCZJXSA-N 0.000 description 1
- RTYHOZSKZMLUKB-BWZSGCSDSA-N (4r)-3-methoxycarbonyl-7-oxabicyclo[2.2.1]heptane-2-carboxylic acid Chemical compound C1CC2C(C(O)=O)C(C(=O)OC)[C@@H]1O2 RTYHOZSKZMLUKB-BWZSGCSDSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- RQNOFUZGXHSHOT-UHFFFAOYSA-N 1-(diethylamino)ethanol Chemical compound CCN(CC)C(C)O RQNOFUZGXHSHOT-UHFFFAOYSA-N 0.000 description 1
- LDMOEFOXLIZJOW-UHFFFAOYSA-N 1-dodecanesulfonic acid Chemical class CCCCCCCCCCCCS(O)(=O)=O LDMOEFOXLIZJOW-UHFFFAOYSA-N 0.000 description 1
- HMNZRTFPIMZOCU-UHFFFAOYSA-N 2-(piperazin-4-ium-1-carbonyl)-7-oxabicyclo[2.2.1]heptane-3-carboxylate Chemical compound OC(=O)C1C(O2)CCC2C1C(=O)N1CCNCC1 HMNZRTFPIMZOCU-UHFFFAOYSA-N 0.000 description 1
- PEZJGMJYKMOOGW-UHFFFAOYSA-N 2-(piperazine-1-carbonyl)-7-oxabicyclo[2.2.1]heptane-3-carbothioic s-acid Chemical class OC(=S)C1C(O2)CCC2C1C(=O)N1CCNCC1 PEZJGMJYKMOOGW-UHFFFAOYSA-N 0.000 description 1
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- DJIOGHZNVKFYHH-UHFFFAOYSA-N 2-hexadecylpyridine Chemical compound CCCCCCCCCCCCCCCCC1=CC=CC=N1 DJIOGHZNVKFYHH-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 1
- JTDYUFSDZATMKU-UHFFFAOYSA-N 6-(1,3-dioxo-2-benzo[de]isoquinolinyl)-N-hydroxyhexanamide Chemical compound C1=CC(C(N(CCCCCC(=O)NO)C2=O)=O)=C3C2=CC=CC3=C1 JTDYUFSDZATMKU-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 241001550224 Apha Species 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- KYFKTJQSUNWACN-UHFFFAOYSA-M C1=CC=C(CN2CCCCC2)C=C1.CO.COC(=O)C1C2CCC(O2)C1C(=O)N1CCN(CC2=CC=CC=C2)CC1.COC(=O)C1C2CCC(O2)C1C(=O)O.O=C(O)C1C2CCC(O2)C1C(=O)N1CCN(CC2=CC=CC=C2)CC1.O=C1OC(=O)C2C3CCC(O3)C12.O[Na] Chemical compound C1=CC=C(CN2CCCCC2)C=C1.CO.COC(=O)C1C2CCC(O2)C1C(=O)N1CCN(CC2=CC=CC=C2)CC1.COC(=O)C1C2CCC(O2)C1C(=O)O.O=C(O)C1C2CCC(O2)C1C(=O)N1CCN(CC2=CC=CC=C2)CC1.O=C1OC(=O)C2C3CCC(O3)C12.O[Na] KYFKTJQSUNWACN-UHFFFAOYSA-M 0.000 description 1
- ZSWFCLXCOIISFI-UHFFFAOYSA-N C1=CCC=C1 Chemical compound C1=CCC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N C1=COC=C1 Chemical compound C1=COC=C1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- PGHLLRVYUKWHMX-FSMLFXEMSA-M C=C[C@H]1OCC(C(=O)N2CCN(C(=O)CC(C)(C)C)CC2)C1C(=O)[O-].CC(C)(C)OC(=O)N1CCN(C(=O)C2C(C(=O)O)[C@H]3C=C[C@@H]2O3)CC1 Chemical compound C=C[C@H]1OCC(C(=O)N2CCN(C(=O)CC(C)(C)C)CC2)C1C(=O)[O-].CC(C)(C)OC(=O)N1CCN(C(=O)C2C(C(=O)O)[C@H]3C=C[C@@H]2O3)CC1 PGHLLRVYUKWHMX-FSMLFXEMSA-M 0.000 description 1
- QKAWWEYDWLSYAA-SGNQUONSSA-N CB(O)N1CCCCC1.CB(O)N1CCN(C(=O)C2C3CCC(O3)C2C(=O)O)CC1.O=C1OC(=O)C2C3CCC(O3)C12.[2HH] Chemical compound CB(O)N1CCCCC1.CB(O)N1CCN(C(=O)C2C3CCC(O3)C2C(=O)O)CC1.O=C1OC(=O)C2C3CCC(O3)C12.[2HH] QKAWWEYDWLSYAA-SGNQUONSSA-N 0.000 description 1
- RIFNWDNKRJCAPN-MDKSODDCSA-N CC(=O)OC(C)=O.O=C1OC(=O)C2C1[C@@H]1CC[C@H]2O1.[H][C@@]1(C(=O)O)[C@H]2CC[C@H](O2)[C@]1([H])C(=O)O Chemical compound CC(=O)OC(C)=O.O=C1OC(=O)C2C1[C@@H]1CC[C@H]2O1.[H][C@@]1(C(=O)O)[C@H]2CC[C@H](O2)[C@]1([H])C(=O)O RIFNWDNKRJCAPN-MDKSODDCSA-N 0.000 description 1
- GZIHGUOBNFQZEU-UHFFFAOYSA-N CC(C)(C)CC([NH+](CC1)CCN1C(C(COC1C=C)C1C([O-])=O)=O)=O Chemical compound CC(C)(C)CC([NH+](CC1)CCN1C(C(COC1C=C)C1C([O-])=O)=O)=O GZIHGUOBNFQZEU-UHFFFAOYSA-N 0.000 description 1
- ORJCZEHVNGPBGF-UHFFFAOYSA-N CC(C)(C)N1CCCCC1.CN(C)CCCC(C)(C)C.COC1=CC=C(CCN2CCC(CC(C)(C)C)CC2)C=C1 Chemical compound CC(C)(C)N1CCCCC1.CN(C)CCCC(C)(C)C.COC1=CC=C(CCN2CCC(CC(C)(C)C)CC2)C=C1 ORJCZEHVNGPBGF-UHFFFAOYSA-N 0.000 description 1
- OOXMNFVHTHADGM-UAGRHRBOSA-L CC(C)(C)OC(=O)N1CCN(C(=O)C2C(C(=O)O)[C@H]3C=C[C@@H]2O3)CC1.CCN1CCN(C(=O)C2C(C(=O)[O-])[C@H]3C=C[C@@H]2O3)CC1.COC1=CC=C(CCN2CCC(NC(=O)C3C(C(=O)O)[C@H]4C=C[C@@H]3O4)CC2)C=C1.O=C([O-])C1C(C(=O)N2CCN(CC3=CC=CC=C3)CC2)[C@@H]2C=C[C@H]1O2.[H][N+]1(C)CCN(C(=O)C2C(C(=O)[O-])[C@H]3C=C[C@@H]2O3)CC1 Chemical compound CC(C)(C)OC(=O)N1CCN(C(=O)C2C(C(=O)O)[C@H]3C=C[C@@H]2O3)CC1.CCN1CCN(C(=O)C2C(C(=O)[O-])[C@H]3C=C[C@@H]2O3)CC1.COC1=CC=C(CCN2CCC(NC(=O)C3C(C(=O)O)[C@H]4C=C[C@@H]3O4)CC2)C=C1.O=C([O-])C1C(C(=O)N2CCN(CC3=CC=CC=C3)CC2)[C@@H]2C=C[C@H]1O2.[H][N+]1(C)CCN(C(=O)C2C(C(=O)[O-])[C@H]3C=C[C@@H]2O3)CC1 OOXMNFVHTHADGM-UAGRHRBOSA-L 0.000 description 1
- RLHDOUHSSWRRIH-PDSXTLAWSA-M CC(C)(C)OC(=O)N1CCN(C(=O)C2C(C(=O)O)[C@H]3CC[C@@H]2O3)CC1.CC(C)(C)OC(=O)N1CCN(C(=O)C2C(C(=O)[O-])[C@H]3CC[C@@H]2O3)CC1 Chemical compound CC(C)(C)OC(=O)N1CCN(C(=O)C2C(C(=O)O)[C@H]3CC[C@@H]2O3)CC1.CC(C)(C)OC(=O)N1CCN(C(=O)C2C(C(=O)[O-])[C@H]3CC[C@@H]2O3)CC1 RLHDOUHSSWRRIH-PDSXTLAWSA-M 0.000 description 1
- DZGSYMVANVUDMI-KKBRBERQSA-M CC(C)(C)OC(=O)N1CCN(C(=O)C2C(C(=O)O)[C@H]3CC[C@@H]2O3)CC1.CCN1CCN(C(=O)C2C(C(=O)[O-])[C@H]3CC[C@@H]2O3)CC1.COC1=CC=C(CCN2CCC(NC(=O)C3C(C(=O)O)[C@H]4CC[C@@H]3O4)CC2)C=C1.O=C(O)C1C(C(=O)N2CCN(CC3=CC=CC=C3)CC2)[C@@H]2CC[C@H]1O2 Chemical compound CC(C)(C)OC(=O)N1CCN(C(=O)C2C(C(=O)O)[C@H]3CC[C@@H]2O3)CC1.CCN1CCN(C(=O)C2C(C(=O)[O-])[C@H]3CC[C@@H]2O3)CC1.COC1=CC=C(CCN2CCC(NC(=O)C3C(C(=O)O)[C@H]4CC[C@@H]3O4)CC2)C=C1.O=C(O)C1C(C(=O)N2CCN(CC3=CC=CC=C3)CC2)[C@@H]2CC[C@H]1O2 DZGSYMVANVUDMI-KKBRBERQSA-M 0.000 description 1
- GOOGOFRIKLFKNW-ZFDZMSFRSA-N CC(C)(C)OC(N(CC1)CCN1C(C(C1C(O)=O)[C@H]2O[C@@H]1C=C2)=O)=O Chemical compound CC(C)(C)OC(N(CC1)CCN1C(C(C1C(O)=O)[C@H]2O[C@@H]1C=C2)=O)=O GOOGOFRIKLFKNW-ZFDZMSFRSA-N 0.000 description 1
- NMHOEXOUVQHPHG-RCUQKECRSA-M CCCCNC.CN1CCCCC1.CN1CCN(C(=O)C2C3CCC(O3)C2C(=O)[S-])CC1.O=C1SC(=O)C2C3CCC(O3)C12.[2HH] Chemical compound CCCCNC.CN1CCCCC1.CN1CCN(C(=O)C2C3CCC(O3)C2C(=O)[S-])CC1.O=C1SC(=O)C2C3CCC(O3)C12.[2HH] NMHOEXOUVQHPHG-RCUQKECRSA-M 0.000 description 1
- ORWLNCLAWPSGMY-UHFFFAOYSA-N CCCN(CC)C(C)(C)C Chemical compound CCCN(CC)C(C)(C)C ORWLNCLAWPSGMY-UHFFFAOYSA-N 0.000 description 1
- QZCHCDFNSOPATI-UHFFFAOYSA-N CCCN(CC)C(C)(C)C.CN(C)CCCC(C)(C)C.COC1=CC=C(CCN2CCC(CC(C)(C)C)CC2)C=C1 Chemical compound CCCN(CC)C(C)(C)C.CN(C)CCCC(C)(C)C.COC1=CC=C(CCN2CCC(CC(C)(C)C)CC2)C=C1 QZCHCDFNSOPATI-UHFFFAOYSA-N 0.000 description 1
- AWSLAYRFEDAFPV-UPZGEUDKSA-M CCN1CCN(C(=O)C2C(C(=O)O)[C@H]3C=C[C@@H]2O3)CC1.CCN1CCN(C(=O)C2C(C(=O)[O-])[C@H]3C=C[C@@H]2O3)CC1 Chemical compound CCN1CCN(C(=O)C2C(C(=O)O)[C@H]3C=C[C@@H]2O3)CC1.CCN1CCN(C(=O)C2C(C(=O)[O-])[C@H]3C=C[C@@H]2O3)CC1 AWSLAYRFEDAFPV-UPZGEUDKSA-M 0.000 description 1
- RTTYWMMHPZRJMR-DMOGRIERSA-N CCN1CCN(C(=O)C2C(C(=O)O)[C@H]3CC[C@@H]2O3)CC1 Chemical compound CCN1CCN(C(=O)C2C(C(=O)O)[C@H]3CC[C@@H]2O3)CC1 RTTYWMMHPZRJMR-DMOGRIERSA-N 0.000 description 1
- NMTGRCLGWSYMRY-UPZGEUDKSA-M CCN1CCN(C(=O)C2C(C(=O)O)[C@H]3CC[C@@H]2O3)CC1.CCN1CCN(C(=O)C2C(C(=O)[O-])[C@H]3CC[C@@H]2O3)CC1 Chemical compound CCN1CCN(C(=O)C2C(C(=O)O)[C@H]3CC[C@@H]2O3)CC1.CCN1CCN(C(=O)C2C(C(=O)[O-])[C@H]3CC[C@@H]2O3)CC1 NMTGRCLGWSYMRY-UPZGEUDKSA-M 0.000 description 1
- PFOZUPWAVFGBEJ-LWALXPGCSA-N CCN1CCN(C(=O)C2C[C@H]3CC[C@@H]2O3)CC1 Chemical compound CCN1CCN(C(=O)C2C[C@H]3CC[C@@H]2O3)CC1 PFOZUPWAVFGBEJ-LWALXPGCSA-N 0.000 description 1
- IGPCLNDYIXGACC-UHFFFAOYSA-N CCO1CCNCC1 Chemical compound CCO1CCNCC1 IGPCLNDYIXGACC-UHFFFAOYSA-N 0.000 description 1
- XJKYABAMOUAVPX-CXAMJNLCSA-M CN1CCN(C(=O)C2C(C(=O)O)[C@H]3C=C[C@@H]2O3)CC1.[H]N1(C)CCN(C(=O)C2C(C(=O)[O-])[C@H]3C=C[C@@H]2O3)CC1 Chemical compound CN1CCN(C(=O)C2C(C(=O)O)[C@H]3C=C[C@@H]2O3)CC1.[H]N1(C)CCN(C(=O)C2C(C(=O)[O-])[C@H]3C=C[C@@H]2O3)CC1 XJKYABAMOUAVPX-CXAMJNLCSA-M 0.000 description 1
- YQXBOIVQJMGGRB-CXAMJNLCSA-M CN1CCN(C(=O)C2C(C(=O)O)[C@H]3CC[C@@H]2O3)CC1.[H]N1(C)CCN(C(=O)C2C(C(=O)[O-])[C@H]3CC[C@@H]2O3)CC1 Chemical compound CN1CCN(C(=O)C2C(C(=O)O)[C@H]3CC[C@@H]2O3)CC1.[H]N1(C)CCN(C(=O)C2C(C(=O)[O-])[C@H]3CC[C@@H]2O3)CC1 YQXBOIVQJMGGRB-CXAMJNLCSA-M 0.000 description 1
- CJIXRASZJOCVJF-LURBOGOUSA-N CN1CCN(C(=O)C2C(C(=O)[S-])[C@H]3CC[C@@H]2O3)CC1.COC(=O)C1C(C(=O)N2CCCCC2)[C@@H]2CC[C@H]1O2.COC(=O)C1C(C(=O)N2CCN(C)CC2)[C@@H]2C=C[C@H]1O2.[NH3+]C1CCCCC1 Chemical compound CN1CCN(C(=O)C2C(C(=O)[S-])[C@H]3CC[C@@H]2O3)CC1.COC(=O)C1C(C(=O)N2CCCCC2)[C@@H]2CC[C@H]1O2.COC(=O)C1C(C(=O)N2CCN(C)CC2)[C@@H]2C=C[C@H]1O2.[NH3+]C1CCCCC1 CJIXRASZJOCVJF-LURBOGOUSA-N 0.000 description 1
- DQZMIFFQWIHYKD-SVDLCREBSA-N CN1CCN(C(=O)C2C(C(=O)[S-])[C@H]3CC[C@@H]2O3)CC1.[NH3+]C1CCNCC1 Chemical compound CN1CCN(C(=O)C2C(C(=O)[S-])[C@H]3CC[C@@H]2O3)CC1.[NH3+]C1CCNCC1 DQZMIFFQWIHYKD-SVDLCREBSA-N 0.000 description 1
- UJWZSGMUSXILPJ-UHFFFAOYSA-N CN1CCN(C(=O)C2C3CCC(O3)C2C(=O)O)CC1.COC(=O)C1C2CCC(O2)C1C(=O)N1CCN(C)CC1 Chemical compound CN1CCN(C(=O)C2C3CCC(O3)C2C(=O)O)CC1.COC(=O)C1C2CCC(O2)C1C(=O)N1CCN(C)CC1 UJWZSGMUSXILPJ-UHFFFAOYSA-N 0.000 description 1
- WAKNQQVWPGKEKU-UHFFFAOYSA-N CN1CCN(C(C)(C)C)CC1 Chemical compound CN1CCN(C(C)(C)C)CC1 WAKNQQVWPGKEKU-UHFFFAOYSA-N 0.000 description 1
- SGTPPAPHWXAWRF-DMOGRIERSA-N COC(=O)C1C(C(=O)N2CCN(C)CC2)[C@@H]2C=C[C@H]1O2 Chemical compound COC(=O)C1C(C(=O)N2CCN(C)CC2)[C@@H]2C=C[C@H]1O2 SGTPPAPHWXAWRF-DMOGRIERSA-N 0.000 description 1
- XWGYRUJSUADGDX-DMOGRIERSA-N COC(=O)C1C(C(=O)N2CCN(C)CC2)[C@@H]2CC[C@H]1O2 Chemical compound COC(=O)C1C(C(=O)N2CCN(C)CC2)[C@@H]2CC[C@H]1O2 XWGYRUJSUADGDX-DMOGRIERSA-N 0.000 description 1
- TWONGLXFESTVRB-UHFFFAOYSA-N COC1=CC=C(CCN2CCC(CC(=O)C3C4CCC(O4)C3C(=O)O)CC2)C=C1.NC1CCN(CCC2=CC=C(CO)C=C2)CC1.O=C1OC(=O)C2C3CCC(O3)C12 Chemical compound COC1=CC=C(CCN2CCC(CC(=O)C3C4CCC(O4)C3C(=O)O)CC2)C=C1.NC1CCN(CCC2=CC=C(CO)C=C2)CC1.O=C1OC(=O)C2C3CCC(O3)C12 TWONGLXFESTVRB-UHFFFAOYSA-N 0.000 description 1
- DABXATJVRKLOCH-WBCRXPSESA-N COC1=CC=C(CCN2CCC(NC(=O)C3C(C(=O)O)[C@H]4CC[C@@H]3O4)CC2)C=C1.COC1=CC=C(CC[NH+]2CCC(NC(=O)C3C(C(=O)[O-])[C@H]4CC[C@@H]3O4)CC2)C=C1 Chemical compound COC1=CC=C(CCN2CCC(NC(=O)C3C(C(=O)O)[C@H]4CC[C@@H]3O4)CC2)C=C1.COC1=CC=C(CC[NH+]2CCC(NC(=O)C3C(C(=O)[O-])[C@H]4CC[C@@H]3O4)CC2)C=C1 DABXATJVRKLOCH-WBCRXPSESA-N 0.000 description 1
- QNEVUDLNHBJAPK-WBYGSUFKSA-N COc1ccc(CCN(CC2)CCC2NC(C(C2C(O)=O)[C@H]3O[C@@H]2C=C3)=O)cc1 Chemical compound COc1ccc(CCN(CC2)CCC2NC(C(C2C(O)=O)[C@H]3O[C@@H]2C=C3)=O)cc1 QNEVUDLNHBJAPK-WBYGSUFKSA-N 0.000 description 1
- 101000611262 Caenorhabditis elegans Probable protein phosphatase 2C T23F11.1 Proteins 0.000 description 1
- 238000003734 CellTiter-Glo Luminescent Cell Viability Assay Methods 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 201000007336 Cryptococcosis Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 108010002156 Depsipeptides Proteins 0.000 description 1
- DLVJMFOLJOOWFS-UHFFFAOYSA-N Depudecin Natural products CC(O)C1OC1C=CC1C(C(O)C=C)O1 DLVJMFOLJOOWFS-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000001692 EU approved anti-caking agent Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 1
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 1
- 101001095320 Homo sapiens Serine/threonine-protein phosphatase PP1-beta catalytic subunit Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 150000000994 L-ascorbates Chemical class 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010023774 Large cell lung cancer Diseases 0.000 description 1
- 101000688229 Leishmania chagasi Protein phosphatase 2C Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241000623906 Lytta vesicatoria Species 0.000 description 1
- 240000004658 Medicago sativa Species 0.000 description 1
- 235000017587 Medicago sativa ssp. sativa Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 241000124079 Mylabris Species 0.000 description 1
- PTJGLFIIZFVFJV-UHFFFAOYSA-N N'-hydroxy-N-(3-pyridinyl)octanediamide Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CN=C1 PTJGLFIIZFVFJV-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 108090000913 Nitrate Reductases Proteins 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- ZTSWBUOMLFPBHY-IZUQBHJASA-N O=C(O)C1C(C(=O)N2CCCCC2)[C@@H]2CC[C@H]1O2 Chemical compound O=C(O)C1C(C(=O)N2CCCCC2)[C@@H]2CC[C@H]1O2 ZTSWBUOMLFPBHY-IZUQBHJASA-N 0.000 description 1
- RQLOXPAUMLTSQY-XBRWPBQWSA-M O=C(O)C1C(C(=O)N2CCN(CC3=CC=CC=C3)CC2)[C@@H]2C=C[C@H]1O2.O=C([O-])C1C(C(=O)N2CCN(CC3=CC=CC=C3)CC2)[C@@H]2C=C[C@H]1O2 Chemical compound O=C(O)C1C(C(=O)N2CCN(CC3=CC=CC=C3)CC2)[C@@H]2C=C[C@H]1O2.O=C([O-])C1C(C(=O)N2CCN(CC3=CC=CC=C3)CC2)[C@@H]2C=C[C@H]1O2 RQLOXPAUMLTSQY-XBRWPBQWSA-M 0.000 description 1
- ZBEKVJZYPSHZNP-XBRWPBQWSA-M O=C(O)C1C(C(=O)N2CCN(CC3=CC=CC=C3)CC2)[C@@H]2CC[C@H]1O2.O=C([O-])C1C(C(=O)N2CCN(CC3=CC=CC=C3)CC2)[C@@H]2CC[C@H]1O2 Chemical compound O=C(O)C1C(C(=O)N2CCN(CC3=CC=CC=C3)CC2)[C@@H]2CC[C@H]1O2.O=C([O-])C1C(C(=O)N2CCN(CC3=CC=CC=C3)CC2)[C@@H]2CC[C@H]1O2 ZBEKVJZYPSHZNP-XBRWPBQWSA-M 0.000 description 1
- TURLJUTYWHCHFP-NQJGDFRCSA-N O=C(O)C1C(C(=O)N2CCNCC2)[C@@H]2C=C[C@H]1O2.O=C([O-])C1C(C(=O)N2CC[NH2+]CC2)[C@@H]2C=C[C@H]1O2 Chemical compound O=C(O)C1C(C(=O)N2CCNCC2)[C@@H]2C=C[C@H]1O2.O=C([O-])C1C(C(=O)N2CC[NH2+]CC2)[C@@H]2C=C[C@H]1O2 TURLJUTYWHCHFP-NQJGDFRCSA-N 0.000 description 1
- RQXCYJVJGKTQAS-UACHFPBZSA-M O=C(O)C1C(C(=O)N2CCNCC2)[C@@H]2CC[C@H]1O2.O=C([O-])C1C(C(=O)N2CCCCC2)[C@@H]2CC[C@H]1O2 Chemical compound O=C(O)C1C(C(=O)N2CCNCC2)[C@@H]2CC[C@H]1O2.O=C([O-])C1C(C(=O)N2CCCCC2)[C@@H]2CC[C@H]1O2 RQXCYJVJGKTQAS-UACHFPBZSA-M 0.000 description 1
- ILUXQMKCWCCBFP-UHFFFAOYSA-N O=C(O)C1C2CCC(O2)C1C(=O)N1CCN(CC2=CC=CC=C2)CC1.O=C(O)C1C2CCC(O2)C1C(=O)N1CCNCC1 Chemical compound O=C(O)C1C2CCC(O2)C1C(=O)N1CCN(CC2=CC=CC=C2)CC1.O=C(O)C1C2CCC(O2)C1C(=O)N1CCNCC1 ILUXQMKCWCCBFP-UHFFFAOYSA-N 0.000 description 1
- WDBSFMAGIDPLAF-IZUQBHJASA-M O=C([O-])C1C(C(=O)N2CCCCC2)[C@@H]2cc[C@H]1O2 Chemical compound O=C([O-])C1C(C(=O)N2CCCCC2)[C@@H]2cc[C@H]1O2 WDBSFMAGIDPLAF-IZUQBHJASA-M 0.000 description 1
- DJMWDXDXTAVFKH-LVFLEHKBSA-M O=C([O-])C1C(CN2CCCCC2)[C@@H]2cc[C@H]1O2 Chemical compound O=C([O-])C1C(CN2CCCCC2)[C@@H]2cc[C@H]1O2 DJMWDXDXTAVFKH-LVFLEHKBSA-M 0.000 description 1
- FCAPQGUNGKPOGJ-JADJALSWSA-N O=C1CC(=O)[C@]2(F)[C@H]3CC[C@H](O3)[C@]12F.[H][C@@]12C(=O)CC(=O)[C@]1(Br)[C@H]1CC[C@@H]2O1.[H][C@@]12C(=O)CC(=O)[C@]1(C(=O)OC)[C@H]1CC[C@@H]2O1.[H][C@@]12C(=O)CC(=O)[C@]1(Cl)[C@H]1CC[C@@H]2O1.[H][C@@]12C(=O)CC(=O)[C@]1(F)[C@H]1CC[C@@H]2O1.[H][C@@]12C(=O)CC(=O)[C@]1(S(=O)(=O)C1=CC=CC=C1)[C@H]1CC[C@@H]2O1 Chemical compound O=C1CC(=O)[C@]2(F)[C@H]3CC[C@H](O3)[C@]12F.[H][C@@]12C(=O)CC(=O)[C@]1(Br)[C@H]1CC[C@@H]2O1.[H][C@@]12C(=O)CC(=O)[C@]1(C(=O)OC)[C@H]1CC[C@@H]2O1.[H][C@@]12C(=O)CC(=O)[C@]1(Cl)[C@H]1CC[C@@H]2O1.[H][C@@]12C(=O)CC(=O)[C@]1(F)[C@H]1CC[C@@H]2O1.[H][C@@]12C(=O)CC(=O)[C@]1(S(=O)(=O)C1=CC=CC=C1)[C@H]1CC[C@@H]2O1 FCAPQGUNGKPOGJ-JADJALSWSA-N 0.000 description 1
- JAABVEXCGCXWRR-LAXKNYFCSA-N O=C1OC(=O)C2C1[C@@H]1CC[C@H]2O1 Chemical compound O=C1OC(=O)C2C1[C@@H]1CC[C@H]2O1 JAABVEXCGCXWRR-LAXKNYFCSA-N 0.000 description 1
- DKRHKGBVBLPFAL-WIPSSNENSA-N O=C1OC(=O)C2C1[C@@H]1CC[C@H]2O1.[CH2+]N1CCNCC1.[H][N+]1(C)CCN(C(=O)C2C(C(=O)[O-])[C@H]3CC[C@@H]2O3)CC1 Chemical compound O=C1OC(=O)C2C1[C@@H]1CC[C@H]2O1.[CH2+]N1CCNCC1.[H][N+]1(C)CCN(C(=O)C2C(C(=O)[O-])[C@H]3CC[C@@H]2O3)CC1 DKRHKGBVBLPFAL-WIPSSNENSA-N 0.000 description 1
- FPLBPRMBENXSGL-AFWXGSBKSA-N OC(C(C1C(N2CCOCC2)=O)[C@@H]2O[C@H]1C=C2)=O Chemical compound OC(C(C1C(N2CCOCC2)=O)[C@@H]2O[C@H]1C=C2)=O FPLBPRMBENXSGL-AFWXGSBKSA-N 0.000 description 1
- CIYPJPKQMIBCBH-UHFFFAOYSA-N OC(c1c(cc2)[o]c2c1)=O Chemical compound OC(c1c(cc2)[o]c2c1)=O CIYPJPKQMIBCBH-UHFFFAOYSA-N 0.000 description 1
- FOSOUTINBJEZDQ-UHFFFAOYSA-N OC(c1c(cc2)[o]c2c1C(N1CCNCC1)=O)=O Chemical compound OC(c1c(cc2)[o]c2c1C(N1CCNCC1)=O)=O FOSOUTINBJEZDQ-UHFFFAOYSA-N 0.000 description 1
- JWOGUUIOCYMBPV-UHFFFAOYSA-N OT-Key 11219 Natural products N1C(=O)C(CCCCCC(=O)CC)NC(=O)C2CCCCN2C(=O)C(C(C)CC)NC(=O)C1CC1=CN(OC)C2=CC=CC=C12 JWOGUUIOCYMBPV-UHFFFAOYSA-N 0.000 description 1
- 229940122907 Phosphatase inhibitor Drugs 0.000 description 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 229920000148 Polycarbophil calcium Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 229940122454 Protein phosphatase 2A inhibitor Drugs 0.000 description 1
- 235000013752 Rhizopus oryzae Nutrition 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 241000656145 Thyrsites atun Species 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- GXVXXETYXSPSOA-UHFFFAOYSA-N Trapoxin A Natural products C1OC1C(=O)CCCCCC(C(NC(CC=1C=CC=CC=1)C(=O)N1)=O)NC(=O)C2CCCCN2C(=O)C1CC1=CC=CC=C1 GXVXXETYXSPSOA-UHFFFAOYSA-N 0.000 description 1
- LLOKIGWPNVSDGJ-UHFFFAOYSA-N Trapoxin B Natural products C1OC1C(=O)CCCCCC(C(NC(CC=1C=CC=CC=1)C(=O)N1)=O)NC(=O)C2CCCN2C(=O)C1CC1=CC=CC=C1 LLOKIGWPNVSDGJ-UHFFFAOYSA-N 0.000 description 1
- 241000222126 [Candida] glabrata Species 0.000 description 1
- JUQMLSGOTNKJKI-IZUQBHJASA-N [H][N+]1(C)CCN(C(=O)C2C(C(=O)[O-])[C@H]3CC[C@@H]2O3)CC1 Chemical compound [H][N+]1(C)CCN(C(=O)C2C(C(=O)[O-])[C@H]3CC[C@@H]2O3)CC1 JUQMLSGOTNKJKI-IZUQBHJASA-N 0.000 description 1
- HMNZRTFPIMZOCU-AFWXGSBKSA-N [H][NH+]1CCN(C(=O)C2C(C(=O)[O-])[C@H]3CC[C@@H]2O3)CC1 Chemical compound [H][NH+]1CCN(C(=O)C2C(C(=O)[O-])[C@H]3CC[C@@H]2O3)CC1 HMNZRTFPIMZOCU-AFWXGSBKSA-N 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 101150045355 akt1 gene Proteins 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 108010082820 apicidin Proteins 0.000 description 1
- 229930186608 apicidin Natural products 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 229940091771 aspergillus fumigatus Drugs 0.000 description 1
- 230000003140 astrocytic effect Effects 0.000 description 1
- 150000001541 aziridines Chemical class 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 208000032343 candida glabrata infection Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 210000004289 cerebral ventricle Anatomy 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- UXJFDYIHRJGPFS-WPWMEQJKSA-N chembl380797 Chemical compound C=1C=CC=C(\N=C\C=2C3=CC=CC=C3C=CC=2O)C=1C(=O)NC(C)C1=CC=CC=C1 UXJFDYIHRJGPFS-WPWMEQJKSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 208000024207 chronic leukemia Diseases 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- CMKBCTPCXZNQKX-UHFFFAOYSA-N cyclohexanethiol Chemical compound SC1CCCCC1 CMKBCTPCXZNQKX-UHFFFAOYSA-N 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- DLVJMFOLJOOWFS-INMLLLKOSA-N depudecin Chemical compound C[C@@H](O)[C@@H]1O[C@H]1\C=C\[C@H]1[C@H]([C@H](O)C=C)O1 DLVJMFOLJOOWFS-INMLLLKOSA-N 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 150000001990 dicarboxylic acid derivatives Chemical class 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000013100 final test Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 150000004675 formic acid derivatives Chemical class 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000003082 hepatotoxic effect Effects 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940121372 histone deacetylase inhibitor Drugs 0.000 description 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 125000004356 hydroxy functional group Chemical class O* 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 201000009546 lung large cell carcinoma Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 150000004701 malic acid derivatives Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000004784 molecular pathogenesis Effects 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- XVDBWWRIXBMVJV-UHFFFAOYSA-N n-[bis(dimethylamino)phosphanyl]-n-methylmethanamine Chemical compound CN(C)P(N(C)C)N(C)C XVDBWWRIXBMVJV-UHFFFAOYSA-N 0.000 description 1
- OYKBQNOPCSXWBL-SNAWJCMRSA-N n-hydroxy-3-[(e)-3-(hydroxyamino)-3-oxoprop-1-enyl]benzamide Chemical compound ONC(=O)\C=C\C1=CC=CC(C(=O)NO)=C1 OYKBQNOPCSXWBL-SNAWJCMRSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- 150000004707 phenolate Chemical class 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 229950009215 phenylbutanoic acid Drugs 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 230000008635 plant growth Effects 0.000 description 1
- 229950005134 polycarbophil Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 238000012794 pre-harvesting Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical class [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 108090000721 thyroid hormone receptors Proteins 0.000 description 1
- 102000004217 thyroid hormone receptors Human genes 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- GXVXXETYXSPSOA-UFEOFEBPSA-N trapoxin A Chemical compound C([C@H]1C(=O)N2CCCC[C@@H]2C(=O)N[C@H](C(N[C@@H](CC=2C=CC=CC=2)C(=O)N1)=O)CCCCCC(=O)[C@H]1OC1)C1=CC=CC=C1 GXVXXETYXSPSOA-UFEOFEBPSA-N 0.000 description 1
- 108010060597 trapoxin A Proteins 0.000 description 1
- 108010060596 trapoxin B Proteins 0.000 description 1
- WORJEOGGNQDSOE-ASTXPPQBSA-N trichloro(deuterio)methane;trideuterio(deuteriooxy)methane Chemical compound [2H]C(Cl)(Cl)Cl.[2H]OC([2H])([2H])[2H] WORJEOGGNQDSOE-ASTXPPQBSA-N 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 1
- 229960000604 valproic acid Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 1
- 229960000237 vorinostat Drugs 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N47/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid
- A01N47/08—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having one or more single bonds to nitrogen atoms
- A01N47/10—Carbamic acid derivatives, i.e. containing the group —O—CO—N<; Thio analogues thereof
- A01N47/16—Carbamic acid derivatives, i.e. containing the group —O—CO—N<; Thio analogues thereof the nitrogen atom being part of a heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Definitions
- N-CoR Nuclear receptor co-repressor
- the phosphatase inhibitor, Cantharidin has anti-tumor activity against human cancers of the liver (hepatomas) and of the upper gastrointestinal tract but is toxic to the urinary tract (Wang, 1989).
- a and B is each independently H, F, Cl, Br, SO 2 Ph, CO 2 CH 3 , CN, COR 14 or SR 14 ,
- the invention further contemplates a method of controlling undesired vegetation comprising contacting the vegetation or its environment with a herbicidally effective amount of the compounds of the invention.
- the invention further contemplates a method of inhibiting plant phosphatase activity comprising contacting the plant or its environment with a herbicidally effective amount of the compounds of the invention.
- This invention further contemplates a method of preventing or treating fungal infections in a subject comprising administering to the subject an effective amount of the compounds of this invention.
- This invention further contemplates a method of treating cancer in a subject comprising administering to the subject an effective amount of the compounds of the invention.
- FIG. 1 Logarithmic curve of gliomal cell line U373 treated with endothal (End), endothal thioanhydride (ET), nor-cantharidin (nor-Can) or Compound 100. Increasing dosages demonstrate a greater inhibition of growth. Error bars indicate SD.
- FIG. 2 Inhibition of gliomal cell line U373 treated with endothal (End) or Compound 100 or each with and without all-trans Retinoic acid (ATRA) for 7 days. Individual treatment with endothal and Compound 100 shows modest inhibition of growth. Combination of End or Compound 100 with ATRA shows synergistic reduction in cell growth. Error bars indicate SD.
- FIG. 3 Inhibition of growth of kidney cancer cell line, UMRC by endothal thioanhydride (ET), endothal (End), all-trans Retinoic Acid (ATRA), Trichostatin A (TSA) and norcantharidin (nor-Can) for 7 days. Error bars indicate SD.
- FIG. 4 Inhibition of growth of gliomal cell line U373 by endothal thioanhydride (ET), endothal (End), all-trans Retinoic Acid (ATRA), Trichostatin A (TSA) and norcantharidin (nor-Can) for 7 days. Individual treatment with endothal thioanhydride showed the greatest inhibition of growth. Error bars indicate SD.
- FIG. 5 Inhibition of growth of breast cancer cell line, MCF-7 by Inhibition of UMRC by endothal thioanhydride (ET), endothal (End), all-trans Retinoic Acid (ATRA), Trichostatin A (TSA) and norcantharidin (nor-Can) for 7 days. Treatment with individual doses of endothal, ATRA and TSA showed an inhibition in growth. Error bars indicate SD.
- FIG. 6 Logarithmic curve of gliomal cell line U373 treated with 1-(3-Exocarboxy-7-oxabicyclo[2.2.1]heptane-2-exocarbonyl)-4-ethylpiperazine (Compound 105) after three days. Increasing dosages demonstrate a greater inhibition of growth.
- FIG. 7 Logarithmic curve of human GBM cell line U373 treated with 1-(3-Exocarboxy-7-oxabicyclo[2.2.1]heptane-2-exocarbonyl)-4-ethylpiperazine (Compound 105) after seven days. Increasing dosages demonstrate a greater inhibition of growth.
- FIG. 8 Inhibition of growth of human GBM cell line U373 treated with Compound 105 for seven days. Graph shows inhibition of growth over seven days at the following dosages: 1, 2, 5, 10, 50 and 100 ⁇ M of compound 105, 10 ⁇ M of compound 100, and a control dosage.
- FIG. 9 Inhibition of growth of gliomal cell line U373 by Compound 105 over 7 days.
- FIG. 10 Inhibition of growth of gliomal cell line U373 by Compound 102 over 7 days.
- FIG. 11 Inhibition of growth of gliomal cell line U373 by Compound 101 over 7 days.
- FIG. 12 Inhibition of growth of gliomal cell line U373 by Compound 103 over 7 days.
- FIG. 13 Inhibition of growth of gliomal cell line U373 by Compound 104 over 7 days.
- FIG. 14 Inhibition of growth of gliomal cell line U373 by Compound 106 over 7 days.
- FIG. 15 Inhibition of growth of gliomal cell line U373 by Compound 100 over 7 days.
- FIG. 16 Inhibition of growth of medulloblastoma cell line DAOY by compound 100 over 7 days.
- FIG. 17 Effect of compound 100 on U87 xenograft tumor volume over 26 days.
- FIG. 18 Effect of compound 100 and compound 102 on DAOY xenograft tumor volume over 23 days.
- FIG. 19A Graphical representation (I) and curve fit with IC 50 value (II) of data obtained following exposure of MDA-MB-231 cells to compound 100 and compound 102 using the CellTiter-Glo assay. The effects of 10 ⁇ M doxorubicin that was used as a positive control are also shown in I. Each point represents the mean ⁇ SD of at least triplicate samples.
- FIG. 19B Graphical representation (I) and curve fit with IC 50 value (II) of data obtained following exposure of HT-29 cells to compound 100 and compound 102 using the CellTiter-Glo assay. The effects of 10 ⁇ M doxorubicin that was used as a positive control are also shown in I. Each point represents the mean ⁇ SD of at least triplicate samples.
- FIG. 19C Graphical representation (I) and curve fit with IC 50 value (II) of data obtained following exposure of NCI-H460 cells to compound 100 and compound 102 using the CellTiter-Glo assay. The effects of 10 ⁇ M doxorubicin that was used as a positive control are also shown in I. Each point represents the mean ⁇ SD of at least triplicate samples.
- FIG. 19D Graphical representation (I) and curve fit with IC 50 value (II) of data obtained following exposure of NCI-H522 cells to compound 100 and compound 102 using the CellTiter-Glo assay. The effects of 10 ⁇ M doxorubicin that was used as a positive control are also shown in I. Each point represents the mean ⁇ SD of at least triplicate samples.
- FIG. 19E Graphical representation (I) and curve fit with IC 50 value (II) of data obtained following exposure of NCI-H69 cells to compound 100 and compound 102 using the CellTiter-Glo assay. The effects of 10 ⁇ M doxorubicin that was used as a positive control are also shown in I. Each point represents the mean ⁇ SD of at least triplicate samples.
- FIG. 19F Graphical representation (I) and curve fit with IC 50 value (II) of data obtained following exposure of GXF-209 cells to compound 100 and compound 102 using the CellTiter-Glo assay. The effects of 10M doxorubicin that was used as a positive control are also shown in I. Each point represents the mean ⁇ SD of at least triplicate samples.
- FIG. 19G Graphical representation (I) and curve fit with IC 50 value (II) of data obtained following exposure of HepG2 cells to compound 100 and compound 102 using the CellTiter-Glo assay. The effects of 10 ⁇ M doxorubicin that was used as a positive control are also shown in I. Each point represents the mean ⁇ SD of at least triplicate samples.
- FIG. 19H Graphical representation (I) and curve fit with IC 50 value (II) of data obtained following exposure of OVCAR-3 cells to compound 100 and compound 102 using the CellTiter-Glo assay. The effects of 10 ⁇ M doxorubicin that was used as a positive control are also shown in I. Each point represents the mean ⁇ SD of at least triplicate samples.
- FIG. 19I Graphical representation (I) and curve fit with IC 50 value (II) of data obtained following exposure of PANC-1 cells to compound 100 and compound 102 using the CellTiter-Glo assay. The effects of 10M doxorubicin that was used as a positive control are also shown in I. Each point represents the mean ⁇ SD of at least triplicate samples.
- FIG. 19K Graphical representation (I) and curve fit with IC 50 value (II) of data obtained following exposure of LNCAP cells to compound 100 and compound 102 using the CellTiter-Glo assay. The effects of 10 ⁇ M doxorubicin that was used as a positive control are also shown in I. Each point represents the mean ⁇ SD of at least triplicate samples.
- FIG. 19M Graphical representation (I) and curve fit with IC 50 value (II) of data obtained following exposure of K-562 cells to compound 100 and compound 102 using the CellTiter-Glo assay. The effects of 10 ⁇ M doxorubicin that was used as a positive control are also shown in I. Each point represents the mean ⁇ SD of at least triplicate samples.
- R 1 and R 2 is each independently H, O ⁇ , OR 9 , where R 9 is H, alkyl, alkenyl, alkynyl or aryl, or R 1 and R 2 together are ⁇ O; R 3 and R 4 are each different and each is OH, O ⁇ , OR 9 , SH, S ⁇ , SR 9
- the invention further provides the instant composition, wherein R 1 and R 2 together are ⁇ O; R 3 is O ⁇ or OR 9 , where R 9 is H, methyl, ethyl or phenyl; R 4 is
- the invention further provides the instant composition, wherein R 3 is O ⁇ .
- the invention further provides the instant composition, wherein R 4 is
- the invention provides a compound having the structure (Compound 104)
- the invention provides a compound having the structure (Compound 104E)
- the invention provides a compound having the structure (Compound 106)
- the invention provides a compound having the structure (Compound 106)
- the invention further provides the instant composition, wherein R 4 is
- the invention further provides the instant composition, wherein R 4 is
- the invention further provides the instant composition, wherein R 4 is
- the invention further provides the instant composition, wherein R 4 is
- the invention also provides a compound having the structure
- the invention further provides an embodiment wherein X is NH + R 10 , where R 10 is H, alkyl, substituted C2-C12 alkyl, alkenyl, substituted C4-C12 alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl where the substituent is other than chloro,
- the invention further provides an embodiment, wherein R 10 is methyl.
- the invention further provides an embodiment, wherein R 10 is ethyl.
- the invention further provides an embodiment, wherein R 10 is absent.
- the invention provides the structure
- R 10 is cyclopropyl
- the invention provides the structure
- the invention provides a compound having the structure (Compound 100)
- the invention provides a compound having the structure (Compound 102)
- the invention provides a compound having the structure (Compound 101)
- the invention provides a compound having the structure (Compound 103)
- the invention provides a compound having the structure (Compound 105)
- the invention provides the structure
- R 10 is cyclopropyl
- the invention provides a compound having the structure (Compound 111)
- the invention provides a compound having the structure (Compound 104E)
- the invention provides a compound having the structure (Compound 100E)
- the invention provides a compound having the structure (Compound 102E)
- the invention provides a compound having the structure (Compound 101E)
- the invention provides a compound having the structure (Compound 103E)
- the invention provides a compound having the structure (Compound 105E)
- the invention provides a compound having the structure (Compound 111E)
- This invention provides a compound having the structure (compound 106)
- This invention provides a compound having the structure (compound 106E)
- This invention provides a compound having the structure (compound 108)
- This invention provides a compound having the structure (compound 107E)
- the invention provides a compound having the structure
- a and B is each independently H, F, Cl, Br, SO 2 Ph, CO 2 CH 3 , COR 14 , SR 14 , where R 14 is H or aryl or a substituted or unsubstituted alkyl, alkenyl or alkynyl;
- X is O, NH or S;
- Z is O, S, SR 15 , NH, NR 15 , CH 2 OH, CH 2 OR 15 , where R 15 is an aryl or a substituted or unsubstituted alkyl, alkenyl or alkynyl; and
- Y and W is each independently CHOH CH 2 , C ⁇ S or C ⁇ O, or a salt of the compound.
- Y and W are each independently CH 2 or C ⁇ S.
- the invention further provides an embodiment wherein X is O; Z is S; and Y and W are each C ⁇ S.
- the invention further provides an embodiment wherein A and B are each F.
- the invention further provides an embodiment wherein A is H; and B is F.
- the invention provides a compound having the structure
- A is F or SR 14 , where R 14 is aryl or a substituted or unsubstituted alkyl, alkenyl or alkynyl; and B is F, Cl, Br, SO 2 Ph, CO 2 CH 3 , or SR 14 , where R 14 is aryl or a substituted or unsubstituted alkyl, alkenyl or alkynyl.
- the invention provides the structures
- the invention provides a pharmaceutical composition comprising the compounds of the invention and a pharmaceutically acceptable carrier.
- the invention also provides a process for making a compound having the structure
- the solvent is dimethylformamide (DMF) or ethanol.
- the invention provides a method of treating a patient suffering from a tumor overexpressing N-CoR comprising administering to the patient one or more of the compounds of this invention, alone or in combination with one or more retinoid receptor ligand, or one or more histone deacetylase ligands, or both, in each case in an amount effective to treat the patient.
- the histone deacetylase ligand may be an inhibitor, e.g. the histone deacetylase inhibitor of HDAC-3 (histone deacetylase-3).
- the histone deacetylase ligand may also be selected from the group consisting of 2-amino-8-oxo-9,10-epoxy-decanoyl, 3-(4-aroyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamide, APHA Compound 8, apicidin, arginine butyrate, butyric acid, depsipeptide, depudecin, HDAC-3, m-carboxycinnamic acid bis-hydroxamide, N-(2-aminophenyl)-4-[N-(pyridin-3-ylmethoxycarbonyl) aminomethyl] benzamide, MS 275, oxamfiatin, phenylbutyrate, pyroxamide, scriptaid, sirtinol
- the compounds of this invention may be used in combination with compounds which inhibit the enzyme histone deacetylase (HDAC).
- HDAC histone deacetylase
- Histones are groups of proteins which associate with DNA in eukaryotic cells to form compacted structures called chromatin. This compaction allows an enormous amount of DNA to be located within the nucleus of a eukaryotic cell, but the compact structure of chromatin restricts the access of transcription factors to the DNA. Acetylation of the histones decreases the compaction of the chromatin allowing transcription factors to bind to the DNA.
- HDACs histone deacetylases
- an assessment of the percentage of cells with N-CoR in the cytoplasm relative to the percentage of cells with N-CoR in the nucleus is representative of the ratio of the number of more-differentiated cells to the number of less-differentiated cells in a given tissue.
- tumors that overexpress N-CoR may include glioblastoma multiforme, breast cancer, colorectal cancer, small cell lung cancer or ovarian cancer.
- This invention also provides a method of inhibiting growth of a tumor overexpressing N-CoR in a patient, comprising administering to the patient one or more of the compounds of this invention, alone or in combination with one or more retinoid receptor ligand, one or more histone deacetylase ligand, or both, in each case in amounts effective to affect N-CoR so as to thereby induce differentiation of cells of the tumor overexpressing N-CoR and inhibit growth of the tumor in the patient.
- the compound is selected from Compound 100 and Compound 102.
- an assessment of the percentage of cells with N-CoR in the cytoplasm relative to the percentage of cells with N-CoR in the nucleus is representative of the ratio of the number of more-differentiated cells to ratio of less-differentiated cells in a given tissue.
- tumors that overexpress N-CoR may include glioblastoma multiforme, breast cancer, colorectal cancer, small cell lung cancer or ovarian cancer.
- This invention further contemplates a method of preventing or treating fungal infections in a subject comprising administering to the subject an effective amount of the compounds of this invention.
- This invention further contemplates a method of treating cancer in a subject comprising administering to the subject an effective amount of the compounds of the invention.
- the invention further contemplates the use of prodrugs which are converted in vivo to the compounds of the invention (see, e.g., R. B. Silverman, 1992, “The Organic Chemistry of Drug Design and Drug Action”, Academic Press, Chapter 8, the entire contents of which are hereby incorporated by reference).
- prodrugs can be used to alter the biodistribution (e.g., to allow compounds which would not typically enter a reactive site) or the pharmacokinetics of the compound.
- zwitterion means a compound that is electrically neutral but carries formal positive and negative charges on different atoms. Zwitterions are polar, have high solubility in water and have poor solubility, in most organic solvents.
- Aziridines are organic compounds sharing the aziridine functional group which is a three membered heterocycle with one amine group and two methylene groups.
- Precursors to aziridinyl intermediates include compounds known to those skilled in the art which readily provide aziridinyl intermediates under suitable conditions.
- the compounds described in the present invention are in racemic form or as individual enantiomers.
- the enantiomers can be separated using known techniques, such as those described, for example, in Pure and Applied Chemistry 69, 1469-1474, (1997) IUPAC.
- N-CoR nuclear receptor co-repressor
- the nuclear receptor co-repressor (N-CoR) of the subject invention may be any molecule that binds to the ligand binding domain of the DNA-bound thyroid hormone receptor (T 3 R) and retinoic acid receptor (RAR).
- tumors that overexpress N-CoR may include glioblastoma multiforme, breast cancer (Myers et al.), colorectal cancer (Giannini and Cavallini), small cell lung carcinoma (Waters et al.) or ovarian cancer (Hdressesky et al.).
- solvent as used herein is intended to include compounds such as, hexanes, benzene, toluene, diethyl ether, chloroform, methylene chloride, ethyl acetate, 1,4-dioxane, water, THF, acetone, acetonitrile, DMF, DMSO, acetic acid, n-butanol, isopropanol, n-propanol, ethanol, methanol, formic acid, carbon tetrachloride, benzenethiol, chlorobenzene, cyclohexanethiol, 1-diethylaminoethanol, ethylene dichloride, ethylene glycol, xylene, 1,1,2,2-tetrachloroethane, phenol, acetic acid, 1-butanol, 2-butanol, 2-butanone, diglyme, dimethylether, dioxane, petroleum ether, (NMP) N-methyl
- Certain embodiments of the disclosed compounds can contain a basic functional group, such as amino or alkylamino, and are thus capable of forming pharmaceutically acceptable salts with pharmaceutically acceptable acids, or contain an acidic functional group and are thus capable of forming pharmaceutically acceptable salts with bases.
- the instant compounds therefore may be in a salt form.
- a “salt” is a salt of the instant compounds which has been modified by making acid or base salts of the compounds.
- the salt may be pharmaceutically acceptable.
- Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as phenols.
- the salts can be made using an organic or inorganic acid.
- Such acid salts are chlorides, bromides, sulfates, nitrates, phosphates, sulfonates, formates, tartrates, maleates, malates, citrates, benzoates, salicylates, ascorbates, and the like.
- Phenolate salts are the alkaline earth metal salts, sodium, potassium or lithium.
- pharmaceutically acceptable salt in this respect, refers to the relatively non-toxic, inorganic and organic acid or base addition salts of compounds of the present invention.
- salts can be prepared in situ during the final isolation and purification of the compounds of the invention, or by separately reacting a purified compound of the invention in its free base or free acid form with a suitable organic or inorganic acid or base, and isolating the salt thus formed.
- Representative salts include the hydrobromide, hydrochloride, sulfate, bisulfate, phosphate, nitrate, acetate, valerate, oleate, palmitate, stearate, laurate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, napthylate, mesylate, glucoheptonate, lactobionate, and laurylsulphonate salts and the like.
- suitable salts see, e.g., Berge et al. (1977) “Pharmaceutical Salts”, J. Pharm. Sci. 66:1-19.
- terapéuticaally effective amount means an amount sufficient to treat a subject afflicted with a disease (e.g. tumors overexpressing N-CoR) or to alleviate a symptom or a complication associated with the disease.
- “herbicidally effective” means an amount sufficient to adversely affect plant growth, particularly through inhibition of plant phosphatase 2 A activity.
- treating means slowing, stopping or reversing the progression of a disease, particularly tumors overexpressing N-CoR.
- alkyl is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms.
- C 1 -C n as in “C 1 -C n alkyl” is defined to include groups having 1, 2, . . . , n ⁇ 1 or n carbons in a linear or branched arrangement, and specifically includes methyl, ethyl, propyl, butyl, pentyl, hexyl, and so on.
- An embodiment can be C 1 -C 12 alkyl.
- Alkoxy represents an alkyl group as described above attached through an oxygen bridge.
- alkenyl refers to a non-aromatic hydrocarbon radical, straight or branched, containing at least 1 carbon to carbon double bond, and up to the maximum possible number of non-aromatic carbon-carbon double bonds may be present.
- C 2 -C n alkenyl is defined to include groups having 1, 2, . . . , n ⁇ 1 or n carbons.
- C 2 -C 6 alkenyl means an alkenyl radical having 2, 3, 4, 5, or 6 carbon atoms, and at least 1 carbon-carbon double bond, and up to, for example, 3 carbon-carbon double bonds in the case of a C 6 alkenyl, respectively.
- Alkenyl groups include ethenyl, propenyl, butenyl and cyclohexenyl. As described above with respect to alkyl, the straight, branched or cyclic portion of the alkenyl group may contain double bonds and may be substituted if a substituted alkenyl group is indicated. An embodiment can be C 2 -C 12 alkenyl.
- alkynyl refers to a hydrocarbon radical straight or branched, containing at least 1 carbon to carbon triple bond, and up to the maximum possible number of non-aromatic carbon-carbon triple bonds may be present.
- C 2 -C n alkynyl is defined to include groups having 1, 2, . . . , n ⁇ 1 or n carbons.
- C 2 -C 6 alkynyl means an alkynyl radical having 2 or 3 carbon atoms, and 1 carbon-carbon triple bond, or having 4 or 5 carbon atoms, and up to 2 carbon-carbon triple bonds, or having 6 carbon atoms, and up to 3 carbon-carbon triple bonds.
- Alkynyl groups include ethynyl, propynyl and butynyl. As described above with respect to alkyl, the straight or branched portion of the alkynyl group may contain triple bonds and may be substituted if a substituted alkynyl group is indicated. An embodiment can be a C 2 -C n alkynyl.
- aryl is intended to mean any stable monocyclic or bicyclic carbon ring of up to 10 atoms in each ring, wherein at least one ring is aromatic.
- aryl elements include phenyl, naphthyl, tetrahydro-naphthyl, indanyl, biphenyl, phenanthryl, anthryl or acenaphthyl.
- the aryl substituent is bicyclic and one ring is non-aromatic, it is understood that attachment is via the aromatic ring.
- the substituted aryls included in this invention include substitution at any suitable position with amines, substituted amines, alkylamines, hydroxys and alkylhydroxys, wherein the “alkyl” portion of the alkylamines and alkylhydroxys is a C 2 -C n alkyl as defined hereinabove.
- the substituted amines may be substituted with alkyl, alkenyl, alkynl, or aryl groups as hereinabove defined.
- alkyl, alkenyl, alkynyl, and aryl substituents may be unsubstituted or unsubstituted, unless specifically defined otherwise.
- a (C 1 -C 6 ) alkyl may be substituted with one or more substituents selected from OH, oxo, halogen, alkoxy, dialkylamino, or heterocyclyl, such as morpholinyl, piperidinyl, and so on.
- alkyl, alkenyl, and alkynyl groups can be further substituted by replacing one or more hydrogen atoms by non-hydrogen groups described herein to the extent possible.
- non-hydrogen groups include, but are not limited to, halo, hydroxy, mercapto, amino, carboxy, cyano and carbamoyl.
- substituted means that a given structure has a substituent which can be an alkyl, alkenyl, or aryl group as defined above.
- the term shall be deemed to include multiple degrees of substitution by a named substitutent.
- the substituted compound can be independently substituted by one or more of the disclosed or claimed substituent moieties, singly or plurally.
- independently substituted it is meant that the (two or more) substituents can be the same or different.
- administering an agent may be performed using any of the various methods or delivery systems well known to those skilled in the art.
- the administering can be performed, for example, orally, parenterally, intraperitoneally, intravenously, intraarterially, transdermally, sublingually, intramuscularly, rectally, transbuccally, intranasally, liposomally, via inhalation, vaginally, intraoccularly, via local delivery, subcutaneously, intraadiposally, intraarticularly, intrathecally, into a cerebral ventricle, intraventicularly, intratumorally, into cerebral parenchyma or intraparenchchymally.
- compositions in accordance with the invention may be used but are only representative of the many possible systems envisioned for administering compositions in accordance with the invention.
- Injectable drug delivery systems include solutions, suspensions, gels, microspheres and polymeric injectables, and can comprise excipients such as solubility-altering agents (e.g., ethanol, propylene glycol and sucrose) and polymers (e.g., polycaprylactones and PLGA's).
- solubility-altering agents e.g., ethanol, propylene glycol and sucrose
- polymers e.g., polycaprylactones and PLGA's.
- Implantable systems include rods and discs, and can contain excipients such as PLGA and polycaprylactone.
- Oral delivery systems include tablets and capsules. These can contain excipients such as binders (e.g., hydroxypropylmethylcellulose, polyvinyl pyrilodone, other cellulosic materials and starch), diluents (e.g., lactose and other sugars, starch, dicalcium phosphate and cellulosic materials), disintegrating agents (e.g., starch polymers and cellulosic materials) and lubricating agents (e.g., stearates and talc).
- excipients such as binders (e.g., hydroxypropylmethylcellulose, polyvinyl pyrilodone, other cellulosic materials and starch), diluents (e.g., lactose and other sugars, starch, dicalcium phosphate and cellulosic materials), disintegrating agents (e.g., starch polymers and cellulosic materials) and lubricating agents (e.
- Transmucosal delivery systems include patches, tablets, suppositories, pessaries, gels and creams, and can contain excipients such as solubilizers and enhancers (e.g., propylene glycol, bile salts and amino acids), and other vehicles (e.g., polyethylene glycol, fatty acid esters and derivatives, and hydrophilic polymers such as hydroxypropylmethylcellulose and hyaluronic acid).
- solubilizers and enhancers e.g., propylene glycol, bile salts and amino acids
- other vehicles e.g., polyethylene glycol, fatty acid esters and derivatives, and hydrophilic polymers such as hydroxypropylmethylcellulose and hyaluronic acid.
- Dermal delivery systems include, for example, aqueous and nonaqueous gels, creams, multiple emulsions, microemulsions, Liposomes, ointments, aqueous and nonaqueous solutions, lotions, aerosols, hydrocarbon bases and powders, and can contain excipients such as solubilizers, permeation enhancers (e.g., fatty acids, fatty acid esters, fatty alcohols and amino acids), and hydrophilic polymers (e.g., polycarbophil and polyvinylpyrolidone).
- the pharmaceutically acceptable carrier is a liposome or a transdermal enhancer.
- Solutions, suspensions and powders for reconstitutable delivery systems include vehicles such as suspending agents (e.g., gums, zanthans, cellulosics and sugars), humectants (e.g., sorbitol), solubilizers (e.g., ethanol, water, PEG and propylene glycol), surfactants (e.g., sodium lauryl sulfate, Spans, Tweens, and cetyl pyridine), preservatives and antioxidants (e.g., parabens, vitamins E and C, and ascorbic acid), anti-caking agents, coating agents, and chelating agents (e.g., EDTA).
- suspending agents e.g., gums, zanthans, cellulosics and sugars
- humectants e.g., sorbitol
- solubilizers e.g., ethanol, water, PEG and propylene glycol
- substituents and substitution patterns on the compounds of the instant invention can be selected by one of ordinary skill in the art to provide compounds that are chemically stable and that can be readily synthesized by techniques known in the art, as well as those methods set forth below, from readily available starting materials. If a substituent is itself substituted with more than one group, it is understood that these multiple groups may be on the same carbon or on different carbons, so long as a stable structure results.
- N-CoR nuclear receptor co-repressor
- N-CoR is expressed in the nucleus of neural stem cells (NSCs).
- NSCs neural stem cells
- N-CoR Following phosphatidyl-inositol-3-OH kinase/Akt1 kinase-dependent phosphorylation, N-CoR translocates to the cytoplasm and leads to astrocytic differentiation of NSCs.
- the nuclear retention of N-CoR therefore, is essential for the maintenance of NSCs in the undifferentiated state (Hermanson et al.).
- BTSC brain tumor stem cells
- BTSC are capable of proliferation, self-renewal, and differentiation.
- BTSC but not CD133 ⁇ differentiated tumor cells, are able to recapitulate tumors upon xenograft transplantation.
- N-CoR is closely associated with the retinoid receptor and is released upon ligand binding to the receptor.
- Bastien et al. (2004) We hypothesized that one effect of retinoids on malignant gliomas may be the induction of differentiation by the binding of retinoids to the retinoid receptor followed by dissociation of the N-CoR/retinoid receptor complex and translocation of N-CoR to the cytoplasm. This idea would explain the previous observation of increase GFAP expression in a glioma cell line (U343 MG-A) treated with retinoids.
- Cell line U343 MG-A is available from the University of California at San Francisco (UCSF) Brain Tumor Research Center Tissue Bank. (University of California, San Francisco, Health Sciences West building, San Francisco, Calif. 94143-0520.) In addition, cell lines U343 and U87 are commercially available from EPO-GmbH, Robert-R ⁇ hacek over (o) ⁇ ssle-Str. 10, 13092 Berlin-Buch, Germany.
- Cantharidin has anti-tumor activity against human cancers of the liver (hepatomas) and of the upper gastrointestinal tract but is toxic to the urinary tract (Wang, 1989).
- Norcantharidin a demethylated cantharidin, maintains antitumor activity of cantharidin against hepatomas and cancers of the stomach and esophagus, but has little or no urinary tract toxicity.
- Norcantharidin also stimulates white blood cell production in patients and mice, a phenomenon not understood mechanistically, but a pharmacological effect of potential benefit as an anticancer agent (Wang et al., 1986; Wang, 1989).
- cantharidin analogues had been previously synthesized and evaluated as pesticides and for antitumor activity against cancer cell lines. Forty-three analogues of endothal and cantharidin have been developed and assessed for their activity as herbicides and their lethality to mice (Matsuzawa et al., 1987). Endothal thioanhydride was shown to be a more potent herbicide than endothal but was toxic to the liver of mice (Matsuzawa et al., 1987; Kawamura et al., 1990).
- endothal thioanhydride is an active agent against PP2A and PP1 in vivo (Erdodi et al., 1995). Endothal and endothal thioanhydride, like cantharidin, inhibit the activity of PP2A and to some extent, the activity of PP1 (Erdodi et al., 1995). In the liver, the principal target appears to be PP1. In fibroblasts, only endothal thioanhydride caused marked morphological changes whereas cantharidin and endothal did not (Erdodi et al., 1995).
- endothal thioanhydride in vivo is thought to be related to its enhanced lipophilicity resulting in increased diffusion across the plasmalemma (Essers et al., 2001).
- a more recent publication has described the synthesis of the mono-, and the di-fluoro analogues of Endothal and also the corresponding anhydrides, however no pharmacological data accompanied this synthetic work (Essers et al., 2001).
- the compounds described herein have an antagonistic effect on phosphatase-2A and phosphatase 1.
- Compounds 100, 105, and 102 are effective in inhibiting the growth of cells of tumors overexpressing N-CoR.
- Compounds 100 and 105 are advantageous over other cantharidin homologs as they exist as zwitterions, which renders them water soluble and stable at acid pH, features desirable for orally effective drugs.
- Compound 102 is lipid soluble, which affords a greater ability than Compounds 100 and 105 to cross the blood-brain barrier. This is especially important when treating such tumors as glioblastoma multiforme.
- Compound 100 norcantharidin (nor-Can), endothal (End), and endothal thioanhydride (ET) were evaluated for their ability to inhibit the growth of GBMs in a dose dependent manner in vivo as shown in FIG. 1 .
- retinoids synergistically inhibit the proliferation of glioblastoma multiforme.
- Synergism (potentiation) of the inhibitory activity of two drugs in combination is said to be present when the percent survival in the presence of two drugs is greater than the sum of the percent survivals of the two drugs used alone at the same doses in the combination.
- the inhibitory activity of Compound 100 was further evaluated in combination with retinoids as well as individually. As shown in FIG. 2 , the combination of Compound 100 with all-trans retinoic acid (ATRA) demonstrated a synergistic reduction in cell growth.
- ATRA all-trans retinoic acid
- the expected percent survival in the presence of the combination of ATRA and Compound 100 is 60% (77% by ATRA ⁇ 78% by Compound 100-60%), whereas the observed survival was 53%.
- retinoic acid and Trichostatin A we measured their inhibitory effects as single agents against the GBM line U373, a breast cancer line, MCF-7 (obtained from ATCC) and a kidney cancer cell line, UMRC (UMRC obtained by Dr. Zhuang, NINDS, NIH from the Intramural Research Support Program, SAIC, National Cancer Institute, Frederick Cancer Research and Development Center).
- the kidney cancer cell line, UMRC ( FIG. 3 ) was less sensitive than the brain tumor line, U373 ( FIG. 4 ) whereas the breast cancer line, MCF-7 ( FIG. 5 ) was as sensitive as U373 to all-trans retinoic acid, endothal thioanhydride, norcantharidin, endothal, and Trichostatin A.
- MCF-7 ( FIG. 5 ) was as sensitive as U373 to all-trans retinoic acid, endothal thioanhydride, norcantharidin, endothal, and Trichostatin A.
- GBMs cell type specificity of these drugs for GBMs.
- the activity of the drugs against MCF-7 cells indicates that regimens being developed for brain tumor treatment are likely also useful against breast cancer and other tumors that overexpress N-CoR.
- Compound 100 will have similar inhibitory effects in the treatment of breast cancer and other tumors that overexpress N-CoR due to the structural similarities of Compound 100 to endothal as well as their similar effects in the treatment of glioblastoma multiforme.
- Endothal is also known as an active defoliant and potent contact herbicide used in many agricultural situations. It is considered effective as a pre-harvest desiccant and as a selective pre-emergence herbicide (Crafts, 1953).
- Endothal, norcantharidins and cantharidin are all well known inhibitors of mammalian protein phosphatase as well as potent herbicides (Matsuzawa et al., 1987). The mechanism by which endothal and other homologs exert their potent herbicidal activity has not been studied extensively despite the widespread use of endothal internationally in agriculture. It should be noted that endothal is water soluble where cantharidin and norcantharidin are not.
- endothal As a contact herbicide and defoliant is related to the known irritating toxicity of its parent compound, norcantharidin.
- the herbicidal activity of endothal may be a function primarily of its anti-plant protein phosphatase (PP2A) activity.
- PP2A anti-plant protein phosphatase
- Li et al. (1993) showed that cantharidin and endothal inhibit spinach leaf PP2A and PP1 and inhibit the activation of nitrate reductase by light in the intact spinach leaf, a process mediated by PP2A. Smith et al.
- Baskin and Wilson showed inhibitors of serine-threonine protein phosphatases including cantharidin inhibit organization of plant microtubules.
- Ayaydin et al. (2000) show that endothal inhibited PP2A activity causing alteration of cell division in cultured alfalfa cells. They noted that endothal was cell permeable.
- Compounds 100 and 105 do not have the acidic character of endothal.
- Endothall anhydride (85 mg) (5) prepared as described above was dissolved in benzene (2 mL) and N-methylpiperazine (60 mg)(6) was added in one portion at room temperature. Almost immediately a white crystalline appeared. The mixture was left at room temperature overnight and the product was then removed by filtration washed with a little benzene then dried (145 mg). A negative ion mass spectrum showed a parent ion at m/z 267 (theo. 267) confirming the molecular weight as 268 mass units. The product was recrystallized from hot DMF to give 95 mg of the pure monoamide, Compound 100 (1) m.p. 226-227° C. with some decomposition beginning at 224° C.
- Mass spectrometry data measuring the mass to charge ratio of compound 102 showed peaks at 141.1 m/z, 185 m/z, and 354 m/z.
- Endothal anhydride (1) 500 mg, 3 mmole
- amine (4) (2.34 g, 10 mmole) were added to dry toluene (8 mL) and heated at 100° C. for 20 h. The solvent was then evaporated under reduced pressure and the residue was taken in water and the solution was acidified to pH to 5.5 to 6 with dilute HCl. The solid which was filtered and recrystallized from methanol to give pure (5) (compound 104). Yield 450 mg (36%). Mp 140-142° C. The mass spectrum and the 1 HNMR data confirmed the identity of compound 104. Mass spectrometry data measuring the mass to charge ratio of compound 104 showed peaks at 385.
- Table 1 shows the correlation between the mass to charge ratio of the ions and corresponding structures.
- a sample of the compound 100 was ionized in the mass spectrometer. Ions of different masses were separated and their relative abundance was measured
- Table 2 shows the correlation between the mass to charge ratio of the ions and corresponding structures.
- a sample of the compound 105 was ionized in the mass spectrometer. Ions of different masses were separated and their relative abundance was measured
- GBM glioblastoma multiforme
- cantharidin analogues were evaluated for their ability to inhibit growth of glioblastoma multiforme cells.
- GBM cell line U373 was used in evaluations.
- Cells were plated in triplicate on day one with and without different amounts of each drug dissolved in media (Compound 100, Compound 105, and endothal) or in dimethylsulfoxide (endothal thioanhydride and norcantharidin). The total number of cells is counted in the triplicate cultures at each dose and in controls after 7 days and the average number of cells and the standard deviation is determined.
- the amount of inhibition of GBM cell growth is expressed as the proportion of the number of cells in the experimental dishes compared to the number of cells in control dishes containing only the drug vehicle and culture medium.
- the average percent of control is plotted and bracketed by one standard deviation calculated from the triplicate measurements.
- Each of the norcantharidin analogues inhibited the growth of GBMs in a dose dependent manner in vivo as shown in FIG. 1 .
- IC50 concentration of each compound that inhibited brain tumor cell proliferation by 50%
- IC50s expressed in micro-molarity (uM) were: 2.5, 3.0, 12.0, and 15.0 for endothal thioanhydride, Compound 100, norcantharidin, and endothal respectively as seen in FIG. 1 .
- FIG. 8 is a dose-response curve for compound 105 against the human GBM cell growth over seven days at various concentrations of compound 105. It should be noted that Compound 100 was included at a single concentration of 10 ⁇ M and that at this concentration the two compounds have identical inhibitory values.
- Cells were plated in triplicate on day one with and without different amounts of each drug dissolved in media (Compound 100 and endothal). The total number of cells is counted in the triplicate cultures at each dose and in controls after 7 days and the average number of cells and the standard deviation is determined.
- the amount of inhibition of GBM cell growth is expressed as the proportion of the number of cells in the experimental dishes compared to the number of cells in control dishes containing only the drug vehicle and culture medium.
- the average percent of control is plotted and bracketed by one standard deviation calculated from the triplicate measurements.
- FIG. 2 shows that Compound 100 as well as Endothal, each in combination with ATRA, synergistically inhibited proliferation of GBM cell line U373.
- Synergism (potentiation) of the inhibitory activity of two drugs in combination is said to be present when the percent survival in the presence of two drugs is less than the product of the percent survivals of the two drugs used alone at the same doses in the combination.
- the extent of synergism of Compound 100 and endothal (end) in combination with ATRA is quantified below in Table 3.
- Compound 100 when combined with Trichostatin A or when combined with 13-cis retinoic acid synergistically inhibited the growth of GBM cell line U373 as shown below in Table 4.
- the kidney cancer cell line, UMRC ( FIG. 3 ) was less sensitive than the brain tumor line, U373 ( FIG. 4 ) whereas the breast cancer line, MCF-7 ( FIG. 5 ) was as sensitive as U373 to all-trans retinoic acid, endothal thioanhydride, norcantharidin, endothal, and Trichostatin A.
- MCF-7 ( FIG. 5 ) was as sensitive as U373 to all-trans retinoic acid, endothal thioanhydride, norcantharidin, endothal, and Trichostatin A.
- GBMs cell type specificity of these drugs for GBMs.
- the activity of the drugs against MCF-7 cells indicates that regimens being developed for brain tumor treatment may also be useful against breast cancer as well as other tumors that overexpress N-CoR.
- the compound 100 suppresses the growth of the GBM cell line U87 growing subcutaneously in SCID mice ( FIG. 17 ). It is also demonstrated the compound 100 and compound 102 both inhibit the proliferation of DAOY cells when implanted subcutaneously in SCID mice ( FIG. 18 ).
- the adherent cell lines MDA-MB-231, HT-29, NCI-H460, NCI-H522, GXF-209, HepG2, OVAR-3, PANC-1, DU-145, and LNCAP cells were each seeded into two 96-well plates at 2,500 cells per well in a total volume of 50 uL and incubated in a 37° C. humidified 5% CO 2 cell culture incubator overnight.
- the suspension cell lines NCI-H69, HL-60, K-562, and MOLT-4 were each seeded into two 96-well plates at 10,000 cell per well in a total volume of 50 uL and incubated in a 37° C. humidified 5% CO 2 incubator overnight.
- a total of 23 isolates were tested to include 3 Candida albicans, 3 Candida glabrata, 3 Cryptococcus neoformans, 3 Aspergillus fumigatus, 3 Rhizopus oryzae, 3, Fusarium solani, 3 Pseudallescheria boydii , and 2 Trichosporon rubrum . All isolates were clinical isolates submitted to the Fungus Testing Laboratory for evaluation.
- Antifungal susceptibility testing was accomplished according to the methods outlined in the National Committee for Clinical Laboratory Standards, M-27A2, Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard, and M38-A “Reference Method for Broth Dilution Antifungal Susceptibility Testing of Conidium-Forming Filamentous Fungi; Approved Standard”. This includes testing in RPMI-1640 with glutamine and without bicarbonate, an inoculum size of 0.5-2.5 ⁇ 10 3 for yeasts or 1-5 ⁇ 10 4 for moulds, and incubation at 35° C. for 24 and 48 hours. The minimum inhibitory concentration (MIC) was defined as the lowest concentration that resulted in an 50% reduction in turbidity as compared to a drug-free control tube for the yeast and 80% inhibition for the moulds.
- MIC minimum inhibitory concentration
- this compound may be a viable contender for dermatophytic infections caused by Trichosporon rubrum .
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Dentistry (AREA)
- Environmental Sciences (AREA)
- Agronomy & Crop Science (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
-
- wherein
- bond α is present or absent;
- R1 and R2 is each independently H, O−, or OR9,
- where R9 is H, alkyl, alkenyl, alkynyl or aryl, or R1 and R2 together are ═O;
- R3 and R4 are each different and each is OH, O−, OR9, SH, S−, SR9
-
-
- where X is O, S, NR10, or N+R10R10,
- where each R10 is independently alkyl, substituted C2-C12 alkyl, alkenyl, substituted C4-C12 alkenyl, alkynyl, substituted alkynl, aryl, substituted aryl where the substituent is other than chloro when R1 and R2 are ═O,
- where X is O, S, NR10, or N+R10R10,
-
-
-
-
- —CH2CN, —CH2CO2R11, —CH2COR11, —NHR11, or —NH*(R11)2, wherein R11 is alkyl, alkenyl or alkynyl, each of which is substituted or unsubstituted, or H;
-
- R5 and R6 is each independently H, OH, or R5 and R6 taken together are ═O; and
- R7 and R8 is each independently H, F, Cl, Br, SO2Ph, CO2CH3, or SR12,
- where R12 is H, aryl or a substituted or unsubstituted alkyl, alkenyl or alkynyl,
- or a salt, enantiomer or zwitterion of the compound.
-
-
- wherein
- bond α is present or absent;
- R9 is present or absent and when present is H, alkyl, alkenyl, alkynyl or phenyl; and
- X is O, NR10, or NH+R10,
- where each R10 is independently H, alkyl, substituted C2-C12 alkyl, alkenyl, substituted C4-C12 alkenyl, alkynyl, substituted alkynl, aryl, substituted aryl where the substitutent is other than chloro,
-
-
-
- —CH2CN, —CH2CO2R12, or —CH2COR12, where R12 is H or alkyl,
-
- or a salt, zwitterions, or enantiomer of the compound.
-
-
- where R14 is H or aryl or a substituted or unsubstituted alkyl, alkenyl or alkynyl;
X is O, NH or S;
Z is O, S, SR15, NH, NR15, CH2OH, CH2OR15, - where R15 is an aryl or a substituted or unsubstituted alkyl, alkenyl or alkynyl; and
Y and W is each independently CH2, CHOH, C═O, or C═S,
or a salt of the compound.
- where R14 is H or aryl or a substituted or unsubstituted alkyl, alkenyl or alkynyl;
wherein bond α is present or absent; R1 and R2 is each independently H, O−, OR9, where R9 is H, alkyl, alkenyl, alkynyl or aryl, or R1 and R2 together are ═O; R3 and R4 are each different and each is OH, O−, OR9, SH, S−, SR9
where X is O, S, NR10, N+R10R10, where each R10 is independently alkyl, substituted C2-C12 alkyl, alkenyl, substituted C4-C12 alkenyl, alkynyl, substituted alkynl, aryl, substituted aryl where the substituent is other than chloro when R1 and R2 are ═O,
-
- —CH2CN, —CH2CO2R11, —CH2COR11, —NHR11, —NH+(R11)2 wherein each R11 is independently alkyl, alkenyl or alkynyl, each of which is substituted or unsubstituted, or H;
R5 and R6 is each independently H, OH, or R5 and R6 taken together are ═O; and R7 and R8 is each independently H, F, Cl, Br, SO2Ph, CO2CH3, CN, COR12, or SR12, where R12 is H, aryl or a substituted or unsubstituted alkyl, alkenyl or alkynyl, or a salt, enantiomer or zwitterion of the compound.
- —CH2CN, —CH2CO2R11, —CH2COR11, —NHR11, —NH+(R11)2 wherein each R11 is independently alkyl, alkenyl or alkynyl, each of which is substituted or unsubstituted, or H;
-
- where X is O, S, NR10 or N+R10R10,
- where each R10 is independently H, alkyl, substituted C2-C12 alkyl, alkenyl, substituted C4-C12 alkenyl, alkynyl, substituted alkynl, aryl, substituted aryl where the substituent is other than chloro when R1 and R2 are ═O,
-
- —CH2CN, —CH2CO2R11, —CH2COR11, —NHR11, —NH+(R11)2 where R11 is alkyl, alkenyl or alkynl, each of which is substituted or unsubstituted, or H;
R5 and R6 taken together are ═O; and R7 and R8 is each independently H, F, Cl, Br, SO2Ph, CO2CH3, CN, COR12, or SR12, where R12 is H or a substituted or unsubstituted alkyl, alkenyl or alkynyl.
- —CH2CN, —CH2CO2R11, —CH2COR11, —NHR11, —NH+(R11)2 where R11 is alkyl, alkenyl or alkynl, each of which is substituted or unsubstituted, or H;
where X is O, NR10, or N+R10R10, where each R10 is independently H, alkyl, substituted C2-C12 alkyl, alkenyl, substituted C4-C12 alkenyl, alkynyl, substituted alkynyl,
where R10H, alkyl, substituted C2-C12 alkyl, alkenyl, substituted C4-C12 alkenyl, alkynyl, substituted alkynyl, substituted aryl where the substituent is other than chloro when R1 and R2 are ═O,
-
- —CH2CN, —CH2CO2R11, —CH2COR11, —NHR11, or NH+(R11)2, where R11 is H or alkyl.
-
- wherein bond α is present or absent; R9 is present or absent and when present is H, C1-C10 alkyl, C2-C10 alkenyl or phenyl; and X is O, S, NR10 or N+R10R10, where each R10 is independently alkyl, C2-C12 substituted alkyl, alkenyl, C4-C12 substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl where the substitutent is other than chloro,
—CH2CO2R11, —CH2COR11, —CH2CN, or —CH2CH2R16, where R11 is H or alkyl, and where R16 is any substitutent that is a precursor to an aziridinyl intermediate, or a salt, enantiomer or zwitterion of the compound.
-
- wherein, bond α is present or absent; X is O, S, NR10 or N+R10R10, where each R10 is independently H, alkyl, C2-C12 substituted alkyl, alkenyl, C4-C12 substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl where the substitutent is other than chloro,
-
-
- —CH2CO2R11, —CH2COR11, —CH2CN, or —CH2CH2R16, where R11 is H or alkyl, and where R16 is any substitutent that is a precursor to an aziridinyl intermediate,
or a salt, enantiomer or zwitterion of the compound.
- —CH2CO2R11, —CH2COR11, —CH2CN, or —CH2CH2R16, where R11 is H or alkyl, and where R16 is any substitutent that is a precursor to an aziridinyl intermediate,
- The invention further provides an embodiment wherein X is O or NH+R10, where R10 is H, alkyl, C2-C12 substituted alkyl, alkenyl, C4-C12 substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl where the substitutent is other than chloro,
-
-
- —CH2CO2R11, —CH2COR11, —CH2CN, or —CH2CH2R16, where R11 is H or alkyl, and where R16 is any substitutent that is a precursor to an aziridinyl intermediate.
-
- wherein R9 is present or absent and when present is H, alkyl, alkenyl, alkynyl or phenyl; and X is O, NR10 or N+R10R10, where each R10 is independently alkyl, C2-C12 substituted alkyl, alkenyl, C4-C12 substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl where the substitutent is other than chloro,
-
-
- —CH2CO2R11, —CH2COR11, or —CH2CN, where R11 is H or alkyl,
or a salt, zwitterion or enantiomer of the compound.
- —CH2CO2R11, —CH2COR11, or —CH2CN, where R11 is H or alkyl,
-
-
- wherein X is O or NH+R10, where R10 is present or absent and when present is alkyl, alkenyl or alkynyl, each of which is substituted or unsubstituted,
-
-
- —CH2CO2R11, —CH2COR11, or —CH2CN, where R11 is H or alkyl.
-
-
- wherein X is O, NR10 or NH+R10,
- wherein R9 is alkyl, alkenyl, alkynyl or aryl, and
- where R10 is present or absent and when present is alkyl, alkenyl or alkynyl, each of which is substituted or unsubstituted,
wherein A and B is each independently H, F, Cl, Br, SO2Ph, CO2CH3, COR14, SR14, where R14 is H or aryl or a substituted or unsubstituted alkyl, alkenyl or alkynyl; X is O, NH or S; Z is O, S, SR15, NH, NR15, CH2OH, CH2OR15, where R15 is an aryl or a substituted or unsubstituted alkyl, alkenyl or alkynyl; and Y and W is each independently CHOH CH2, C═S or C═O, or a salt of the compound.
wherein A is F or SR14, where R14 is aryl or a substituted or unsubstituted alkyl, alkenyl or alkynyl; and B is F, Cl, Br, SO2Ph, CO2CH3, or SR14, where R14 is aryl or a substituted or unsubstituted alkyl, alkenyl or alkynyl.
- The invention also provides a process for making a compound comprising reacting a compound having the structure
-
- with a compound having the structure
-
- to form a compound having the following structure
-
- reacting a compound having the above structure with hydrogen in the presence of a catalyst to form
- The invention also provides a process for making a compound comprising reacting a compound having the structure
-
- with a compound having the structure
-
- to form a compound having the following structure
-
- reacting a compound having the above structure with hydrogen in the presence of a catalyst a catalyst to form
-
- dissolving a compound having the following structure
-
- in benzene and adding a compound having the structure
-
- at room temperature to produce a compound having the structure
-
- and recrystallizing the compound produced from a hot solvent.
-
- dissolving a compound having the following structure
-
- in benzene and adding a compound having the structure
-
- at room temperature to produce a compound having the structure
-
- recrystallizing the compound produced from a hot solvent.
TABLE 1 |
Mass to Charge Ratio of Ions |
Mass to Charge Ratio (m/z) | Theoretical Structure of Ions | |
141 |
|
|
167 |
|
|
254 |
|
|
199 |
|
|
185 |
|
|
TABLE 2 |
Mass to Charge Ratio of Ions |
Mass to Charge Ratio (m/z) | Theoretical Structure of Ions |
141 |
|
167 |
|
249 |
|
199 |
|
185 |
|
TABLE 3 |
Endothal and |
Percent of Control |
Expected if | |||
Observed | Additive | ||
ATRA 25 uM | 77% | — |
END 10 uM | 65% | — |
ATRA 25 uM + |
32% | 50 |
Compound | ||
100 1 uM | 78% | — |
ATRA 25 uM + |
53% | 60% |
TABLE 4 |
|
Trichostatin A (TSA) Inhibition of GBM Cell Line U373 |
Percent of Control |
Expected If | |||
Observed | Additive | ||
Cis- |
93.3 +/− 2.2 | |
TSA 0.033 μM (0.01 μg/ml) | 71.6 +/− 0.4 | |
Compound 100 - 1 μM | 97.9 +/− 1.0 | |
Compound 100 - 5 μM | 52.5 +/− 2.9 | |
Cis- |
79.3 +/− 3.2 | 91.3 |
Cis- |
31.6 +/− 2.0 | 49.0 |
TSA 0.033 μM + Compound 100 - 1 μM | 65.7 +/− 2.0 | 70.1 |
TSA 0.033 μM + Compound 100 - 5 μM | 13.9 +/− 1.0 | 37.6 |
- TABLE 5: The Concentration of
Compound FIGS. 19A-N )
Cell Line | IC50 μM |
Cancer Type | Compound-100 | Compound-102 | ||
MDA-MB-231 | 9.5 | 6.6 | ||
Breast | ||||
HT-29 | 5.3 | 3.6 | ||
Colon | ||||
NCI-H460- | 24.3 | 17.5 | ||
Lung: large | ||||
cell | ||||
NCI-H522 Lung | 3.4 | 2.2 | ||
adenoca | ||||
NCI-H69 | 23.9 | 24.6 | ||
Lung small | ||||
cell | ||||
GXF-209 | 7.9 | 5.3 | ||
Stomach | ||||
HepG2 | 31.6 | 22.1 | ||
Liver | ||||
OVCAR-3 Ovary | 2.9 | 5.1 | ||
adenoca | ||||
PANC-1 | 25.1 | 20.7 | ||
Pancreas | ||||
DU-145 | 16.4 | 13.0 | ||
Prostate | ||||
LNCAP | 1.5 | 0.48 | ||
Prostate | ||||
HL-60 | 7.7 | 6.5 | ||
Leukemia | ||||
promyelocytic | ||||
K-562 | 10.7 | 13.7 | ||
Leukemia | ||||
chronic myelo | ||||
MOLT-4 | 5.7 | 5.6 | ||
acute lympho | ||||
TABLE 6 | |||||
Com- | Com- | Com- | Com- | ||
pound | pound | pound | pound | ||
100/24 | 100/48 | 102/24 | 102/48 | ||
Hours | Hours | Hours | Hours | ||
CP | Control | >64 | >64 | >64 | >64 |
07-3006 | C. albicans | >64 | >64 | >64 | >64 |
07-3011 | C. albicans | >64 | >64 | >64 | >64 |
07-3012 | C. albicans | >64 | >64 | >64 | >64 |
07-2964 | C. glabrata | >64 | >64 | >64 | >64 |
07-2965 | C. glabrata | >64 | >64 | >64 | >64 |
07-3013 | C. glabrata | >64 | >64 | >64 | >64 |
07-2665 | C. neoformans | >64 | >64 | >64 | >64 |
07-2737 | C. neoformans | >64 | >64 | >64 | >64 |
07-2829 | C. neoformans | >64 | >64 | >64 | >64 |
07-1870 | R. arrhizus | >64 | >64 | >64 | >64 |
07-2044 | R. arrhizus | >64 | >64 | >64 | >64 |
07-2078 | R. arrhizus | >64 | >64 | >64 | >64 |
07-1399 | F. solani | >64 | >64 | >64 | >64 |
07-1755 | F. solani | >64 | >64 | >64 | >64 |
07-1867 | F. solani | >64 | >64 | >64 | >64 |
07-1333 | P. boydii | >64 | >64 | >64 | >64 |
07-1502 | P. boydii | >64 | >64 | >64 | >64 |
07-1601 | P. boydii | >64 | >64 | >64 | >64 |
05-388 | A. fumigatus | >64 | >64 | >64 | >64 |
06-4126 | A. fumigatus | >64 | >64 | >64 | >64 |
07-2039 | A. fumigatus | >64 | >64 | >64 | >64 |
07-1743 | T. rubrum | >64 | >64 | 2 | 2 |
07-2055 | T. rubrum | >64 | >64 | 2 | 2 |
- Alder, B., (1938) Ann. Chem., 113, 120.
- Ayaydin, F. et al., (2000) The Plant Journal, 23:85-96.
- Baskin, T. and Wilson, J., (1997) Plant Physiol. 113:493-502.
- Bastien et al. (2004), Gene, Vol. 328, pp. 1-16.
- Bhongle, N. N. et al., (1984) Indian J. Chem. Sect. B., 23, 465-468.
- Blaheta, A et al. (2002), Current Medicinal Chemistry, Vol. 9, pp. 1417-1433.
- Crafts, A. S., (1953) Rev. Plant. Physiol., 4:253-282.
- Drewinko et al. (1967) Cancer Biochem. Biophys., Vol. 1, pp. 187-195.
- Erdodi, F. et al., (1985) Am. J. Physiol., 269 (Cell Physiol. 38) C1176-C1184.
- Essers, M. et al., (2001) Tetrahedron Lett., 42, 5429-5433.
- Fanghaemel, F. et al., (1994) Synthesis, 10, 1067-1071.
- Giannini, R. and Cvallini, A. (2005) Anticancer Research, Vol. 36, No. 6B, pp. 4287-4292.
- Göttlicher, M et al. (2001) Eur. Mol. Bio. Journal, Vol. 20, no. 24, pp. 6969-6978.
- Graziano, M. J. and Casida, J. E. (1987) Toxicol Lett., 37, 143-148.
- Hart, M E et al. (2004) Bioorganic & Medicinal Chemistry Letters, Vol. 14, pp. 1969-1973.
- Havrilesky, L J et al. (2001) J. Soc. Gynecology. Investig., Vol. 8, pp. 104-113.
- Hermanson et al. (2002) Nature, Vol. 419, pp. 934-939.
- Honkanan, R. E. et al., (1993) FEBS Lett., 330, 283-286.
- Hughes et al. (1988) Nature, Vol. 335, pp. 70-73.
- Kayser, M. M. et al., (1989)Can. J. Chem., 67, 1401-1410.
- Kayser, M. M. et al., (1982)Can. J. Chem., 60, 1199-1208.
- Kawamura, N. et al. (1990) Chem. Res. Toxicol., Vol. 3, pp. 318-324.
- Kovach, J S et al. (1985) Cancer Treat. Rep., Vol. 69, pp. 97-103.
- Li, Y. M. et al., (1992) Proc. Natl. Acad. Sci. USA, 89, 11867-11870.
- Li, Y. M. et al., (1993) Biochem. Pharmacol., 46, 1435-1443.
- Matsuzawa, M. et al. (1987) J. Agric. Food Chem., Col. 35, No. 5.
- Momparlet, R L. (1980) Pharmacol. Ther., Vol. 8, pp. 21-35.
- Myers, E. et al. (2005) Clin. Cancer Res., Vol. 11, pp. 2111-2122.
- Park, D M. et al., (2007) Cell Cycle, 6(4): 467-70.
- Peng, F. et al. (2002), J. Cancer Res. Clin. Oncol., Vol. 128, pp. 223-230.
- Ramezanian, M. et al., (1989) J. Org. Chem., 54, 2852-2854.
- Rutka et al. (1988) Int. J. Cancer, Vol. 42, pp. 419-427.
- Sanderson, L et al. (2004) Drug Metabolism and Disposition, Vol. 32, No. 10, pp. 1132-1138.
- Sakoff, J A. (2004) Current Pharmaceutical Design, Vol. 10, pp. 1139-1159.
- Schweizer, H. R., (1989) Helv. Chin. Acta., 2221-2235.
- Shimi, I R et al. (1982) European Journal of Cancer and Clinical Oncology, 18:785-793.
- Singh et al. (2003) Cancer Research, Vol. 63, pp. 5821-5828.
- Singh et al. (2004 Nature, Vol. 432, pp. 396-401.
- Smith et al., (1994) Planta 194:516-524.
- Stupp at al. (2005) N. Engl. J. Med., Vol. 352, pp. 987-996.
- Trost, L., (1977) J. Am. Chem Soc., 99, 7079.
- Tsauer, W. et al., (1997) Anticancer Research 17, 2095-2098.
- Uchida et al. (2000) Proc. Natl. Acad. Sci. USA, Vol. 97, pp. 14720-14725.
- Wang, D S, (1989) Journal of Ethnopharmacology, 26:147-162.
- Yi, S N et al., Bulletin of Hunan Medical University, (1988), 13:327-330.
- U.S. Pat. No. 6,949,624, Liu et al.
- U.S. Patent Publication No. 2004/0197888, Armour et al.
- U.S. Patent Publication No. 2004/0253637, Buechler et al.
- U.S. Patent Publication No. 2005/0203082, Hsu et al.
- U.S. Patent Application No. 2006/0030616A1, filed Feb. 9, 2006 (McCluskey et al.)
- Valeriote, F., (1975) Cancer Chemother. Rep., Vol. 59, pp. 895-900.
- Wang, G S (1983) Chin. Pharmac. Bull., Col. 18, pp. 18-19.
- Wang, G S (1989 J. Ethnopharmacol., Vol. 26, pp. 147-162.
- Wang, G S et al. (1986), Chinese. Pharm. Bull., Vol. 21, pp. 90-93.
- Wang, G S et al. (1987) Chinese Pharm. Bull., Vol. 22, pp. 517-519.
- Waters, C E et al. (2004) J. Endocrinol., Vol. 183, pp. 375-383.
- Yoshida, M et al. (1990) Journal of Biological Chem., Vol. 265, No. 28, pp. 17174-17179.
- Yung et al. (1996) Clin. Cancer Res. Vol. 2, pp. 1931-1935.
Claims (14)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/018,924 US10399993B2 (en) | 2007-02-06 | 2018-06-26 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use |
Applications Claiming Priority (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US89990307P | 2007-02-06 | 2007-02-06 | |
US96490407P | 2007-08-14 | 2007-08-14 | |
US1132308P | 2008-01-15 | 2008-01-15 | |
US12/069,147 US7998957B2 (en) | 2007-02-06 | 2008-02-06 | Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use |
US13/174,249 US8426444B2 (en) | 2007-02-06 | 2011-06-30 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use |
US13/866,854 US8822461B2 (en) | 2007-02-06 | 2013-04-19 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use |
US14/328,384 US9079917B2 (en) | 2007-02-06 | 2014-07-10 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use |
US201514794110A | 2015-07-08 | 2015-07-08 | |
US201615004525A | 2016-01-22 | 2016-01-22 | |
US201615150129A | 2016-05-09 | 2016-05-09 | |
US201615275954A | 2016-09-26 | 2016-09-26 | |
US15/425,550 US10023587B2 (en) | 2007-02-06 | 2017-02-06 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use |
US16/018,924 US10399993B2 (en) | 2007-02-06 | 2018-06-26 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/425,550 Continuation US10023587B2 (en) | 2007-02-06 | 2017-02-06 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use |
Publications (2)
Publication Number | Publication Date |
---|---|
US20180370983A1 US20180370983A1 (en) | 2018-12-27 |
US10399993B2 true US10399993B2 (en) | 2019-09-03 |
Family
ID=39682021
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/069,147 Active 2030-02-20 US7998957B2 (en) | 2007-02-06 | 2008-02-06 | Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use |
US13/174,249 Active US8426444B2 (en) | 2007-02-06 | 2011-06-30 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use |
US13/866,854 Active US8822461B2 (en) | 2007-02-06 | 2013-04-19 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use |
US14/328,384 Active US9079917B2 (en) | 2007-02-06 | 2014-07-10 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use |
US15/425,550 Active US10023587B2 (en) | 2007-02-06 | 2017-02-06 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use |
US16/018,924 Active US10399993B2 (en) | 2007-02-06 | 2018-06-26 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use |
Family Applications Before (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/069,147 Active 2030-02-20 US7998957B2 (en) | 2007-02-06 | 2008-02-06 | Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use |
US13/174,249 Active US8426444B2 (en) | 2007-02-06 | 2011-06-30 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use |
US13/866,854 Active US8822461B2 (en) | 2007-02-06 | 2013-04-19 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use |
US14/328,384 Active US9079917B2 (en) | 2007-02-06 | 2014-07-10 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use |
US15/425,550 Active US10023587B2 (en) | 2007-02-06 | 2017-02-06 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use |
Country Status (10)
Country | Link |
---|---|
US (6) | US7998957B2 (en) |
EP (1) | EP2124550B1 (en) |
JP (1) | JP5693850B2 (en) |
CN (2) | CN103788108B (en) |
AU (1) | AU2008214299B2 (en) |
BR (1) | BRPI0806365B8 (en) |
CA (1) | CA2676422C (en) |
EA (1) | EA023804B1 (en) |
MX (1) | MX2009008347A (en) |
WO (1) | WO2008097561A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11236102B2 (en) | 2015-05-15 | 2022-02-01 | Lixte Biotechnology, Inc. | Oxabicycloheptane prodrugs |
US11931354B2 (en) | 2013-04-09 | 2024-03-19 | Lixte Biotechnology, Inc. | Formulations of oxabicycloheptanes and oxabicycloheptenes |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090018142A9 (en) * | 2006-05-02 | 2009-01-15 | Zhengping Zhuang | Use of phosphatases to treat tumors overexpressing N-CoR |
CA2676422C (en) | 2007-02-06 | 2018-10-16 | Lixte Biotechnology Holdings, Inc. | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use |
CA2718472A1 (en) * | 2007-08-03 | 2009-02-12 | Lixte Biotechnology, Inc. | Use of phosphatases to treat neuroblastomas and medulloblastomas |
WO2009039407A1 (en) * | 2007-09-19 | 2009-03-26 | University Of Massachusetts | Water-soluble and water-insoluble, ring opening metathesis polymerization products, monomers and related methods |
EP2200439B1 (en) | 2007-10-01 | 2017-03-22 | Lixte Biotechnology, Inc. | Hdac inhibitors |
WO2010014220A1 (en) | 2008-08-01 | 2010-02-04 | Lixte Biotechnology, Inc. | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases |
WO2010147612A1 (en) | 2009-06-18 | 2010-12-23 | Lixte Biotechnology, Inc. | Methods of modulating cell regulation by inhibiting p53 |
EP2309853A4 (en) * | 2008-08-01 | 2012-04-25 | Lixte Biotechnology Inc | Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase |
US8227473B2 (en) * | 2008-08-01 | 2012-07-24 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use |
US10149847B2 (en) | 2012-06-29 | 2018-12-11 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes |
US20150174123A1 (en) | 2012-06-29 | 2015-06-25 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes for the treatment of reperfusion injury |
EP3068398A4 (en) * | 2013-11-15 | 2017-11-15 | Lixte Biotechnology, Inc. | Protein phosphatase inhibitors that cross the blood brain barrier |
CN103664978B (en) * | 2013-11-29 | 2016-06-22 | 西北农林科技大学 | A kind of halobenzene base aromatic amine ring substituent norcantharidin and its preparation method and application |
WO2015175487A1 (en) | 2014-05-13 | 2015-11-19 | Novartis Ag | Compounds and compositions for inducing chondrogenesis |
WO2015196073A1 (en) * | 2014-06-20 | 2015-12-23 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes for the treatment of ovarian cancer |
US20170209434A1 (en) | 2014-07-24 | 2017-07-27 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Protein phosphatase 2a inhibitors for treating myelodysplastic syndromes |
WO2016040877A1 (en) * | 2014-09-12 | 2016-03-17 | Lixte Biotechnology, Inc. | Human dosing of phosphatase inhibitor |
WO2016061193A1 (en) * | 2014-10-15 | 2016-04-21 | Lixte Biotechnology, Inc. | Process of synthesizing 3-(4-methylpiperazine-1-carbonyl)-7-oxabicyclo[2.2.1] heptane-2-carboxylic acid |
EP3233817B1 (en) | 2014-12-19 | 2020-10-14 | Nederlandse Organisatie voor toegepast- natuurwetenschappelijk onderzoek TNO | Improved process for the preparation of a benzene compound |
US9833450B2 (en) * | 2015-02-19 | 2017-12-05 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders |
EP3407887B1 (en) | 2016-01-27 | 2021-09-01 | Lixte Biotechnology, Inc. | Clinical regimen for treating myelodysplastic syndrome with phosphatase inhibitor |
CN106083877A (en) * | 2016-06-21 | 2016-11-09 | 遵义医学院附属医院 | Unsaturated norcantharidin methyl ester barium salt and antitumor application thereof |
EP4324477A3 (en) * | 2016-12-08 | 2024-05-22 | Lixte Biotechnology, Inc. | Oxabicycloheptanes for modulation of immune response |
KR20230136624A (en) * | 2021-01-19 | 2023-09-26 | 릭스트 바이오테크놀로지, 인코포레이티드 | Oxabicycloheptane for the treatment of small cell lung cancer |
WO2024097784A2 (en) * | 2022-11-03 | 2024-05-10 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes for treating refractory cancers |
CN116531361A (en) * | 2022-12-01 | 2023-08-04 | 武汉大学 | Application of oxygen bridge bicyclo- [2.2.1] -heptene compound in preparation of anti-novel coronavirus drugs |
Citations (111)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SU201598A1 (en) | Институт проблем лить Академии наук Украинской ССР | DEVICE FOR FLUSHING WEIGHING | ||
US2957906A (en) | 1955-10-25 | 1960-10-25 | Monsanto Chemicals | Ketones |
JPS5069091A (en) | 1973-10-22 | 1975-06-09 | ||
JPS5132733A (en) | 1974-09-10 | 1976-03-19 | Kyowa Hakko Kogyo Kk | Josozai |
JPS5188631A (en) | 1975-01-31 | 1976-08-03 | Hiiryoyosatsukinzai oyobi sonoseizoho | |
JPS5198755A (en) | 1975-01-06 | 1976-08-31 | ||
US3980674A (en) | 1974-01-28 | 1976-09-14 | Delmar Chemicals Limited | 2,3-Disubstituted 7-oxabicyclo-[2.2.1]-5-heptene |
US4143054A (en) | 1977-11-04 | 1979-03-06 | E. R. Squibb & Sons, Inc. | 7-oxabicycloheptane- and 7-oxabicycloheptene compounds |
US4218478A (en) | 1979-01-05 | 1980-08-19 | Ruiko Oiwa | Trichostatin as an antiprotozoal agent |
US4298752A (en) | 1980-09-19 | 1981-11-03 | Regents Of The University Of California | Cycloadduct precursors of cantharidin and method |
US4463015A (en) | 1982-08-18 | 1984-07-31 | E. R. Squibb & Sons, Inc. | Aryl substituted 7-oxabicycloheptane compounds, useful in inhibiting platelet aggregation |
US4524151A (en) | 1983-11-14 | 1985-06-18 | E. R. Squibb & Sons, Inc. | 7-Oxabicycloheptane thio ethers useful as cardiovascular agents |
US4614825A (en) | 1982-05-17 | 1986-09-30 | E. R. Squibb & Sons, Inc. | 7-oxabicycloheptane and 7-oxabicycloheptene compounds |
US4654355A (en) | 1985-08-01 | 1987-03-31 | E. R. Squibb & Sons, Inc. | 7-oxabicycloheptane substituted amide-thioamide prostaglandin analogs |
US4690918A (en) | 1985-01-30 | 1987-09-01 | Teruhiko Beppu | Use of trichostatin compounds for treating tumor cells |
US4816579A (en) | 1986-06-04 | 1989-03-28 | E. R. Squibb & Sons, Inc. | 7-oxabicycloheptane amino-alcohol intermediates useful in making thromboxane A2 receptor antagonists |
US4851553A (en) | 1986-06-04 | 1989-07-25 | E. R. Squibb & Sons, Inc. | 7-oxabicycloheptane amido-carboxylic acids |
US4851423A (en) | 1986-12-10 | 1989-07-25 | Schering Corporation | Pharmaceutically active compounds |
SU1553533A1 (en) | 1988-01-28 | 1990-03-30 | Военная Краснознаменная академия химической защиты им.Маршала Советского Союза С.К.Тимошенко | Method of producing 1,4-bispolyfluoroalkyl-7-oxabicyclo/2.2.1/heptanes |
JPH02256650A (en) | 1988-12-14 | 1990-10-17 | Shionogi & Co Ltd | Dicarboxylic acid monoester and production thereof |
US5266710A (en) | 1990-12-18 | 1993-11-30 | Patel Ramesh N | (Exo,exo)-7-oxabicyclo[2.2.1]heptane-2,3-dimethanol; monoacyl ester and diacyl ester |
US5326898A (en) | 1992-02-11 | 1994-07-05 | Allergan, Inc. | Substituted phenylethenyl compounds having retinoid-like biological activity |
DE19600707A1 (en) | 1996-01-11 | 1997-07-17 | Gluesenkamp Karl Heinz Dr | New bi:cyclic anhydride derivatives of active agents |
JPH10504305A (en) | 1994-08-12 | 1998-04-28 | バックマン・ラボラトリーズ・インターナショナル・インコーポレーテッド | Pesticidal compositions containing ethoxylated fatty amines for increasing the effectiveness of endartals and salts thereof |
US5763647A (en) | 1990-03-30 | 1998-06-09 | Shionogi & Co., Ltd. | Preparation of optically active 1,4-bridged-cyclohexane carboxylic acid derivatives |
US5770382A (en) | 1994-12-30 | 1998-06-23 | Ligand Pharmaceuticals, Inc. | Tricyclic retinoids, methods for their production and use |
US5925651A (en) | 1996-04-03 | 1999-07-20 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5968965A (en) | 1996-01-30 | 1999-10-19 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
WO2000004023A1 (en) | 1998-07-14 | 2000-01-27 | The University Of Newcastle Research Associates Limited | Anhydride modified cantharidin analogues useful in the treatment of cancer |
US6222055B1 (en) | 1995-07-06 | 2001-04-24 | Fraunhofer-Gesellschaft Zur Foerderung Der Angwandten Forschung E.V. | Hydrolyzable and polymerizable and/or polyadditive silanes |
JP2001329061A (en) | 2000-03-14 | 2001-11-27 | Asahi Kasei Corp | Hydroxylated polyamide |
WO2002042310A2 (en) | 2000-11-23 | 2002-05-30 | Bayer Cropscience Ag | Oxabicyclo[2.2.1]heptane derivatives as pesticidal agents |
US20020115826A1 (en) | 2000-03-24 | 2002-08-22 | Daniel Delorme | Inhibitors of histone deacetylase |
WO2002076989A1 (en) | 2001-03-23 | 2002-10-03 | The University Of Newcastle Research Associates Limited | Protein phosphate inhibitors |
US20020147345A1 (en) | 1998-08-07 | 2002-10-10 | Nabil El Tayer | FSH mimetics for the treatment of infertility |
US20020177692A1 (en) | 2001-04-16 | 2002-11-28 | Myriad Genetics, Incorporated | BCL-XL-interacting protein and use thereof |
US20030162186A1 (en) | 2001-05-25 | 2003-08-28 | Genset, S.A. | Human cDNAs and proteins and uses thereof |
US6632823B1 (en) | 1997-12-22 | 2003-10-14 | Merck & Co., Inc. | Substituted pyridine compounds useful as modulators of acetylcholine receptors |
WO2003092616A2 (en) | 2002-05-01 | 2003-11-13 | The Cleveland Clinic Foundation | Therapeutic compositions comprised of pentamidine and methods of using same to treat cancer |
US20040010045A1 (en) | 2001-09-07 | 2004-01-15 | Taolin Yi | Therapeutic compositions comprised of pentamidine and methods of using same to treat cancer |
US6696483B2 (en) | 2000-10-03 | 2004-02-24 | Oncopharmaceutical, Inc. | Inhibitors of angiogenesis and tumor growth for local and systemic administration |
US6706762B1 (en) | 1997-05-01 | 2004-03-16 | The Salk Institute For Biological Studies | Methods for the use of inhibitors of co-repressors for the treatment of neoplastic diseases |
US20040087657A1 (en) | 2001-10-16 | 2004-05-06 | Richon Victoria M. | Treatment of neurodegenerative diseases and cancer of the brain using histone deacetylase inhibitors |
US20040106141A1 (en) | 2002-11-05 | 2004-06-03 | The Regents Of The University Of California | Methods and materials for examining pathways associated with glioblastoma progression |
US20040116366A1 (en) | 2001-02-09 | 2004-06-17 | Monia Brett P | Antisense modulation of protein phosphatase 2 catalytic subunit beta expression |
US20040122101A1 (en) | 2002-03-04 | 2004-06-24 | Miller Thomas A. | Polymorphs of suberoylanilide hydroxamic acid |
EP1443967A1 (en) | 2001-11-06 | 2004-08-11 | Novartis AG | Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination |
US6777217B1 (en) | 1996-03-26 | 2004-08-17 | President And Fellows Of Harvard College | Histone deacetylases, and uses related thereto |
US20040161475A1 (en) | 1997-10-15 | 2004-08-19 | Polarx Biopharmaceuticals, Inc. | Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds |
US20040197888A1 (en) | 2002-12-31 | 2004-10-07 | Armour Christopher D. | Alternatively spliced isoforms of histone deacetylase 3 (HDAC3) |
US20040253637A1 (en) | 2001-04-13 | 2004-12-16 | Biosite Incorporated | Markers for differential diagnosis and methods of use thereof |
US20050014839A1 (en) | 2003-07-07 | 2005-01-20 | Kozikowski Alan P. | Histone deacetylase inhibitors and methods of use thereof |
US20050020831A1 (en) | 2001-08-03 | 2005-01-27 | Inman John K. | Acylthiols and component thiol compositions as anti-hiv and anti-retroviral agents |
WO2005018673A1 (en) | 2003-08-21 | 2005-03-03 | Osaka University | Pharmaceutical composition for preventing or remedying cardiac hypertrophy and cardiocascular disease caused thereby |
US20050054626A1 (en) | 2003-08-21 | 2005-03-10 | Carter Percy H. | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity |
WO2005049084A2 (en) | 2003-11-13 | 2005-06-02 | Board Of Regents, The University Of Texas System | Inhibition of trp channels as a treatment for cardiac hypertrophy and heart failure |
US20050119229A1 (en) | 2002-03-08 | 2005-06-02 | Eberhard Ammermann | Fungicidal mixtures based on prothioconazole and containing an insecticide |
US6905669B2 (en) | 2001-04-24 | 2005-06-14 | Supergen, Inc. | Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase |
WO2005054257A1 (en) | 2003-12-04 | 2005-06-16 | Imperial College Innovations Limited | Vanadium compounds as inhibitors of phosphatases |
US20050136090A1 (en) | 2003-12-19 | 2005-06-23 | Robert Falotico | Local vascular delivery of trichostatin a alone or in combination with sirolimus to prevent restenosis following vascular injury |
WO2005058280A2 (en) | 2003-12-12 | 2005-06-30 | Myogen, Inc. | Enoximone formulations and their use in the treatment of cardiac hypertrophy and heart failure |
US20050171202A1 (en) | 1999-11-23 | 2005-08-04 | Gerhart Graupner | Modulation of signal transduction |
WO2005074941A1 (en) | 2004-02-02 | 2005-08-18 | Myogen, Inc. | Inhibition of protein kinase c-related kinase (prk) as a treatment for cardiac hypertrophy and heart failure |
US20050203082A1 (en) | 2003-08-13 | 2005-09-15 | Hsu Chung Y. | Combination therapy with inhibitors of inducible nitric oxide synthase and alkylating agents |
US6949624B1 (en) | 1999-08-03 | 2005-09-27 | The United States Of America As Represented By The Department Of Health And Human Services | Cloning of the human nuclear receptor co-repressor gene |
US20050215526A1 (en) | 2003-08-13 | 2005-09-29 | Christopher Hulme | Melanin concentrating hormone receptor antagonist |
US20050220831A1 (en) | 2003-02-27 | 2005-10-06 | Novasel Australia Pty Ltd | Poloxamer emulsion preparations |
US20050222013A1 (en) | 2003-01-16 | 2005-10-06 | Georgetown University | Methods for the use of inhibitors of histone deacetylase as synergistic agents in cancer therapy |
US20050272644A1 (en) | 2002-07-25 | 2005-12-08 | Yih-Lin Chung | Method for increasing therapeutic gain in radiotherapy and chemotherapy |
US20050277583A1 (en) | 2002-02-20 | 2005-12-15 | Minoru Yoshida | Histone deacetylase inhibitors and process for producing the same |
US20050282893A1 (en) | 2004-01-30 | 2005-12-22 | Au Jessie L | Methods and compositions for using suramin, pentosan, polysulfate, telomerase antisense and telomerase inhibitors |
FR2872704A1 (en) | 2004-07-12 | 2006-01-13 | Laurent Schwartz | PLURITHERAPY AGAINST CANCER |
US20060030616A1 (en) | 1998-07-14 | 2006-02-09 | Mccluskey Adam | Anhydride modified cantharidin analogues useful in the treatment of cancer |
WO2006023603A2 (en) | 2004-08-17 | 2006-03-02 | The Johns Hopkins University | Pde5 inhibitor compositions and methods for treating cardiac indications |
US20060117994A1 (en) | 2004-11-12 | 2006-06-08 | Ryu Seung-Min | Ink composition |
US20060134682A1 (en) | 1999-06-18 | 2006-06-22 | Roberts Bruce L | Preparation and use of superior vaccines |
US7067551B2 (en) | 2000-09-01 | 2006-06-27 | Novartis Ag | Deacetylase inhibitors |
US20060167103A1 (en) | 2002-03-04 | 2006-07-27 | Aton Pharma, Inc. | Methods of treating cancer with HDAC inhibitors |
JP2006519609A (en) | 2003-03-12 | 2006-08-31 | サマリタン・ファーマシューティカルズ・インコーポレイテッド | Neurological disease mimicry animal model |
US20060235231A1 (en) | 2002-11-18 | 2006-10-19 | Simon Joel | Histone deacetylase inhibitors |
US20060264415A1 (en) | 2005-04-01 | 2006-11-23 | Methylgene Inc. | Inhibitors of histone deacetylase |
WO2006129105A1 (en) | 2005-06-02 | 2006-12-07 | University Of Southampton | Fk 228 derivates as hdac inhibitors |
US7154002B1 (en) | 2002-10-08 | 2006-12-26 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
US20070004771A1 (en) | 2003-10-06 | 2007-01-04 | Glaxo Group Limited | Preparation of 1,6,7-trisubstituted azabenzimidazoles as kinase inhibitors |
US20070010669A1 (en) | 1999-09-08 | 2007-01-11 | Ronald Breslow | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof |
WO2007014029A2 (en) | 2005-07-22 | 2007-02-01 | The Regents Of The University Of Colorado, A Body Corporate | Yin yang 1 as a treatment for cardiac hypertrophy and heart failure |
WO2007021682A1 (en) | 2005-08-10 | 2007-02-22 | Novartis Ag | Method of use of deacetylase inhibitors |
US20070049576A1 (en) | 2005-08-26 | 2007-03-01 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
US20070110669A1 (en) | 2001-09-20 | 2007-05-17 | Bastiaan Driehuys | Methods for In Vivo Evaluation of Pulmonary Physiology And/Or Function Using NMR Signals of Polarized 129Xe |
US20070135433A1 (en) | 2000-09-21 | 2007-06-14 | Dean David K | Imidazole derivatives as raf kinase inhibitors |
US20070155751A1 (en) | 2002-09-23 | 2007-07-05 | Schering Corporation | Novel imidazopyrazines as cyclin dependent kinase inhibitors |
WO2007092414A2 (en) | 2006-02-06 | 2007-08-16 | Lixte Biotechnology Holdings, Inc. | Use of phosphatases to treat tumors overexpressing n-cor |
US20070197550A1 (en) | 2005-12-19 | 2007-08-23 | Nafsika Georgopapadakou | Histone deacetylase inhibitors for enhancing activity of antifungal agents |
US20070208166A1 (en) | 2003-10-24 | 2007-09-06 | Exelixis, Inc. | Tao Kinase Modulators And Method Of Use |
US20070213330A1 (en) | 2004-03-26 | 2007-09-13 | Methylgene Inc. | Inhibitors of Histone Deacetylase |
WO2007118137A1 (en) | 2006-04-07 | 2007-10-18 | Methylgene Inc. | Benzamide derivatives as inhibitors of histone deacetylase |
WO2008028965A2 (en) | 2006-09-08 | 2008-03-13 | Institut Gustave Roussy | Inhibitors of protein phosphatase 1, gadd34 and protein phosphatase 1/gadd34 complex, preparation and uses thereof |
WO2008030617A2 (en) | 2006-09-07 | 2008-03-13 | Stemline Therapeutics, Inc. | Cancer therapy with cantharidin and cantharidin analogs |
WO2008058342A1 (en) | 2006-11-15 | 2008-05-22 | Genetic Technologies Limited | Compounds, compositions and methods for controlling invertebrate pests |
WO2008097561A1 (en) | 2007-02-06 | 2008-08-14 | Lixte Biotechology Holdings, Inc. | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use |
US20080214569A1 (en) | 2006-05-02 | 2008-09-04 | Zhengping Zhuang | Use of phosphatases to treat tumors overexpressing N-CoR |
US20090035292A1 (en) | 2007-08-03 | 2009-02-05 | Kovach John S | Use of phosphatases to treat neuroblastomas and medulloblastomas |
WO2009045440A1 (en) | 2007-10-01 | 2009-04-09 | Lixte Biotechnology Holdings, Inc. | Hdac inhibitors |
US20100029640A1 (en) | 2008-08-01 | 2010-02-04 | Lixte Biotechnology, Inc. | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases |
WO2010014254A1 (en) | 2008-08-01 | 2010-02-04 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use |
WO2010014141A1 (en) | 2008-08-01 | 2010-02-04 | Lixte Biotechnology, Inc. | Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase |
WO2010147612A1 (en) | 2009-06-18 | 2010-12-23 | Lixte Biotechnology, Inc. | Methods of modulating cell regulation by inhibiting p53 |
US20120135522A1 (en) | 2009-06-18 | 2012-05-31 | Kovach John S | Methods of modulating cell regulation by inhibiting p53 |
JP5069091B2 (en) | 2007-12-12 | 2012-11-07 | 三菱電機株式会社 | Surveillance camera and surveillance camera system |
JP5188631B2 (en) | 1998-06-05 | 2013-04-24 | ニュートリニア リミテッド | Infant formula supplemented with insulin |
JP5198755B2 (en) | 2006-10-31 | 2013-05-15 | 日精株式会社 | Mechanical parking equipment |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7154022B2 (en) * | 2000-10-06 | 2006-12-26 | Board Of Trustees Operating Michigan State University | Divinyl ether synthase gene, and protein and uses thereof |
CA2520124A1 (en) * | 2003-03-28 | 2004-10-14 | Chiron Corporation | Use of benzazole compounds for immunopotentiation |
US7094193B2 (en) | 2003-08-28 | 2006-08-22 | Philip Morris Usa Inc. | High speed laser perforation of cigarette tipping paper |
-
2008
- 2008-02-06 CA CA2676422A patent/CA2676422C/en active Active
- 2008-02-06 BR BRPI0806365A patent/BRPI0806365B8/en active IP Right Grant
- 2008-02-06 MX MX2009008347A patent/MX2009008347A/en active IP Right Grant
- 2008-02-06 US US12/069,147 patent/US7998957B2/en active Active
- 2008-02-06 WO PCT/US2008/001549 patent/WO2008097561A1/en active Application Filing
- 2008-02-06 EA EA200970737A patent/EA023804B1/en unknown
- 2008-02-06 CN CN201310655668.5A patent/CN103788108B/en active Active
- 2008-02-06 CN CN200880004292.9A patent/CN101662939B/en active Active
- 2008-02-06 AU AU2008214299A patent/AU2008214299B2/en active Active
- 2008-02-06 EP EP08725214.4A patent/EP2124550B1/en active Active
- 2008-02-06 JP JP2009549092A patent/JP5693850B2/en active Active
-
2011
- 2011-06-30 US US13/174,249 patent/US8426444B2/en active Active
-
2013
- 2013-04-19 US US13/866,854 patent/US8822461B2/en active Active
-
2014
- 2014-07-10 US US14/328,384 patent/US9079917B2/en active Active
-
2017
- 2017-02-06 US US15/425,550 patent/US10023587B2/en active Active
-
2018
- 2018-06-26 US US16/018,924 patent/US10399993B2/en active Active
Patent Citations (134)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SU201598A1 (en) | Институт проблем лить Академии наук Украинской ССР | DEVICE FOR FLUSHING WEIGHING | ||
US2957906A (en) | 1955-10-25 | 1960-10-25 | Monsanto Chemicals | Ketones |
JPS5069091A (en) | 1973-10-22 | 1975-06-09 | ||
US3980674A (en) | 1974-01-28 | 1976-09-14 | Delmar Chemicals Limited | 2,3-Disubstituted 7-oxabicyclo-[2.2.1]-5-heptene |
JPS5132733A (en) | 1974-09-10 | 1976-03-19 | Kyowa Hakko Kogyo Kk | Josozai |
JPS5198755A (en) | 1975-01-06 | 1976-08-31 | ||
JPS5188631A (en) | 1975-01-31 | 1976-08-03 | Hiiryoyosatsukinzai oyobi sonoseizoho | |
US4143054A (en) | 1977-11-04 | 1979-03-06 | E. R. Squibb & Sons, Inc. | 7-oxabicycloheptane- and 7-oxabicycloheptene compounds |
US4218478A (en) | 1979-01-05 | 1980-08-19 | Ruiko Oiwa | Trichostatin as an antiprotozoal agent |
US4298752A (en) | 1980-09-19 | 1981-11-03 | Regents Of The University Of California | Cycloadduct precursors of cantharidin and method |
US4614825A (en) | 1982-05-17 | 1986-09-30 | E. R. Squibb & Sons, Inc. | 7-oxabicycloheptane and 7-oxabicycloheptene compounds |
US4463015A (en) | 1982-08-18 | 1984-07-31 | E. R. Squibb & Sons, Inc. | Aryl substituted 7-oxabicycloheptane compounds, useful in inhibiting platelet aggregation |
US4524151A (en) | 1983-11-14 | 1985-06-18 | E. R. Squibb & Sons, Inc. | 7-Oxabicycloheptane thio ethers useful as cardiovascular agents |
US4690918A (en) | 1985-01-30 | 1987-09-01 | Teruhiko Beppu | Use of trichostatin compounds for treating tumor cells |
US4654355A (en) | 1985-08-01 | 1987-03-31 | E. R. Squibb & Sons, Inc. | 7-oxabicycloheptane substituted amide-thioamide prostaglandin analogs |
US4816579A (en) | 1986-06-04 | 1989-03-28 | E. R. Squibb & Sons, Inc. | 7-oxabicycloheptane amino-alcohol intermediates useful in making thromboxane A2 receptor antagonists |
US4851553A (en) | 1986-06-04 | 1989-07-25 | E. R. Squibb & Sons, Inc. | 7-oxabicycloheptane amido-carboxylic acids |
US4851423A (en) | 1986-12-10 | 1989-07-25 | Schering Corporation | Pharmaceutically active compounds |
SU1553533A1 (en) | 1988-01-28 | 1990-03-30 | Военная Краснознаменная академия химической защиты им.Маршала Советского Союза С.К.Тимошенко | Method of producing 1,4-bispolyfluoroalkyl-7-oxabicyclo/2.2.1/heptanes |
JPH02256650A (en) | 1988-12-14 | 1990-10-17 | Shionogi & Co Ltd | Dicarboxylic acid monoester and production thereof |
US5763647A (en) | 1990-03-30 | 1998-06-09 | Shionogi & Co., Ltd. | Preparation of optically active 1,4-bridged-cyclohexane carboxylic acid derivatives |
US5266710A (en) | 1990-12-18 | 1993-11-30 | Patel Ramesh N | (Exo,exo)-7-oxabicyclo[2.2.1]heptane-2,3-dimethanol; monoacyl ester and diacyl ester |
US5326898A (en) | 1992-02-11 | 1994-07-05 | Allergan, Inc. | Substituted phenylethenyl compounds having retinoid-like biological activity |
JPH10504305A (en) | 1994-08-12 | 1998-04-28 | バックマン・ラボラトリーズ・インターナショナル・インコーポレーテッド | Pesticidal compositions containing ethoxylated fatty amines for increasing the effectiveness of endartals and salts thereof |
US5770382A (en) | 1994-12-30 | 1998-06-23 | Ligand Pharmaceuticals, Inc. | Tricyclic retinoids, methods for their production and use |
US6222055B1 (en) | 1995-07-06 | 2001-04-24 | Fraunhofer-Gesellschaft Zur Foerderung Der Angwandten Forschung E.V. | Hydrolyzable and polymerizable and/or polyadditive silanes |
DE19600707A1 (en) | 1996-01-11 | 1997-07-17 | Gluesenkamp Karl Heinz Dr | New bi:cyclic anhydride derivatives of active agents |
US5968965A (en) | 1996-01-30 | 1999-10-19 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US6777217B1 (en) | 1996-03-26 | 2004-08-17 | President And Fellows Of Harvard College | Histone deacetylases, and uses related thereto |
US5925651A (en) | 1996-04-03 | 1999-07-20 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US6706762B1 (en) | 1997-05-01 | 2004-03-16 | The Salk Institute For Biological Studies | Methods for the use of inhibitors of co-repressors for the treatment of neoplastic diseases |
US20040161475A1 (en) | 1997-10-15 | 2004-08-19 | Polarx Biopharmaceuticals, Inc. | Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds |
US6632823B1 (en) | 1997-12-22 | 2003-10-14 | Merck & Co., Inc. | Substituted pyridine compounds useful as modulators of acetylcholine receptors |
JP5188631B2 (en) | 1998-06-05 | 2013-04-24 | ニュートリニア リミテッド | Infant formula supplemented with insulin |
WO2000004023A1 (en) | 1998-07-14 | 2000-01-27 | The University Of Newcastle Research Associates Limited | Anhydride modified cantharidin analogues useful in the treatment of cancer |
JP2002520415A (en) | 1998-07-14 | 2002-07-09 | ザ ユニバーシティ オブ ニューキャッスル リサーチ アソシエイツ リミテッド | Anhydrous modified cansalidin analogues useful for the treatment of cancer |
US20060030616A1 (en) | 1998-07-14 | 2006-02-09 | Mccluskey Adam | Anhydride modified cantharidin analogues useful in the treatment of cancer |
US20020147345A1 (en) | 1998-08-07 | 2002-10-10 | Nabil El Tayer | FSH mimetics for the treatment of infertility |
US20060134682A1 (en) | 1999-06-18 | 2006-06-22 | Roberts Bruce L | Preparation and use of superior vaccines |
US6949624B1 (en) | 1999-08-03 | 2005-09-27 | The United States Of America As Represented By The Department Of Health And Human Services | Cloning of the human nuclear receptor co-repressor gene |
US20070010669A1 (en) | 1999-09-08 | 2007-01-11 | Ronald Breslow | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof |
US20050171202A1 (en) | 1999-11-23 | 2005-08-04 | Gerhart Graupner | Modulation of signal transduction |
JP2001329061A (en) | 2000-03-14 | 2001-11-27 | Asahi Kasei Corp | Hydroxylated polyamide |
US20020115826A1 (en) | 2000-03-24 | 2002-08-22 | Daniel Delorme | Inhibitors of histone deacetylase |
US7067551B2 (en) | 2000-09-01 | 2006-06-27 | Novartis Ag | Deacetylase inhibitors |
US20070135433A1 (en) | 2000-09-21 | 2007-06-14 | Dean David K | Imidazole derivatives as raf kinase inhibitors |
US6696483B2 (en) | 2000-10-03 | 2004-02-24 | Oncopharmaceutical, Inc. | Inhibitors of angiogenesis and tumor growth for local and systemic administration |
JP2005507852A (en) | 2000-11-23 | 2005-03-24 | バイエル・クロツプサイエンス・アクチエンゲゼルシヤフト | Use of oxabicyclo [2.2.1] heptane derivatives as pest control agents |
WO2002042310A2 (en) | 2000-11-23 | 2002-05-30 | Bayer Cropscience Ag | Oxabicyclo[2.2.1]heptane derivatives as pesticidal agents |
US20040053996A1 (en) | 2000-11-23 | 2004-03-18 | Gesing Ernst Rudolf F. | Use of oxabicyclo[2.2.1]heptane derivatives as pesticidal agents |
US20040116366A1 (en) | 2001-02-09 | 2004-06-17 | Monia Brett P | Antisense modulation of protein phosphatase 2 catalytic subunit beta expression |
WO2002076989A1 (en) | 2001-03-23 | 2002-10-03 | The University Of Newcastle Research Associates Limited | Protein phosphate inhibitors |
JP2004531500A (en) | 2001-03-23 | 2004-10-14 | ザ ユニバーシティ オブ ニューキャッスル リサーチ アソシエイツ リミテッド | Protein phosphate inhibitors |
US20040209934A1 (en) | 2001-03-23 | 2004-10-21 | Mccluskey Adam | Protein phosphate inhibitors |
US20040253637A1 (en) | 2001-04-13 | 2004-12-16 | Biosite Incorporated | Markers for differential diagnosis and methods of use thereof |
US20020177692A1 (en) | 2001-04-16 | 2002-11-28 | Myriad Genetics, Incorporated | BCL-XL-interacting protein and use thereof |
US6905669B2 (en) | 2001-04-24 | 2005-06-14 | Supergen, Inc. | Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase |
US20030162186A1 (en) | 2001-05-25 | 2003-08-28 | Genset, S.A. | Human cDNAs and proteins and uses thereof |
US20050020831A1 (en) | 2001-08-03 | 2005-01-27 | Inman John K. | Acylthiols and component thiol compositions as anti-hiv and anti-retroviral agents |
US20040010045A1 (en) | 2001-09-07 | 2004-01-15 | Taolin Yi | Therapeutic compositions comprised of pentamidine and methods of using same to treat cancer |
US20070110669A1 (en) | 2001-09-20 | 2007-05-17 | Bastiaan Driehuys | Methods for In Vivo Evaluation of Pulmonary Physiology And/Or Function Using NMR Signals of Polarized 129Xe |
US20040087657A1 (en) | 2001-10-16 | 2004-05-06 | Richon Victoria M. | Treatment of neurodegenerative diseases and cancer of the brain using histone deacetylase inhibitors |
EP1443967A1 (en) | 2001-11-06 | 2004-08-11 | Novartis AG | Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination |
US20050277583A1 (en) | 2002-02-20 | 2005-12-15 | Minoru Yoshida | Histone deacetylase inhibitors and process for producing the same |
US20060167103A1 (en) | 2002-03-04 | 2006-07-27 | Aton Pharma, Inc. | Methods of treating cancer with HDAC inhibitors |
US20040122101A1 (en) | 2002-03-04 | 2004-06-24 | Miller Thomas A. | Polymorphs of suberoylanilide hydroxamic acid |
US20050119229A1 (en) | 2002-03-08 | 2005-06-02 | Eberhard Ammermann | Fungicidal mixtures based on prothioconazole and containing an insecticide |
WO2003092616A2 (en) | 2002-05-01 | 2003-11-13 | The Cleveland Clinic Foundation | Therapeutic compositions comprised of pentamidine and methods of using same to treat cancer |
US20050272644A1 (en) | 2002-07-25 | 2005-12-08 | Yih-Lin Chung | Method for increasing therapeutic gain in radiotherapy and chemotherapy |
US20070155751A1 (en) | 2002-09-23 | 2007-07-05 | Schering Corporation | Novel imidazopyrazines as cyclin dependent kinase inhibitors |
US7154002B1 (en) | 2002-10-08 | 2006-12-26 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
US20040106141A1 (en) | 2002-11-05 | 2004-06-03 | The Regents Of The University Of California | Methods and materials for examining pathways associated with glioblastoma progression |
US20060235231A1 (en) | 2002-11-18 | 2006-10-19 | Simon Joel | Histone deacetylase inhibitors |
US20040197888A1 (en) | 2002-12-31 | 2004-10-07 | Armour Christopher D. | Alternatively spliced isoforms of histone deacetylase 3 (HDAC3) |
US20050222013A1 (en) | 2003-01-16 | 2005-10-06 | Georgetown University | Methods for the use of inhibitors of histone deacetylase as synergistic agents in cancer therapy |
US20050220831A1 (en) | 2003-02-27 | 2005-10-06 | Novasel Australia Pty Ltd | Poloxamer emulsion preparations |
JP2006519609A (en) | 2003-03-12 | 2006-08-31 | サマリタン・ファーマシューティカルズ・インコーポレイテッド | Neurological disease mimicry animal model |
US20050014839A1 (en) | 2003-07-07 | 2005-01-20 | Kozikowski Alan P. | Histone deacetylase inhibitors and methods of use thereof |
US20050203082A1 (en) | 2003-08-13 | 2005-09-15 | Hsu Chung Y. | Combination therapy with inhibitors of inducible nitric oxide synthase and alkylating agents |
US20050215526A1 (en) | 2003-08-13 | 2005-09-29 | Christopher Hulme | Melanin concentrating hormone receptor antagonist |
US20050054626A1 (en) | 2003-08-21 | 2005-03-10 | Carter Percy H. | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity |
US20070135365A1 (en) | 2003-08-21 | 2007-06-14 | Katsuyuki Tanizawa | Pharmaceutical composition for preventing or remedying cardiac hypertrophy and cardiovascular disease caused thereby |
WO2005018673A1 (en) | 2003-08-21 | 2005-03-03 | Osaka University | Pharmaceutical composition for preventing or remedying cardiac hypertrophy and cardiocascular disease caused thereby |
US20070004771A1 (en) | 2003-10-06 | 2007-01-04 | Glaxo Group Limited | Preparation of 1,6,7-trisubstituted azabenzimidazoles as kinase inhibitors |
US20070208166A1 (en) | 2003-10-24 | 2007-09-06 | Exelixis, Inc. | Tao Kinase Modulators And Method Of Use |
JP2007511528A (en) | 2003-11-13 | 2007-05-10 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | TRP channel inhibition method as a treatment for cardiac hypertrophy and heart failure |
WO2005049084A2 (en) | 2003-11-13 | 2005-06-02 | Board Of Regents, The University Of Texas System | Inhibition of trp channels as a treatment for cardiac hypertrophy and heart failure |
WO2005054257A1 (en) | 2003-12-04 | 2005-06-16 | Imperial College Innovations Limited | Vanadium compounds as inhibitors of phosphatases |
WO2005058280A2 (en) | 2003-12-12 | 2005-06-30 | Myogen, Inc. | Enoximone formulations and their use in the treatment of cardiac hypertrophy and heart failure |
JP2007514665A (en) | 2003-12-12 | 2007-06-07 | ミオゲン インコーポレイティッド | Enoximone preparations and methods for their use in the treatment of cardiac hypertrophy and heart failure |
US20050136090A1 (en) | 2003-12-19 | 2005-06-23 | Robert Falotico | Local vascular delivery of trichostatin a alone or in combination with sirolimus to prevent restenosis following vascular injury |
US20050282893A1 (en) | 2004-01-30 | 2005-12-22 | Au Jessie L | Methods and compositions for using suramin, pentosan, polysulfate, telomerase antisense and telomerase inhibitors |
WO2005074941A1 (en) | 2004-02-02 | 2005-08-18 | Myogen, Inc. | Inhibition of protein kinase c-related kinase (prk) as a treatment for cardiac hypertrophy and heart failure |
US20070213330A1 (en) | 2004-03-26 | 2007-09-13 | Methylgene Inc. | Inhibitors of Histone Deacetylase |
FR2872704A1 (en) | 2004-07-12 | 2006-01-13 | Laurent Schwartz | PLURITHERAPY AGAINST CANCER |
WO2006023603A2 (en) | 2004-08-17 | 2006-03-02 | The Johns Hopkins University | Pde5 inhibitor compositions and methods for treating cardiac indications |
US20060117994A1 (en) | 2004-11-12 | 2006-06-08 | Ryu Seung-Min | Ink composition |
US20060264415A1 (en) | 2005-04-01 | 2006-11-23 | Methylgene Inc. | Inhibitors of histone deacetylase |
WO2006129105A1 (en) | 2005-06-02 | 2006-12-07 | University Of Southampton | Fk 228 derivates as hdac inhibitors |
WO2007014029A2 (en) | 2005-07-22 | 2007-02-01 | The Regents Of The University Of Colorado, A Body Corporate | Yin yang 1 as a treatment for cardiac hypertrophy and heart failure |
WO2007021682A1 (en) | 2005-08-10 | 2007-02-22 | Novartis Ag | Method of use of deacetylase inhibitors |
US20090012066A1 (en) | 2005-08-10 | 2009-01-08 | Novartis Ag | Method of Use of Deacetylase Inhibitors |
US20070049576A1 (en) | 2005-08-26 | 2007-03-01 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
US20070197550A1 (en) | 2005-12-19 | 2007-08-23 | Nafsika Georgopapadakou | Histone deacetylase inhibitors for enhancing activity of antifungal agents |
WO2007092414A2 (en) | 2006-02-06 | 2007-08-16 | Lixte Biotechnology Holdings, Inc. | Use of phosphatases to treat tumors overexpressing n-cor |
US20080132503A1 (en) | 2006-04-07 | 2008-06-05 | Methylgene Inc. | Inhibitors of Histone Deacetylase |
WO2007118137A1 (en) | 2006-04-07 | 2007-10-18 | Methylgene Inc. | Benzamide derivatives as inhibitors of histone deacetylase |
US20090018142A9 (en) | 2006-05-02 | 2009-01-15 | Zhengping Zhuang | Use of phosphatases to treat tumors overexpressing N-CoR |
US20080214569A1 (en) | 2006-05-02 | 2008-09-04 | Zhengping Zhuang | Use of phosphatases to treat tumors overexpressing N-CoR |
WO2008030617A2 (en) | 2006-09-07 | 2008-03-13 | Stemline Therapeutics, Inc. | Cancer therapy with cantharidin and cantharidin analogs |
WO2008028965A2 (en) | 2006-09-08 | 2008-03-13 | Institut Gustave Roussy | Inhibitors of protein phosphatase 1, gadd34 and protein phosphatase 1/gadd34 complex, preparation and uses thereof |
JP5198755B2 (en) | 2006-10-31 | 2013-05-15 | 日精株式会社 | Mechanical parking equipment |
WO2008058342A1 (en) | 2006-11-15 | 2008-05-22 | Genetic Technologies Limited | Compounds, compositions and methods for controlling invertebrate pests |
US20130302402A1 (en) | 2007-02-06 | 2013-11-14 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use |
US7998957B2 (en) | 2007-02-06 | 2011-08-16 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use |
US20090036309A1 (en) | 2007-02-06 | 2009-02-05 | Kovach John S | Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use |
WO2008097561A1 (en) | 2007-02-06 | 2008-08-14 | Lixte Biotechology Holdings, Inc. | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use |
US20120270736A1 (en) | 2007-02-06 | 2012-10-25 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use |
WO2009020565A1 (en) | 2007-08-03 | 2009-02-12 | Lixte Biotechnology, Inc. | Use of phosphates to treat neuroblastomas and medullogastomas |
US20090035292A1 (en) | 2007-08-03 | 2009-02-05 | Kovach John S | Use of phosphatases to treat neuroblastomas and medulloblastomas |
WO2009045440A1 (en) | 2007-10-01 | 2009-04-09 | Lixte Biotechnology Holdings, Inc. | Hdac inhibitors |
US20090143445A1 (en) | 2007-10-01 | 2009-06-04 | John P. White, Esq | HDAC Inhibitors |
JP5069091B2 (en) | 2007-12-12 | 2012-11-07 | 三菱電機株式会社 | Surveillance camera and surveillance camera system |
US20100029484A1 (en) | 2008-08-01 | 2010-02-04 | Kovach John S | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use |
US8058268B2 (en) | 2008-08-01 | 2011-11-15 | Lixte Biotechnology, Inc. | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases |
US20110287537A1 (en) | 2008-08-01 | 2011-11-24 | Lixte Biotechnology, Inc. | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases |
US8227473B2 (en) | 2008-08-01 | 2012-07-24 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use |
US20100029683A1 (en) | 2008-08-01 | 2010-02-04 | Kovach John S | Methods for regulating cell mitosis by inhibiting serine/threonine phosphateses |
WO2010014141A1 (en) | 2008-08-01 | 2010-02-04 | Lixte Biotechnology, Inc. | Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase |
WO2010014254A1 (en) | 2008-08-01 | 2010-02-04 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use |
WO2010014220A1 (en) | 2008-08-01 | 2010-02-04 | Lixte Biotechnology, Inc. | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases |
US20100029640A1 (en) | 2008-08-01 | 2010-02-04 | Lixte Biotechnology, Inc. | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases |
WO2010147612A1 (en) | 2009-06-18 | 2010-12-23 | Lixte Biotechnology, Inc. | Methods of modulating cell regulation by inhibiting p53 |
US20120135522A1 (en) | 2009-06-18 | 2012-05-31 | Kovach John S | Methods of modulating cell regulation by inhibiting p53 |
Non-Patent Citations (268)
Title |
---|
Abel et al., "Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders," Current Opinion in Pharmacology, vol. 8, No. 1, Feb. 2008 (pp. 57-64). |
Acharya et al., "Rational development of histone deacetylase inhibitors as anticancer agents: a review," Molecular Pharmacology, vol. 68, No. 4, Oct. 2005 (pp. 917-932). |
Adcock, "HDAC inhibitors as anti-inflammatory agents," British Journal of Pharmacology, vol. 150, No. 7, Apr. 2007 (pp. 829-831). |
Advisory Action dated Feb. 22, 2012 in connection with U.S. Appl. No. 12/460,404. |
Advisory Action dated Jan. 13, 2012 in connection with U.S. Appl. No. 12/221,360. |
Albert, "Changing the trajectory of cognitive decline," New England Journal of Medicine, vol. 357, No. 5, Aug. 2007 (pp. 502-503). |
Amendment in Response to Dec. 12, 2012 Communication pursuant to Art. 94(3) EPC filed Apr. 22, 2013 with the European Patent Office in connection with European Patent Application No. 08725214.4. |
Amendment in Response to Dec. 6, 2012 Office Action filed Dec. 10, 2013 in connection with Australian Patent Application No. 2008214299. |
Amendment in Response to Jan. 4, 2011 Office Action filed Feb. 16, 2011 in connection with U.S. Appl. No. 12/069,147. |
Amendment in Response to Mar. 9, 2011 Supplemental European Search Report filed Sep. 26, 2011 with the European Patent Office in connection with European Patent Application No. 08725214.4. |
Amendment in Response to Oct. 26, 2010 Office Action and Supplemental Information Disclosure Statement filed Nov. 26, 2010 in connection with U.S. Appl. No. 12/069,147. |
Amendment Under 37 C.F.R. 1.132 and Supplemental Information Disclosure Statement Pursuant to 37 C.F.R. 1.97(d) and Statement Under 37 C.F.R. 1.97(e)(1) filed Jan. 11, 2013 in connection with U.S. Appl. No. 13/174,249. |
Andrabi et al., "Protein phosphatase 2A regulates life and death decisions via Akt in a context-dependent manner," Proceedings of the National Academy of Sciences U.S.A., vol. 104, No. 48, Nov. 2007 (pp. 19011-19016). |
Australian Office Action dated Dec. 6, 2012 in connection with Australian Patent Application No. 2008214299. |
Avila et al., "Tau Phosphorylation, Aggregation, and Cell Toxicity," Journal of Biomedicine and Biotechnology, vol. 2006, No Month Listed 2006 (pp. 1-5). |
Ayaydin et al., "Inhibition of serine/threonine-specific protein phosphatases causes premature activation of cdc2MsF kinase at G2/M transition and early mitotic microtubule organisation in alfalfa," The Plant Journal, vol. 23, No. 1, Jul. 2000 (pp. 85-96). |
Baskin et al., "Inhibitors of protein kinases and phosphatases alter root morphology and disorganize cortical microtubules," Plant Physiology, vol. 113, No. 2, Feb. 1997 (pp. 493-502). |
Bastien et al., "Nuclear retinoid receptors and the transcription of retinoid-target genes," Gene, vol. 328, Mar. 2004 (pp. 1-16). |
Beglopoulos et al., "Regulation of CRE-dependent transcription by presenilins: prospects for therapy of Alzheimer's disease," Trends in Pharmacological Sciences, vol. 27, No. 1, Jan. 2006 (pp. 33-40). |
Berthold et al., "Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial," The Lancet Biology, vol. 6, No. 9, Sep. 2005 (pp. 649-658). |
Bertini et al., "Structural basis of serine/threonine phosphatase inhibition by the archetypal small molecules cantharidin and norcantharidin," Journal of Medicinal Chemistry, vol. 52, No. 15, Aug. 2009 (pp. 4838-4843). |
Blaheta et al., "Valproate and valproate-analogues: potent tools to fight against cancer," Current Medicinal Chemistry, vol. 9, No. 15, Aug. 2002 (pp. 1417-1433). |
Blaskovich et al., "Recent discovery and development of protein tyrosince phosphatase inhibitors," Expert Opinion on Therapeutic Patents, vol. 12, No. 6, Jun. 2002 (pp. 871-905). |
Bommer et al., "The translationally controlled tumor protein TCTP," International Journal of Biochemistry and Cell Biology, vol. 36, No. 3, Mar. 2004 (pp. 379-385). |
Bonness et al., "Cantharidin-induced mitotic arrest is associated with the formation of aberrant mitotic spindles and lagging chromosomes resulting, in part, from the suppression of PP2Aa," Molecular Cancer Therapeutics, vol. 5, No. 11, Nov. 2006 (pp. 2727-2736). |
Brazil et al., "Advances in protein kinase B signalling AKTion on multiple fronts," Trends in Biochemical Sciences, vol. 29, No. 5, May 2004 (pp. 233-242). |
Burke, "Inhibition of mitogen-activated protein kinase and stimulation of Akt kinase signaling pathways: Two approaches with therapeutic potential in the treatment of neurodegenerative disease," Pharmacology & Therapeutics, vol. 114, No. 3, Jun. 2007 (pp. 261-277). |
Camphausen et al., "Influence of in vivo growth on human glioma cell line gene expression: convergent profiles under orthotopic conditions," Proceedings of the National Academy of Sciences U.S.A., vol. 102, No. 23, Jun. 2005 (pp. 8287-8292). |
CAS Registry No. 61531-23-5, Nov. 16, 1984 (discussed in the Dec. 6, 2012 Australian Office Action issued I connection with Australian Patent Application No. 2008214299). |
Castedo et al., "Cell death by mitotic catastrophe: a molecular definition," Oncogene, vol. 23, No. 16, Apr. 2004 (pp. 2825-2837). |
Chang et al., "All-trans-retinoic acid induces cell growth arrest in a human medullablastoma cell line," Journal of Neuro-Oncology, vol. 84, No. 3, Sep. 2007 (pp. 263-267). |
Chen et al., "A knockout mouse approach reveals that TCTP functions as an essential factor for cell proliferation and survival in a tissue or cell type specific manner," Molecular Biology of the Cell, vol. 18, No. 7, Jul. 2007 (pp. 2525-2532). |
Chen et al., "Mcl-1 Down-regulation Potentiates ABT-737 Lethality by Cooperatively Inducing Bak Activation and Bax Translocation," Cancer Research, vol. 67, No. 2, Jan. 2007 (pp. 782-791). |
Chinese Office Action dated Jan. 14, 2013 in connection with Chinese Patent Application No. 200880004292.9, including English language translation provided by Chinese agent. |
Chinese Office Action dated May 21, 2012 in connection with Chinese Patent Application No. 200880004292.9 including English language translation provided by Chinese agent. |
Cho et al., "Crystal structure of a protein phosphatase 2A heterotrimeric holoenzyme," Nature, vol. 445, No. 7123, Jan. 2007 (pp. 53-57). |
Communication pursuant to Art. 94(3) EPC dated Dec. 12, 2012 in connection with European Patent Application No. 08725214.4, filed Feb. 6, 2008. |
Communication pursuant to Art. 94(3) EPC dated Jan. 30, 2013 in connection with European Patent Application No. 09803283.2, filed Jan. 24, 2011. |
Communication pursuant to Art. 94(3) EPC dated Jul. 16, 2013 in connection with European Patent Application No. 09803283.2, filed Jan. 24, 2011. |
Communication pursuant to Rules 70(2) and 70a(2) EPC dated Mar. 28, 2011 in connection with European Patent Application No. 08725214.4, filed Sep. 2, 2009. |
Crafts, "Herbicides," Annual Review of Plant Physiology, vol. 4, Jun. 1953 (pp. 253-282). |
Craig, "MCL1 provides a window on the role of the BCL2 family in cell proliferation, differentiation and tumorigenesis," Leukemia, vol. 16, No. 4, Apr. 2002 (pp. 444-454). |
D'Adda di Fagagna, "Living on a break: cellular senescence as a DNA-damage response," Nature Reviews Cancer, vol. 8, No. 7, Jul. 2008 (pp. 512-522). |
David et al., "Histone deacetylase associated with mSin3A mediates repression by the acute promyelocytic leukemia-associated PLZF protein," Oncogene, vol. 16, No. 19, May 1998 (pp. 2549-2556). |
Decision of Rejection dated Aug. 22, 2013 by the Chinese Patent Office in connection with Chinese Patent Application No. 200880004292.9 (including English language summary provided by Chinese agent). |
Dreesen et al., "Signaling pathways in cancer and embryonic stem cells," Stem Cell Review, vol. 3, No. 1, Jan. 2007 (pp. 7-17). |
Drewinko et al., "Combination chemotherapy in vitro with adriamycin. Observations of additive, antagonistic, and synergistic effects when used in two-drug combinations on cultured human lymphoma cells," Cancer Biochemistry Biophysics, vol. 1, No. 4, May 1976 (pp. 187-195). |
Erdodi et al., "Endothall thianhydride inhibits protein phosphatases-1 and -2A in vivo," American Journal of Physiology-Cell Physiology, vol. 269, No. 5, Nov. 5 (pp. C1176-C1184). |
Erdodi et al., "Endothall thianhydride inhibits protein phosphatases-1 and -2A in vivo," American Journal of Physiology—Cell Physiology, vol. 269, No. 5, Nov. 5 (pp. C1176-C1184). |
Essers et al., "Synthesis of the first fluorinated cantharidin analogues," Tetrahedron Letters, vol. 42, No. 32, Aug. 2001 (pp. 5429-5433). |
Eurasian Official Action dated Feb. 15, 2013 in connection with Eurasian Patent Application No. 200970737 with English translation. |
Eurasian Official Action dated Jun. 22, 2011 in connection with Eurasian Paten Application No. 200970737 with English Translation. |
Eurasian Official Action dated Jun. 7, 2013 in connection with Eurasian Patent Application No. 201170288, filed Jul. 30, 2009 (including English language summary provided by Eurasian agent). |
Eurasian Official Action dated May 24, 2012 in connection with Eurasian Patent Application No. 200970737 with English translation. |
Eurasian Official Action dated Nov. 19, 2009 in connection with Eurasian Patent Application No. 200970737. |
Eurasian Official Action dated Nov. 19, 2012 in connection with Eurasian Patent Application No. 201170288, filed Jul. 30, 2009 with English translation. |
Eurasian Official Action dated Sep. 19, 2013 in connection with Eurasian Patent Application No. 200970737 (including English language summary provided by Eurasian agent). |
European Search Report dated Mar. 9, 2011 in connection with European Patent Application No. 08725214.4, filed Sep. 2, 2009. |
Fabel et al., "Long-term stabilization in patients with malignant glioma after treatment with liposomal doxorubicin," Cancer, vol. 92, No. 7, Oct. 2001 (pp. 1936-1942). |
Fanghanel et al., "Cycloaddition Reactions of [1,]Dithiolo[1,2]dithiole Derivatives with Dimethyl Acetylenedicarboxylate: Formation of New Bi-, Tri- and Tetracyclic Thiopyran Derivatives," Synthesis, vol. 10, No Month Listed 1994 (pp. 1067-1071). |
Final Office Action dated Dec. 15, 2011 in connection with U.S. Appl. No. 12/460,404. |
Final Office Action dated Mar. 20, 2013 in connection with U.S. Appl. No. 13/493,816. |
Final Office Action dated Nov. 2, 2011 in connection with U.S. Appl. No. 12/221,360. |
Finnin et al., "Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors," Nature, vol. 401, No. 6749, Sep. 1999 (pp. 188-193). |
First Examiner's Report dated Sep. 27, 2013 by the Australian Patent Office in connection with Australian Patent Application No. 2009277031, filed Jan. 11, 2011. |
First Official Action dated Jul. 1, 2013 in connection with Chinese Patent Application No. 200980130568.2 (including English language summary provided by Chinese agent). |
Fischer et al., "Recovery of learning and memory is associated with chromatin remodelling," Nature, vol. 447, No. 7141, May 2007 (pp. 178-182). |
Flicker et al., "Tyrosine kinase signaling pathways control the expression of retinoic acid receptor-alpha in SK-BR-3 breast cancer cells," Cancer Letters, vol. 115, No. 1, May 1997 (pp. 63-72). |
Forester et al., "Control of mitotic exit by PP2A regulation of Cdc25C and Cdk1," Proceedings of the National Academy of Sciences U.S.A., vol. 104, No. 50, Dec. 2007 (pp. 19867-19872). |
Furumai et al., "Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin," Proceedings of the National Academy of Sciences U.S.A., vol. 98, No. 1, Jan. 2001 (pp. 87-92). |
Gachet et al., "The growth-related, translationally controlled protein P23 has properties of a tubulin binding protein and associates transiently with microtubules during the cell cycle," Journal of Cell Science, vol. 112, pt. 8, Apr. 1999 (pp. 1257-1271). |
Garcia-Echeverria et al., "Drug discovery approaches targeting the PI3K/Akt pathway in cancer," Oncogene, vol. 27, No. 41, Sep. 2008 (pp. 5511-5526). |
Giannini et al., "Expression analysis of a subset of coregulators and three nuclear receptors in human colorectal carcinoma," Anticancer Research, vol. 25, No. 6B, Nov. 2005 (pp. 4287-4292). |
Gottlicher et al., "Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells," EMBO Journal, vol. 20, No. 24, Dec. 2001 (pp. 6969-6978). |
Graziano et al., "Comparison of the acute toxicity of endothal and cantharidic acid on mouse liver in vivo," Toxicology Letters, vol. 37, No. 2, Jul. 1987 (pp. 143-148). |
Gumireddy et al., "All-trans-retinoic acid-induced apoptosis in human medulloblastoma: activation of caspase-3/poly (ADP-ribose) polymerase 1 pathway," Clinical Cancer Research, vol. 9, No. 11, Sep. 2003 (pp. 4052-4059). |
Hart et al., Modified norcantharidins; synthesis, protein phosphatases 1 and 2A inhibition, and anticancer activity, Bioorganic and Medicinal Chemistry Letters, vol. 14, No. 8, Apr. 2004 (pp. 1969-1973). |
Havrilesky et al., "Relationship between expression of coactivators and corepressors of hormone receptors and resistance of ovarian cancers to growth regulation by steroid hormones," Journal of Society of Gynecologic Investigation, vol. 8, No. 2, Mar. 2001 (pp. 104-113). |
Hermanson et al., "N-CoR controls differentiation of neural stem cells into astrocytes," Nature, vol. 419, No. 6910, Oct. 2002 (pp. 934-939). |
Hildmann et al., "Histone-deacetylases-an important class of cellular regulators with a variety of functions," Applied Microbiology and Biotechnology, vol. 75, No. 3, Jun. 2007 (pp. 487-497). |
Hildmann et al., "Histone-deacetylases—an important class of cellular regulators with a variety of functions," Applied Microbiology and Biotechnology, vol. 75, No. 3, Jun. 2007 (pp. 487-497). |
Hill et al., "Heterocyclic substituted cantharidin and norcantharidin analogues-synthesis, protein phosphatase (1 and 2A) inhibition, and anti-cancer activity," Bioorganic and Medicinal Chemistry, vol. 17, No. 12, Jun. 2007 (pp. 3392-3397). |
Hill et al., "Heterocyclic substituted cantharidin and norcantharidin analogues—synthesis, protein phosphatase (1 and 2A) inhibition, and anti-cancer activity," Bioorganic and Medicinal Chemistry, vol. 17, No. 12, Jun. 2007 (pp. 3392-3397). |
Hirose et al., "Akt activation suppresses Chk2-mediated methylating agent-induced G2 arrest and protects from temozolomide-induced mitotic catastrophe and cellular senescence," Cancer Research, vol. 65, No. 11, Jun. 2005 (pp. 4861-4869). |
Hong et al., "Norcantharidin-Induced Post-G2/M Apoptosis Is Dependent on Wild-Type p53 Gene," Biochemical and Biophysical Research Communications, vol. 276, No. 1, Sep. 2000 (pp. 278-285). |
Honkanen, "Cantharidin, another natural toxin that inhibits the activity of serine/threonine protein phosphatases types 1 and 2A," FEBS Letters, vol. 330, No. 30, Sep. 1993 (pp. 283-286). |
Hoshikawa et al., "Trichostatin A induces morphological changes and gelsolin expression by inhibiting histone deacetylase in human carcinoma cell lines," Experimental Cell Research, vol. 214, No. 1, Sep. 1994 (pp. 189-197). |
Huang, "Targeting histone deacetylases for the treatment of cancer and inflammatory diseases," Journal of Cell Physiology, vol. 209, No. 3, Dec. 2006 (pp. 611-616). |
Hughes et al., "Ciliary neurotrophic factor induces type-2 astrocyte differentiation in culture," Nature, vol. 335, No. 6185, Sep. 1988 (pp. 70-73). |
Ianzini et al., "Delayed DNA damage associated with mitotic catastrophe following X-irradiation of HeLa S3 cells," Mutagenesis, vol. 13, No. 4, Jul. 1998 (pp. 337-344). |
International Preliminary Report on Patentability in connection with PCT/US2008/011367, dated Apr. 7, 2010. |
International Preliminary Report on Patentability in connection with PCT/US2009/004430, dated Feb. 1, 2011. |
International Preliminary Report on Patentability issued by the United States Patent and Trademark Office as International Searching Authority for International Patent Application No. PCT/US2007/003095 dated Aug. 12, 2008 (7 pages). |
International Preliminary Report on Patentability issued by the United States Patent and Trademark Office as International Searching Authority for International Patent Application No. PCT/US2008/001549 dated Aug. 11, 2009 (6 pages). |
International Preliminary Report on Patentability issued by the United States Patent and Trademark Office as International Searching Authority for International Patent Application No. PCT/US2008/009330 dated Nov. 4, 2008 (6 pages). |
International Preliminary Report on Patentability issued by the United States Patent and Trademark Office as International Searching Authority for International Patent Application No. PCT/US2010/000279 dated Dec. 20, 2011 (7 pages). |
International Search Report and Written Opinion issued by the United States Patent and Trademark Office as International Searching Authority for International Patent Application No. PCT/US2007/003095 dated Feb. 14, 2008 (13 pages). |
International Search Report and Written Opinion issued by the United States Patent and Trademark Office as International Searching Authority for International Patent Application No. PCT/US2008/001549 dated May 16, 2008 (7 pages). |
International Search Report and Written Opinion issued by the United States Patent and Trademark Office as International Searching Authority for International Patent Application No. PCT/US2008/009330 dated Nov. 4, 2008 (7 pages). |
International Search Report and Written Opinion issued by the United States Patent and Trademark Office as International Searching Authority for International Patent Application No. PCT/US2010/000279 dated May 3, 2010 (8 pages). |
International Search Report in connection with PCT/US2008/011367, dated Dec. 12, 2008. |
International Search Report in connection with PCT/US2009/004108, dated Sep. 15, 2009. |
International Search Report in connection with PCT/US2009/004378, dated Sep. 18, 2009. |
International Search Report in connection with PCT/US2009/004430, dated Jan. 12, 2010. |
Janssens et al., "Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling," The Biochemical Journal, vol. 353, Pt. 3, Feb. 2001 (pp. 417-439). |
Japanese Office Action dated Jan. 22, 2013 in connection with Japanese Patent Application No. 2009-549092. |
Japanese Office Action dated Sep. 10, 2013 in connection with Japanese Patent Application No. 2009-549092 (including English language summary provided by Japanese agent). |
Johnson et al., Plk1 activation by Ste20-like kinase (Slk) phosphorylation and polo-box phosphopeptide binding assayed with the substrate translationally controlled tumor protein (TCTP), Biochemistry, vol. 47, No. 12, Mar. 2008 (pp. 3688-3696). |
Joshi et al., "Retinoic acid receptors and tissue-transglutaminase mediate short-term effect of retinoic acid on migration and invasion of neuroblastoma SH-SY5Y cells," Oncogene, vol. 25, No. 2, Jan. 2006 (pp. 240-247). |
Jul. 4, 2013 Communication pursuant to Article 94(3) EPC issued by the European Patent Office in connection with European Patent Application No. 08794986.3. |
Kamitani et al., "Histone acetylation may suppress human glioma cell proliferation when p21 WAF/Cip1 and gelsolin are induced," Neuro-Oncology, vol. 4, No. 2, Apr. 2002 (pp. 95-101). |
Kawamura et al., "Endothall thioanhydride: structural aspects of unusually high mouse toxicity and specific binding site in liver," Chemical Research in Toxicology, vol. 3, No. 4, Jul. 1990 (pp. 318-324). |
Kayser et al., "Metal hydride reductions of unsymmetrical cyclic anhydrides. The importance of the antiperiplanar effect on the regioselectivity of these reactions," Canadian Journal of Chemistry, vol. 60, No. 10, May 1982 (pp. 1192-1198). |
Kayser et al., "On the regioselectivity of Wittig reactions with unsymmetrically substituted succinic anhydrides," Canadian Journal of Chemistry, vol. 67, No. 9, Sep. 1989 (pp. 1401-1410). |
Kelly et al., "Drug insight: Histone deacetylase inhibitors-development of the new targeted anticancer agent suberoylanilide hydroxamic acid," Nature Clinical Practice Oncology, vol. 2, No. 3, Mar. 2005 (pp. 150-157). |
Kelly et al., "Drug insight: Histone deacetylase inhibitors—development of the new targeted anticancer agent suberoylanilide hydroxamic acid," Nature Clinical Practice Oncology, vol. 2, No. 3, Mar. 2005 (pp. 150-157). |
Kijima et al., "Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase," Journal of Biological Chemistry, vol. 268, No. 30, Oct. 1993 (pp. 22429-22435). |
Kim et al., "Selective Induction of cyclin-Dependent Kinase Inhibitors and Their Roles in Cell Cycle Arrest Caused by Trichostatin A, an Inhibitor of Histone Deacetylase," Annals of the New York Academy of Sciences, vol. 886, Dec. 1999 (pp. 200-203). |
Kim et al., "Susceptibility and radiosensitization of human glioblastoma cells to trichostatin A, a histone deacetylase inhibitor," International Journal of Radiation Oncology, Biology, Physics, vol. 59, No. 4, Jul. 2004 (pp. 1174-1180). |
King, "Bioisosteres, Conformational Restriction and Pro-drugs: Approaches to Lead Optimisation-Case history: An Example of a Conformational Restriction Approach," Medicinal Chemistry: Principles and Practice, Chapter 14, No Month Listed 1994 (pp. 206-209). |
King, "Bioisosteres, Conformational Restriction and Pro-drugs: Approaches to Lead Optimisation—Case history: An Example of a Conformational Restriction Approach," Medicinal Chemistry: Principles and Practice, Chapter 14, No Month Listed 1994 (pp. 206-209). |
Kitamura et al., "Histone deacetylase inhibitor but not arsenic trioxide differentiates acute promyelocytic leukaemia cells with t(11;17) in combination with all-trans retinoic acid," British Journal of Haematology, vol. 108, No. 4, Mar. 2000 (pp. 696-702). |
Korzus et al., "CBP histone acetyltransferase activity is a critical component of memory consolidation," Neruon, vol. 42, No. 6, Jun. 2004 (pp. 961-972). |
Kovach et al., "Enhancement of the antiproliferative activity of human interferon by polyamine depletion," Cancer Treatment Reports, vol. 69, No. 1, Jan. 1985 (pp. 97-103). |
Kozikowski et al., "Functional differences in epigenetic modulators-superiority of mercaptoacetamide-based histone deacetylase inhibitors relative to hydroxamates in cortical neuron neuroprotection studies," Journal of Medicinal Chemistry, vol. 50, No. 13, Jun. 2007 (pp. 3054-3061). |
Kozikowski et al., "Functional differences in epigenetic modulators—superiority of mercaptoacetamide-based histone deacetylase inhibitors relative to hydroxamates in cortical neuron neuroprotection studies," Journal of Medicinal Chemistry, vol. 50, No. 13, Jun. 2007 (pp. 3054-3061). |
Kurebayashi et al., "Expression levels of estrogen receptor-alpha, estrogen receptor-beta, coactivators, and corepressors in breast cancer," Clinical Cancer Research, vol. 6, No. 2, Feb. 2000 (pp. 512-518). |
Kwon et al., "Depudecin induces morphological reversion of transformed fibroblasts via the inhibition of histone deacetylase," Proceedings of the National Academy of Sciences U.S.A., vol. 95, No. 7, Mar. 1998 (pp. 3356-3361). |
Langley et al., "Pulse inhibition of histone deacetylases induces complete resistance to oxidative death in cortical neurons without toxicity and reveals a role for cytoplasmic p21(waf1/cip1) in cell cycle-independent neuroprotection," Journal of Neuroscience, vol. 28, No. 1, Jan. 2008 (pp. 163-176). |
Lavinsky et al., "Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes," Proceedings of the National Academy of Sciences U.S.A., vol. 95, No. 6, Mar. 1998 (pp. 2920-2925). |
Lei et al., "Plk1 depletion in nontransformed diploid cells activates the DNA-damage checkpoint," Oncogene, vol. 27, No. 28, Jun. 2008 (pp. 3935-3943). |
Levenson et al., "Regulation of histone acetylation during memory formation in the hippocampus," Journal of Biological Chemistry, vol. 279, No. 39, Sep. 2004 (pp. 40545-40559). |
Levesque, "Reduction of L-DOPA-induced dyskinesias by retinoid agonists: a new way to improve Parkinson's disease treatment," The Parkinson Alliance, 2004 Pilot Study Grants, abstract only. |
Li et al., "Cantharidin-binding protein: identification as protein phosphatase 2A," Proceedings of the National Academy of Sciences U.S.A., vol. 89, No. 24, Dec. 1992 (pp. 11867-11870). |
Li et al., "Protein phosphatase 2A and its[3H]cantharidin/[3H]endothall thioanhydride binging site. Inhibitor specificity of cantharidin and ATP analogues," Biochemical Pharmacology, vol. 46, No. 8, Oct. 1993 (pp. 1435-1443). |
Li et al., "Valproic acid induces growth arrest, apoptosis, and senescence in medulloblastomas by increasing histone hyperacetylation and regulating expression of p21Cip1, CDK4, and CMYC," Molecular Cancer Therapeutics, vol. 4, No. 12, Dec. 2005 (pp. 1912-1922). |
Lim et al., "Tumour maintenance is mediated by eNOS," Nature, vol. 452, Apr. 2008 (pp. 646-649). |
Lin et al., "Role of the histone deacetylase complex in acute promyelocytic leukaemia," Nature, vol. 391, No. 6669, Feb. 1998 (pp. 811-814). |
Liu et al., "Normal cells, but not cancer cells, survive severe Plk1 depletion," Molecular and Cellular Biology, vol. 26, No. 6, Mar. 2006 (pp. 2093-2108). |
Liu et al., "Stabilization and enhancement of the antiapoptic activity of Mcl-1 by TCTP," Molecular and Cellular Biology, vol. 25, No. 8, Apr. 2005 (pp. 3117-3126). |
Lopez-Pajares et al., "Phosphorylation of MDMX mediated by Akt leads to stabilization and induces 14-3-3 binding," Journal of Biological Chemistry, vol. 283, No. 20, May 2008 (pp. 13707-13713). |
Lu et al., "Aqueous ring-opening metathesis polymerization and copolymerization of 2,3-dicarboxylic acid anhydride, 2,3-bis(methoxymethyl) and 2,3-dicarboxylic acid monomethyl ester derivatives of 7-oxanorbornene," European Polymer Journal, vol. 29, No. 2-3, Feb.-Mar. 1993 (pp. 269-279). |
Lu et al., "Aqueous ring-opening metathesis polymerization of 7-oxanorbornene derivatives with oxygen-containing functionalities," Macromolecular Chemistry and Physics, vol. 195, No. 4, Apr. 1994 (pp. 1273-1288). |
Lu et al., "LB-1, an inhibitor of serine-threonine protein phosphatase PP2A, suppresses the growth of glioblastoma cells in vitro and in vivo," AACR Annual Meeting, Apr. 12-16, 2008, San Diego, CA, vol. 68, No. 9, May 2008 (Abstract #5693). |
Managan et al, "Turning Back the Clock on Neurodegeneration," Cell, vol. 129, No. 5, Jun. 2007 (pp. 851-853). |
Manka et al., "Retro Diels-Alder Reactions of 5,6-Disbustituted-7-oxabicyclo[2.2.1]hept-2-enes: Experimental and Density Functional Theory Studies," Journal of Organic Chemistry, vol. 65, No. 17, Aug. 2000 (pp. 5202-5206). |
Mardor et al., "Monitoring response to convection-enhances taxol delivery in brain tumor patients using diffusion-weighted magnetic resonance imaging," Cancer Research, vol. 61, No. 13, Jul. 2001 (pp. 4971-4973). |
Marks et al., "Histone deacetylases," Current Opinion in Pharmacology, vol. 3, No. 4, Aug. 2003 (pp. 344-351). |
Matsuzawa et al., "Endothal and cantharidin analogs: relation of structure to herbicidal activity and mammalian toxicity," Journal of Agricultural and Food Chemistry, vol. 35, No. 5, Sep. 1987 (pp. 823-829). |
Matthay et al., "Treatment of High-Risk Neuroblastoma and Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-cis-Retinoic Acid," New England Journal of Medicine, vol. 341, Oct. 1999 (pp. 1165-1173). |
May 15, 2013 Office Action in connection with U.S. Appl. No. 13/378,623. |
McCluskey et al., "Anhydride modified cantharidin analogues. Is ring opening important in the inhibition of protein phosphatase 2A?," European Journal of Medicinal Chemistry, vol. 35, No. 10, Oct. 2000 (pp. 957-964). |
McCluskey et al., "Anhydride modified cantharidin analogues: synthesis, inhibition of protein phosphatases 1 and2A and anticancer activity," Bioorganic and Medicinal Chemistry Letters, vol. 10, No. 15, Aug. 2000 (pp. 1687-1690). |
McCluskey et al., "Inhibition of Protein Phosphatase 2A by Cantharidin Analogues," Bioorganic and Medicinal Chemistry Letters, vol. 6, No. 9, May 1996 (pp. 1025-1028). |
Mexican Office Action dated Aug. 15, 2012 in connection with Mexican Patent Application No. MX/a/2009/008347 including English language summary provided by Mexican agent. |
Mexican Office Action dated Jan. 24, 2013 in connection with Mexican Patent Application No. MX/a/2009/008347 including English language summary provided by Mexican agent. |
Mexican Office Action dated Jul. 19, 2012 in connection with Mexican Patent Application No. MX/a/2011/001007, filed Jan. 26, 2011 including language summary provided by Mexican agent. |
Mexican Office Action dated Jun. 4, 2012 in connection with Mexican Patent Application No. MX/a/2009/008347 including English language summary provided by Mexican agent. |
Mexican Office Action dated Mar. 23, 2012 in connection with Mexican Patent Application No. MX/a/2009/008347 including English language summary provided by Mexican agent. |
Mexican Office Action dated Mar. 25, 2013 in connection with Mexican Patent Application No. MX/a/2011/001007, filed Jan. 26, 2011 including English language summary provided by Mexican agent. |
Mexican Office Action dated Sep. 25, 2012 in connection with Mexican Patent Application No. MX/a/2011/001007, filed Jan. 26, 2011 including English language summary provided by Mexican agent. |
Mielnicki et al., "Epigenetic regulation of gelsolin expression in human breast cancer cells," Experimental Cell Research, vol. 249, No. 1, May 19999 (pp. 161-176). |
Momparler, "In vitro systems for evaluation of combination chemotherapy," Pharmacology and Therapeutics, vol. 8, No. 1, No Month Listed 1980 (pp. 21-35). |
Morse et al., "Docetaxel induces cell death through mitotic catastrophe in human breast cancer cells," Molecular Cancer Therapeutics, vol. 4, No. 10, Oct. 2005 (pp. 1495-1504). |
Myers et al., "Associations and Interactions between Ets-1 and Ets-2 and Coregulatory Proteins, SRC-1, AIB1, and NCoR in Breast Cancer," Clinical Cancer Research, vol. 11, Mar. 2005 (pp. 2111-2122). |
National Library of Medicine, Medical Subject Headings (MeSH): Phosphatases (2009). |
Neviani et al., "FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia," Journal of Clinical Investigation, vol. 117, No. 9, Sep. 2007 (pp. 2408-2421). |
Ngan et al., "Oxaliplatin induces mitotic catastrophe and apoptosis in esophageal cancer cells," Cancer Science, vol. 99, No. 1, Jan. 2008 (pp. 129-139). |
Non-final Office Action dated Aug. 20, 2012 in connection with U.S. Appl. No. 13/174,249. |
Non-final Office Action dated Aug. 3, 2011 in connection with U.S. Appl. No. 12/460,404. |
Non-Final Office Action dated Dec. 10, 2008 in connection with U.S. Appl. No. 11/703,401. |
Non-Final Office Action dated Dec. 10, 2009 in connection with U.S. Appl. No. 11/703,401. |
Non-final Office Action dated Feb. 16, 2011 in connection with U.S. Appl. No. 12/221,360. |
Non-final Office Action dated Feb. 16, 2011 in connection with U.S. Appl. No. 12/460,407. |
Non-final Office Action dated Jan. 4, 2011 in connection with U.S. Appl. No. 12/069,147. |
Non-Final Office Action dated Mar. 30, 2009 in connection with U.S. Appl. No. 11/703,401. |
Non-Final Office Action dated May 26, 2011 in connection with U.S. Appl. No. 12/221,360. |
Non-final Office Action dated Nov. 20, 2012 in connection with U.S. Appl. No. 13/493,816. |
Non-final Office Action dated Oct. 26, 2010 in connection with U.S. Appl. No. 12/069,147. |
Non-final Office Action dated Sep. 30, 2010 in connection with U.S. Appl. No. 12/460,407. |
Notice of Allowance dated Apr. 6, 2011 in connection with U.S. Appl. No. 12/069,147. |
Notice of Allowance dated Dec. 28, 2012 in connection with U.S. Appl. No. 13/174,249. |
Notice of Allowance dated Mar. 19, 2012 in connection with U.S. Appl. No. 12/460,404. |
Notice of Allowance dated May 23, 2013 in connection with U.S. Appl. No. 13/493,816. |
Notification Concerning Availability of the Publication of the International Application in connection with PCT/US2008/011367, dated Apr. 9, 2009. |
Notification Concerning Transmittal of International Preliminary Report on Patentability in connection with PCT/US2008/001549, dated Aug. 11, 2009. |
Notification of Transmittal of International Preliminary Report on Patentability in connection with PCT/US2008/011367, dated Apr. 15, 2010. |
Notification of Transmittal of the International Preliminary Report on Patentability, in connection with PCT/US2009/004108, dated Feb. 10, 2011. |
Notification of Transmittal of the International Preliminary Report on Patentability, in connection with PCT/US2009/004430, dated Feb. 10, 2011. |
Notification of Transmittal of the International Search Report and the Written Opinion of the International Search Authority, or the Declaration, in connection with PCT/US2009/004108, dated Sep. 15, 2009. |
Notification of Transmittal of the International Search Report and the Written Opinion of the International Search Authority, or the Declaration, in connection with PCT/US2009/004378, dated Sep. 18, 2009. |
Notification of Transmittal of the International Search Report and the Written Opinion of the International Search Authority, or the Declaration, in connection with PCT/US2009/004430, dated Jan. 12, 2010. |
Notification of Transmittal of the International Search Report and Written Opinion of the International Searching Authority, or the Declaration in connection with PCT/US2008/011367, dated Dec. 12, 2008. |
Nov. 9, 2012 Patent Examination Report issued in connection with Australian Patent Application No. 2008284364. |
Oct. 4, 2011 Communication issued in connection with European Patent Application No. 08794986.3. |
Office Action dated Aug. 17, 2010 in connection with U.S. Appl. No. 11/703,401. |
Office Action dated Aug. 20, 2013 in connection with U.S. Appl. No. 13/378,623. |
Office Action dated Dec. 20, 2013 by the Canadian Patent Office in connection with Canadian Patent Application No. 2,676,422. |
Olivier et al., "Recent advances in p53 research: an interdisciplinary perspective," Cancer Gene Therapy, vol. 16, No Month Listed 2009 (pp. 1-12). |
Olmos et al., "Targeting polo-like kinase: learning too little too late?," Journal of Clinical Oncology, vol. 26, No. 34, Dec. 2008 (pp. 5497-5499). |
Paez et al., "PI3K/PTEN/Akt Pathway," Signal Transduction in Cancer, vol. 115, No Month Listed 2006 (pp. 145-167). |
Park et al., "N-CoR pathway targeting induces glioblastoma derived cancer stem cell differentiation," Cell Cycle, vol. 6, No. 4, Feb. 2007 (pp. 467-470). |
Patent Search Report dated Oct. 25, 2011 in connection with Eurasian Patent Application No. 201170288, filed Jul. 30, 2009. |
Peng et al., "Induction of apoptosis by norcantharidin in human colorectal carcinoma cell lines: involvement of the CD95 receptor/ligand," Journal of Cancer Research and Clinical Oncology, vol. 128, No. 4, Apr. 2002 (pp. 223-230). |
Perrotti et al., "Protein phosphatases 2A (PP2A), a drugable tumor suppressor in Ph1(+) leukemias," Cancer and Metastasis Reviews, vol. 27, No. 2, Jun. 2008 (pp. 159-168). |
Prados et al., "Phase II Study of Erlotinib Plus Temozolomide During and After Radiation Therapy in Patients with Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma," Journal of Clinical Oncology, vol. 27, No. 4, Feb. 2009 (pp. 579-584). |
Price et al., "Histone deacetylase inhibitors: an analysis of recent patenting activity," Expert Opinion on Therapeutic Patents, vol. 17, No. 7, Aug. 2007 (pp. 745-765). |
Ramezanian et al., "A new super-electrophile: alpha(phenylsulfonyl)maleic anhydride," Journal of Organic Chemistry, vol. 54, No. 12, Jun. 1989 (pp. 2852-2854). |
Registry (STN) Online, Nov. 16, 1984, CAS registered No. 57958-23-3 (Search Date Jan. 16, 2013). |
Restriction Requirement dated May 18, 2011 in connection with U.S. Appl. No. 12/460,404. |
Restriction Requirement dated Sep. 28, 2012 in connection with U.S. Appl. No. 13/493,816. |
Richon et al., "A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases," Proceedings of the National Academy of Sciences U.S.A., vol. 95, No. 6, Mar. 1998 (pp. 3003-3007). |
Riester et al., "Histone deacetylase inhibitors-turning epigenic mechanisms of gene regulation into tools of therapeutic intervention in malignant and other diseases," Applied Microbiology and Biotechnology, vol. 75, Jun. 2007 (pp. 499-514). |
Riester et al., "Histone deacetylase inhibitors—turning epigenic mechanisms of gene regulation into tools of therapeutic intervention in malignant and other diseases," Applied Microbiology and Biotechnology, vol. 75, Jun. 2007 (pp. 499-514). |
Rinkenberger et al., "Mcl-1 deficiency results in peri-implantation embryonic lethality," Genes and Development, vol. 14, No. 1, Jan. 2000 (pp. 23-27). |
Rubie et al., "Phase II Study of Temozolomide in Relapsed or Refractory high-Risk Neuroblastoma: A Jount Societe Francaise des Cancers del'Enfant and United Kingdom Children Cancer Study Group-New Agents Group Study," Journal of Clinical Oncology, vol. 24, No. 33, Nov. 2006 (pp. 5259-5264). |
Rubie et al., "Phase II Study of Temozolomide in Relapsed or Refractory high-Risk Neuroblastoma: A Jount Societe Francaise des Cancers del'Enfant and United Kingdom Children Cancer Study Group—New Agents Group Study," Journal of Clinical Oncology, vol. 24, No. 33, Nov. 2006 (pp. 5259-5264). |
Rutka et al., "Effect of retinoids on the proliferation, morphology and expression of glial fibrillary acidic protein of an anaplastic astrocytoma cell line," International Journal of Cancer, vol. 42, No. 3, Sep. 1988 (pp. 419-427). |
Sahin et al., "Retinoic acid isomers protect hippocampal neurons from amyloid-beta induced neurodegeneration," Neurotoxicity Research, vol. 7, No. 3, No Month Listed 2005 (pp. 243-250). |
Saito et al., "A synthetic inhibitor of deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors," Proceedings of the National Academy of Sciences U.S.A., vol. 96, No. 8, Apr. 1999 (pp. 4592-4597). |
Sakoff et al., "Anticancer Activity and Protein Phosphatase 1 and 2A Inhibition of a New Generation of Cantharidin Analogues," Investigational New Drugs, vol. 20, No. 1, Feb. 2002 (pp. 1-11). |
Sakoff et al., "Protein Phosphatase Inhibition: Structure Based Design. Towards New Therapeutic Agents," Current Pharmaceutical Design, vol. 10, No. 10, No Month Listed 2004 (pp. 1139-1159). |
Sanderson et al., "Plasma pharmacokinetics and metabolism of the histone deacetylase inhibitor trichostatin a after intraperitoneal administration to mice," Drug Metabolism and Disposition, vol. 32, No. 10, Jul. 2004, (pp. 1132-1138). |
Science IP Search Report dated Sep. 20, 2007. |
Shimi et al., "A new antitumour substance, 7-oxabicyclo (2.2.1)-5-heptene-2,3-dicarboxylic anhydride," European Journal of Cancer, vol. 18, No. 8, Aug. 1982 (pp. 785-793). |
Shore et al., "Unique Biology of Mcl-1: Therapeutic Opportunities in Cancer," Current Molecular Medicine, vol. 8, No. 2, Mar. 2008 (pp. 138-147). |
Short et al., "DNA repair after irradiation in glioma cells and normal human astrocytes," Neuro-Oncology, vol. 9, No. 4, Oct. 2007 (pp. 404-411). |
Singh et al., "Identification of a cancer stem cell in human brain tumors," Cancer Research, vol. 63, No. 18, Sep. 2003 (pp. 5821-5828). |
Singh et al., "Identification of human brain tumour initiating cells," Nature, vol. 432, Nov. 2004 (pp. 396-401). |
Smith et al., "Histone deacetylase inhibitors enhance Candida albicans sensitivity to azoles and related antifungals: correlation with reduction in CDR and ERG upregulation," Antimicrobial Agents and Chemotherapy, vol. 46, No. 11, Nov. 2002 (pp. 3532-3539). |
Song et al., Synthesis and Biological Properties of Amino Acid Amide Ligand-Based Pyridinioalkanoyl Thioesters as Anti-HIV Agents, Bioorganic and Medicinal Chemistry, vol. 10, No. 5, May 2002 (pp. 1263-1273). |
Sridharan et al., "Illuminating the black box of reprogramming," Cell Stem Cell, vol. 2, No. 4, Apr. 2008 (pp. 295-297). |
Stewart et al., "Synthesis and biological evaluation of norcantharidin analogues: towards PP1 selectivity," Bioorganic and Medicinal Chemistry, vol. 15, No. 23, Dec. 2007 (pp. 7301-7310). |
Strebhardt et al., "Targeting polo-like kinase 1 for cancer therapy," Nature Reviews: Cancer, vol. 6, Apr. 2006 (11 pages). |
Stupp et al., Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma, The New England Journal of Medicine, vol. 352, Mar. 2005 (pp. 987-996). |
Supplemental European Search Report and European Search Opinion dated Apr. 2, 2012 in connection with European Patent Application No. 09803283.2, filed Jan. 24, 2011. |
Supplemental European Search Report in connection with EP 08794986.3, dated Dec. 15, 2010. |
Susini et al., "TCTP protects from apoptotic cell death by antagonizing bax function," Cell Death and Differentiation, vol. 15, Feb. 2008 (pp. 1211-1220). |
Suzuki et al., "Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives," Journal of Medicinal Chemistry, vol. 42, No. 15, Jul. 1999 (pp. 3001-3003). |
Sweatt, "Behavioural Neuroscience: Down Memory Lane," Nature, vol. 447, May 2007 (pp. 151-152). |
Tocris Biosciences: retinoic acid receptors product data sheet (2010). |
Toma et al., "Retinoids and human breast cancer: in vivo effects of an antagonist for RAR-alpha," Cancer Letters, vol. 219, No. 1, Feb. 2005 (pp. 27-31). |
Touma et al., "Retinoic acid and the histone deacetylase inhibitor trichostatin a inhibit the proliferation of human renal cell carcinoma in a xenograft tumor model," Clinical Cancer Research, vol. 11, No. 9, May 2005 (pp. 3558-3566). |
Trost et al., "New synthetic reagents, Methylthiomaleic anhydride: a synthon for protected carbomethoxyketene," Journal of the American Chemical Society, vol. 99, No. 21, Oct. 1977 (pp. 7079-7082). |
Tuynder et al., "Biological models and genes of tumor reversion: cellular reprogramming through tpt1/TCTP and SIAH-1," Proceedings of the National Academy of Sciences U.S.A., vol. 99, No. 23, Nov. 2002 (pp. 14976-14981). |
Tuynder et al., "Translationally controlled tumor protein is a target of tumor reversion," Proceedings of the National Academy of Sciences U.S.A., vol. 101, No. 43, Oct. 2004 (pp. 15364-154369). |
Uchida et al., "Direct isolation of human central nervous system stem cells," Proceedings of the National Academy of Sciences U.S.A., vol. 97, No. 26, Dec. 2000 (pp. 14720-14725). |
Valeriote et al., "Synergistic interaction of anticancer agents: a cellular perspective," Cancer Chemotherapy Reports, vol. 59, No. 5, Sep.-Oct. 1975 (pp. 895-900). |
Vazquez et al., "The genetics of the p53 pathway, apoptosis and cancer therapy," Nature Reviews: Drug Discovery, vol. 7, No. 12, Dec. 2008 (pp. 979-987). |
Wang, "Effect of norcantharidin on the number of white blood cells," Chinese Pharm. Bull., vol. 22, No Month Listed 1987 (pp. 517-519) with English translation of abstract prepared at the applicants' attorney' office. |
Wang, "Hydrolysis and demethylation of cantharidin on the relief of its urinary irritation," Chin. Pharmac. Bull., vol. 18, No Month Listed 1983 (pp. 18-19) with English language title available from the journal and English language summary prepared at the applicants' attorneys' office. |
Wang, "Medical uses of mylabris in ancient China and recent studies," Journal of Ethnopharmcology, vol. 26, No. 2, Sep. 1983 (pp. 147-162). |
Wang, "Results of clinical trials in 244 cases of primary hepatoma and with norcantharidin," Chinese Pharm. Bull., vol. 21, No Month Listed 1986 (pp. 90-93) with English translation of abstract prepared at the applicants' attorneys' office. |
Warrell et al., "Therapeutic Targeting of Transcription in Acute Promyelocytic Leukemia by Use of an Inhibitor of Histone Deacetylase," Journal of the National Cancer Institute, vol. 90, No. 21, Nov. 1998 (pp. 1621-1625). |
Waters et al., "Analysis of co-factor function in a glucocorticoid-resistant small cell carcinoma cell line," Journal of Endocrinology, vol. 183, No. 2, Nov. 2004 (pp. 375-383). |
Weinmann et al., "Histone deacetylase inhibitors: a survey of recent patents," Expert Opinion on Therapeutic Patents, vol. 15, No. 12, Nov. 2005 (pp. 1677-1690). |
Westermarck et al., "Multiple pathways regulated by the tumor suppressor PP2A in transformation," Trends in Molecular Medicine, vol. 14, No. 4, Apr. 2008 (pp. 152-160). |
Written Opinion in connection with PCT/US2008/011367, dated Dec. 12, 2008. |
Written Opinion in connection with PCT/US2009/004108, dated Sep. 15, 2009. |
Written Opinion in connection with PCT/US2009/004378, dated Sep. 18, 2009. |
Written Opinion in connection with PCT/US2009/004430, dated Jan. 12, 2010. |
Yan et al., "Inhibition of protein phosphatase activity induces p53-dependent apoptosis in the absence of p53 transactivation," Journal of Biological Chemistry, vol. 272, No. 24, Jun. 1997 (pp. 15220-15226). |
Yang et al., "An N-terminal region of translationally controlled tumor protein is required for its antiapoptotic activity," Oncogene, vol. 24, No. 30, Jul. 2005 (pp. 4778-4788). |
Yarm, "Plk phosphorylation regulates the microtubule-stabilizing protein TCTP," Molecular and Cellular Biology, vol. 22, No. 17, Sep. 2002 (pp. 6209-6221). |
Yoshida et al., "Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A," Journal of Biological Chemistry, vol. 265, No. 28, Oct. 1990 (pp. 17174-17179). |
Yoshida et al., "Trichostatin and leptomycin. Inhibition of histone deacetylation and signal-dependent nuclear export," Annals of the New York Academy of Sciences, vol. 886, No Month Listed 1999 (pp. 23-26). |
Yung et al. "Treatment of recurrent malignant gliomas with high-dose 13-cis-retinoic acid," Clinical Cancer Research, vol. 2, No. 12, Dec. 1996 (pp. 1931-1935). |
Yur'ev et al., Chemical Abstracts, vol. 56, No. 73368, No Month Listed 1961. |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11931354B2 (en) | 2013-04-09 | 2024-03-19 | Lixte Biotechnology, Inc. | Formulations of oxabicycloheptanes and oxabicycloheptenes |
US11236102B2 (en) | 2015-05-15 | 2022-02-01 | Lixte Biotechnology, Inc. | Oxabicycloheptane prodrugs |
US11866444B2 (en) | 2015-05-15 | 2024-01-09 | Lixte Biotechnology, Inc. | Oxabicycloheptane prodrugs |
Also Published As
Publication number | Publication date |
---|---|
CA2676422A1 (en) | 2008-08-14 |
JP5693850B2 (en) | 2015-04-01 |
US9079917B2 (en) | 2015-07-14 |
EP2124550A1 (en) | 2009-12-02 |
BRPI0806365A2 (en) | 2011-09-06 |
AU2008214299A1 (en) | 2008-08-14 |
US20170369503A1 (en) | 2017-12-28 |
WO2008097561A1 (en) | 2008-08-14 |
US20150045373A1 (en) | 2015-02-12 |
EP2124550A4 (en) | 2011-04-06 |
WO2008097561A8 (en) | 2009-10-01 |
BRPI0806365B8 (en) | 2021-05-25 |
JP2010518081A (en) | 2010-05-27 |
EP2124550B1 (en) | 2017-04-19 |
CN101662939A (en) | 2010-03-03 |
US8426444B2 (en) | 2013-04-23 |
BRPI0806365B1 (en) | 2020-01-21 |
US20130302402A1 (en) | 2013-11-14 |
US7998957B2 (en) | 2011-08-16 |
US20120270736A1 (en) | 2012-10-25 |
US20090036309A1 (en) | 2009-02-05 |
EA200970737A1 (en) | 2010-02-26 |
US8822461B2 (en) | 2014-09-02 |
CA2676422C (en) | 2018-10-16 |
CN101662939B (en) | 2015-11-25 |
CN103788108B (en) | 2017-04-12 |
EA023804B1 (en) | 2016-07-29 |
CN103788108A (en) | 2014-05-14 |
US20180370983A1 (en) | 2018-12-27 |
AU2008214299B2 (en) | 2014-01-09 |
US10023587B2 (en) | 2018-07-17 |
MX2009008347A (en) | 2009-10-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10399993B2 (en) | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | |
US8227473B2 (en) | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | |
US20150374705A1 (en) | Substances for treatment or relief of pain | |
JP2016538281A (en) | Protein phosphatase inhibitors that cross the blood-brain barrier | |
US20130079401A1 (en) | Novel use of isothiocyanates for treating cancer | |
ES2634152T3 (en) | Oxabicicloheptanos and oxabicicloheptenos, its preparation and use | |
TWI406658B (en) | Use of isothiocyanates for treating cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: SMAL); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
AS | Assignment |
Owner name: LIXTE BIOTECHNOLOGY, INC., NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KOVACH, JOHN S.;JOHNSON, FRANCIS;REEL/FRAME:047410/0581 Effective date: 20180726 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT RECEIVED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
AS | Assignment |
Owner name: LIXTE BIOTECHNOLOGY, INC., CALIFORNIA Free format text: CHANGE OF ADDRESS FOR ASSIGNEE;ASSIGNOR:LIXTE BIOTECHNOLOGY, INC.;REEL/FRAME:058957/0597 Effective date: 20220201 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2551); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY Year of fee payment: 4 |